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1 ABBREVIATIONS 
 
ALL  Acute Lymphoid Leukemia 
AML  Acute Myeloid Leukemia 
AML1-ETO Acute Myeloid Leukemia Eight Twenty One fusion protein 
AR  Androgen Receptor 
ATRA  All-Trans Retinoic Acid 
BR-LZ  Basic Region-Leucine Zipper 
bZIP  Basic Leucine Zipper 
C/EBP  CCAAT enhancer binding protein 
CBP  CREB Binding Protein 
CDK  Cell Division Protein Kinase 
CHAPS 3-[(3-Cholamidopropyl) Dimethylammonio]-1-Propanesulfonate 
ChIP  Chromatin Immunoprecipitation Assay 
CHOP  C/EBP homologous protein 
CK  Complex Karyotype 
CML  Chronic Myeloid Leukemia  
CREB  cAMP Response Element-Binding Protein 
DBD  DNA Binding Domain 
DHB  2,5-Dihydroxy-Benzoicacid 
DMEM Dulbecco´s Modified Eagle Medium 
DMSO  Dimethylsulfoxide 
DTE  Dithioerythritol 
DTT  Dithiothreitol 
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EDTA  Ethylenediamine Tetra-Acetic Acid 
EGTA  Ethylene Glycol bis (2-aminoethyl ether)-N,N,N'N'-Tetra Acetic Acid 
FAB  French American British Classification 
FBS  Fetal Bovine Serum 
G-CSFR Granulocyte-Colony Stimulating Factor Receptor 
GM-CSF Granulocyte-Macrophage Colony Stimulating Factor 
GMPs   Granulocyte/Macrophage Progenitors 
GST  Glutathione-S-Transferase 
HAT  Histone Acetyltransferase 
HDAC  Histone Deacetyltransferase 
hnRNP Heterogeneous Nuclear Ribonucleoprotein 
HSCs  Hematopoietic Stem Cells 
HTATIP Histone acetyltransferase TIP60 
IB  Immunoblot 
IEF  Isoelectric Focussing 
IP  Immunoprecipitation 
IPTG  Isopropyl-beta-D-Thiogalactopyranoside 
Ivt  In-vitro Translated 
LC-MS/MS Liquid Chromatography/Mass Spectrometry/Mass Spectrometry 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization Time-of-Flight 
MCM5 Mini Chromosome Maintenance 5 
M-CSF Macrophage-Colony Stimulating Factor Receptor 
MS  Mass Spectrometry 
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MYST  MOZ, Ybf2/Sas3, Sas2 and TIP60 
nano-HPLC/MS nano–high-performance liquid chromatography/mass spectrometry 
NK  Normal Karyotype 
NP40  Nonidet P-40 
pI  Isoelectric Point 
PMF  Peptide Mass Fingerprinting 
RB  Retinoblastoma protein 
Rpm  Revolutions per Minute 
RT  Room Temperature 
SDS  Sodium Dodecyl Sulphate 
TAD  Transactivation Domain 
TBE  Tris-Borate EDTA 
TIP60  Tat Interactive Protein 60kD 
TOF  Time of Flight 
TRRAP Transformation/transcription domain-associated protein 
USF  Upstream Stimulatory Factor 
WHO  World Health Organization 
β-ME  β-Mercaptoethanol 
2D  2 Dimensional Gel Electrophoresis 
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 2 INTRODUCTION 
 
2.1 Hematopoiesis 
Hematopoiesis is an orderly process of tightly controlled expression of specific 
transcriptional regulators, growth factors, and growth factor receptors, the combination of 
which determines lineage commitment and maturation of blood cells. The hematopoetic 
cells of all lineages derive originally from a relatively small number of committed 
hematopoetic progenitors, which arise from even fewer hematopoietic stem cells 1. The 
very first step in hematopoietic differentiation involves a commitment of the stem cell to 
one of two main lineages, myeloid or lymphoid. Subsequently, progeny of cells committed 
to each of these two lineages will differentiate further into the various cell types of the 
hematopoietic system. Pluripotential hematopoietic stem cells are an extremely rare 
population in the bone marrow (< 0.1 % of nucleated bone-marrow cells) 2, estimated to be 
approximately one per 105 marrow cells which undergo a decision to either self-renew or 
remain pluripotent or to differentiate into immature but committed progenitor cells. The 
differentiation of HSCs to various hematopoietic lineages has been studied intensively and 
the mechanisms that regulate these processes provide important models for the regulation 
of cell fate determination. Granulocytes and monocytes, collectively called myeloid cells, 
are differentiated descendants from common progenitors derived from HSC in the bone 
marrow. The term myeloid is derived from the Greek word for marrow and, indeed myeloid 
cells constitute the dominant cellular population in bone marrow. Granulocytes and 
monocytes are key mediators of innate immunity and the inflammatory response. 
A classical understanding of the development of mature blood cell types from HSCs is 
presented in Figure 1. This model incorporates findings from immunophenotyping, in vitro 
culture analyses, experimental bone manrow transplantation, and clinical experience. In 
this view, hematopoiesis is a relatively linear and hierarchical process whereby pluripotent 
HSCs undergo successive symmetric and asymmetric divisions to yield committed 
progenitor cells. The latter also possess stem cell-like properties, but exhibit a progressive 
restriction of cellular fate as they differentiate toward mature lymphoid, erythroid, 
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megakaryocytic, or myeloid cells. Committed progenitor cells proliferate to meet the 
enormous daily needs of blood cell production and through this hierarchical system, they 
ultimately yield the mature elements of blood 1,3 
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Fig 1: Role of transcription factors in hematopoietic development: Long-term and 
short-term haematopoietic stem cells (HSCs) provide long-term (more than 3 months) and 
short-term reconstitution in lethally irradiated mice. The common lymphoid progenitors 
(CLPs) gives rise to T and B cells, whereas the common myeloid progenitors (CMPs) gives 
rise to granulocyte/macrophage progenitors (GMPs) and megakaryocyte/erythroid 
progenitors (MEPs). Upregulation of the transcription factor PU.1 is essential for the 
transition from HSC to CLP, whereas downregulation of PU.1 is required for the 
differentiation of CMP to MEP. CCAAT/enhancer binding protein(C/EBP)α upregulation 
initiates the transition from CMP to GMP 4. Adapted from Nature reviews, Tenen DG 2. 
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2.2 Transcription factors involved in normal hematopoiesis 
Beside the role of growth factor receptors and their signaling intermediates, a network of 
transcription factors regulates the expression of a cell type-specific pattern of genes and 
directs the cells down the path from stem cells and early precursors to fully differentiated 
cells of the various lymphoid and myeloid lineages 5. Transcription factors are sequence-
specific DNA binding proteins with a variety of functions that include: (i) folding of the 
DNA molecule, (ii) the initiation of DNA replication and (iii) control of gene transcription. 
Key transcription factors regulate multiple aspects of hematopoietic differentiation - from 
lineage commitment through terminal maturation 6. A number of transcription factors have 
been identified that play a role in the development of myeloid differentiation. Important 
information about the role of transcription factors in haematopoietic lineage development 
has been obtained from studies involving either targeted gene disruption or overexpression 
of these factors. Transcription factors are also the genes most commonly targeted by 
leukemia-associated genetic aberrations 7. An acquired genetic aberration in a relevant 
transctiption factor can perturb normal hematopoietic development and lead to malignant 
disease. The study of factors mutated or altered in leukemia has thus led to the 
identification of new transcription factors involved in hematopoiesis (Table 1). 
 
Table 1: Transcription factors involved in hematopoiesis 
Factor Expression Target Genes Comments 
AML1 HSCs and most others M-CSF receptor; T-cell 
receptor enhancer 
Knockouts lack all 
definitive haematopoiesis; 
conditional knockouts 
develop moderate 
thrombocytosis 
GATA1 HSCs,CMPs,MEPs,not 
GMPs or lymphoid 
Erythropoietin receptor 
and many others 
Knockouts lack all mature 
erythroid cells 
PU.1 All progenitors; 
downregulated in 
erythroid and T-cells 
Receptors for GM-
CSF,G-CSF and M-CSF, 
and many others 
Knockout leads to 
complete loss of 
macrophages and B cells, 
delayed development of T 
cells and granulocytes; 
the block at the HSC to 
CLP transition and at the 
CMP stage 
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C/EBPα HSCs, CMPs, GMPs 
not in MEPs or 
lymphoid  
Receptors for G-CSF,IL-
6, E2F, c-MYC,; and 
primary granule proteins 
Knockout results in 
complete loss of 
granulocytic maturation, 
block at the CMP to GMP 
stage, can induce 
granulocytic 
differentiation and block 
monocytic differentiation 
of multipotential cell 
lines. 
C/EBPβ most hematopoietic 
cells 
G-CSF and others Knockout shows not 
required for myeloid 
development but has role 
in macrophage activation, 
knock-in to 
C/EBPα locus rescues 
granulopoiesis; required 
for emergency 
granulopoiesis. 
C/EBPε Granulocytic and 
lymphoid cells 
Secondary granule 
proteins 
Knockout blocks terminal 
granulocyte maturation 
and function. 
Adapted from Nature Reviews Cancer 2,Tenen DG. 
 
2.3 Transcription factor C/EBPα in myeloid differentiation 
The first C/EBP protein was identified in the laboratory of Steve McKnight as a heat-stable 
factor in rat liver nuclei that was capable of interacting with the CCAAT box motif present 
in several cellular gene promoters and a 'core homology' sequence found in certain viral 
enhancers 8. CCAAT enhancer binding protein (C/EBP)α is the founding member of a 
family of related leucine-zipper transcription factors that play important roles in myeloid 
differentiation (Fig. 2). There are six members of the C/EBP family: α, β, δ, ε, γ, and 
CHOP. All C/EBP isoforms share substantial sequence identity (>90%) in the C-terminal 
55–65 amino acid residues, which contains the bZIP domain. This domain consists of a 
basic amino acid-rich DNA-binding region followed by a dimerization motif termed the 
'leucine zipper' 9. Multiple protein isoforms are generated from each CEBP gene through 
the use of alternative splicing and alternative translational initiation sites. Because some of 
these isoforms exclude the transcription activation domains, heterodimerization can yield a 
large numbers of complexes with different functional properties 10-12. Such interactions are 
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likely to have a profound influence on the regulation of gene transcription. In contrast with 
the bZIP domain, the N-termini of the C/EBP proteins are quite divergent (< 20 % 
sequence identity), except for two short subregions that are conserved in most members. 
These subregions have been shown to represent the activation domains. The major 
exception is CHOP, which lacks an activation domain and, therefore, represses gene 
transcription by forming inactive heterodimers with other C/EBP members 13. 
 
TAD1 TAD2 BR LZ
1 286 306 317 34535870 97 127 200
DBD
C/EBPα
 
Fig 2: The diagram shows the C/EBPα transactivation domains, TAD1, and TAD2 which 
were defined by Friedman et al. 11. The basic zipper (bZip) domain (DNA Binding 
Domain; DBD) mediates DNA binding as well as homo- and heterodimerization with other 
C/EBP proteins. 
 
During differentiation, the fate of a given cell depends as much on the signals that it 
receives as on its unique response to those signals. So the lineage-restricted transcription 
factors do not appear to exercise monopoly in differentiation function. None of the C/EBP 
factors is restricted to myeloid cells, for they are also expressed in other hematopoietic 
lineages, in liver cell, adipocytes, and other tissues. High-levels of C/EBPα, β, and δ 
expression is found in granulocytes, monocytes, and eosinophils 14-16. C/EBPα is the 
predominant C/EBP factor in immature granulocytes 15,17. C/EBPα is also abundant in early 
myeloid cells where it binds and activates key myeloid target genes. In contrast, C/EBPε is 
found predominantly in maturing granulocytes and T lymphocytes 18. CHOP is expressed 
only in granulocytes that are subjected to stress, such as DNA damage 19. Figure 3 depicts 
the temporal expression of various C/EBP proteins during granulopoiesis. The expression 
of C/EBPα mRNA and protein in early myeloid cells increases up to three fold following 
induction of granulocytic differentiation by retinoic acid in myeloid cell lines; in contrast, it 
is rapidly downregulated during monocytic differentiation. These changes in expression are 
also seen in normal human granulocytes 14 and in analysis of single, primary human 
hematopoietic cells 20. Induction of C/EBPα in primary human CD34+ cells, leads to 
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granulocytic differentiation and inhibits erythrocyte differentiation 21. Mouse C/EBPα -/- 
HSCs express elevated levels of the polycomb gene Bmi-1, which can enhance HSC self-
renewal 4 and these cells demonstrate a competitive advantage over wild type HSCs 4,22. 
This indicates that C/EBPα might normally serve to limit HSC self-renewal. Novel targets 
of C/EBPα in HSCs such as Id1, a transcriptional repressor of erythrocyte differentiation, 
have been identified by oligonucleotide arrays, suggesting additional mechanisms by which 
C/EBPα induces granulopoiesis and blocks other differentiation pathways in early 
hematopoietic progenitors 21. 
 
 
Fig 3: Expression pattern of C/EBP proteins during granulopoiesis: Granulopoiesis is 
the formation of mature neutrophil granulocytes from immature myeloblasts through a 
differentiation process that involves the cessation of cellular proliferation concomitant with 
the sequential synthesis of a number of enzymes and structural proteins that are contained 
in the different types of granules of the granulocyte. The figure shows the relative 
contribution of C/EBPs to the granulocytic compartment as percent of total nucleated bone-
marrow cells, as well as the expression pattern of the C/EBPα, C/EBPβ and C/EBPε 
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proteins 23-25 during granulocyte differentiation. Adapted from Nature Reviews Cancer 25, 
Nerlov. 
 
 
Binding sites for the C/EBPs are present in the promoter regions of numerous genes that 
are expressed in myeloid cells like G-CSFR (Granulocyte-Colony Stimulating Factor 
Receptor), myeloperoxidase, neutrophil elastase 26-28. The human CEBPA promoter lacks a 
C/EBP recognition sequence. However, it can still be activated by C/EBPα, which acts 
indirectly via stimulation of the DNA-binding activity of USF (Upstream Stimulatory 
Factor), which in turn interacts with a site present in the proximal promoter region 29. These 
studies suggest a role for C/EBPα in myeloid cell development. C/EBPα is also involved in 
the regulation of cell proliferation 30. Recently it was reported that C/EBPα causes an 
acceleration of cell proliferation after being post-translationally modified (phosphorylated) 
31. There are numerous reports demonstrating that C/EBPα activity is regulated at the level 
of post-translational modifications 31-33. 
 
 
2.4 Acute Myeloid Leukemia (AML) 
Acute myeloid leukemia (AML) can be defined as an accumulation of immature myeloid 
cells in the bone marrow and blood resulting from dysregulation of normal proliferation, 
differentiation, and apoptosis. Lineage-specific transcription factors have been identified as 
key regulators in these differentiation programs 34. AML is the most common type of 
leukemia in adults and occurs in approximately one third of newly diagnosed patients with 
malignant hematological disease. 
 
The fundamental biological feature of the malignant cells in AML is their ability to 
proliferate continuously with an aberrant or arrested differentiation 35. The French-
American-British classification, introduced approximately 25 years ago 36,37 remains the 
foundation on which the morphologic diagnosis of AML and ALL is based (Table 2, Fig. 
4). 
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Table 2: The French-American-British classification of AML 
FAB Subtype Description Comments 
M0 Undifferentiated Myeloperoxidase negative, Myeloid 
markers positive;  
M1 Myeloblastic without 
maturation 
Some evidence of granulocytic 
differentiation 
M2 Myeloblastic with maturation Maturation at or beyond the 
promyelocytic stage of differentiation; 
can be divided into those with an 
AML1-ETO fusion and those without  
M3 Promyelocytic APL; most cases have t(15;17) PML-
RARα or another translocation 
involving RARα 
M4 Myelomonocytic Cases with 11q23/MLL translocations 
were observed. 
M4E0 Myelomonocytic with bone 
marrow eosinophilia 
Characterized by inversion of 
chromosome 16 involving CBFβ, 
which normally forms a heterodimer 
with AML1 
M5 Monocytic Cases with 11q23/MLL translocations 
were observed more frequent than in 
M4 38. 
M6 Erythroleukemia Excess of myeloblasts in an erythroid 
dominant marrow. 
M7 Megakaryoblastic GATA1 mutations in patients with 
Down’s syndrome. 
Adapted from Nature Reviews Cancer 2,37 
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Myeloblastic
Promyelocytic
t(15;17)
Myelomonocytic (M4)
(Mixed granulocytic and monocytic features)
inv(16)
Monocytic (M5)
t(9;11)
Increasing maturation
M0, M1, M2
t(8;21) C/EBPα
mutations  
Fig 4: Differentiation stages of acute myeloid leukemias that affect the granulocytic and 
monocytic lineages, according to the FAB classification. The least differentiated 
myeloblastic leukemia is categorized as M0. Myeloblastic leukemia with some maturation 
is categorized as M1, and with more maturation as M2. The t(8;21) or mutations of 
C/EBPα are found in M2 leukemia. Acute promyelocytic leukemia (M3) is associated with 
the t(15;17). Myelomonocytic leukemia (M4) has both granulocytic and monocytic 
characteristics. The inv(16) is strictly associated with an M4 leukemia with increased 
eosinophils. Monocytic leukemia (M5) is associated in some cases with a t(9;11) leading to 
an MLL/AF9 fusion protein. Adapted from Nature Medicine 39, Hiebert, S. 
 
 
The classification of AML has recently been revised by a group of pathologists and 
clinicians under the auspices of the World Health Organization (WHO). While elements of 
the French-American-British classification were retained (i.e., morphology, 
immunophenotype, cytogenetics and clinical features), the WHO classification incorporates 
more recent discoveries regarding the genetics and clinical features of AML in an attempt 
to define entities that are biologically homogeneous and that have prognostic and 
therapeutic relevance 36,40. Each criterion has prognostic and treatment implications but, for 
practical purposes, antileukemic therapy is similar for all subtypes. 
 
A large number of diverse translocations have been described in AML 41. The most 
frequent are the t(8;21): AML1-ETO, t(15;17): PML-RARα, inv(16): CBFB-MYH11 and 
13 
 
t(9;11): MLL-MLLT3, which, together with their variants, are found in approximately 40 
% of all AMLs 42. Many other chromosome translocations have been described in AML, 
including t(3;5): NPM/MLF1, t(6;9): DEK-CAN, t(16;21): AML1-MTG16, t(7;11): 
NUP98-HOXA9, which are present, however, in less than 10 % of cases. Random 
chromosome aberrations have been described in 30 % of AML cases, whereas 20 % of 
cases displays a normal karyotype 42. Regardless of subtype, AML is characterized by a 
defect in the normal process of maturation that converts a myeloid precursor cell into a 
mature white blood cell. Cytogenetically, AML is probably the most extensively analyzed 
human neoplastic disease. Numerous chromosomal aberrations specific for AML have been 
identified, and in many instances, molecular genetic investigations have identified the 
genes that are affected by these translocations. The study of these genes has elucidated their 
contribution to the neoplastic process and led to the discovery of signal transduction 
pathways and transcription factor networks relevant to leukemogenesis. The majority of 
genes that have been cloned from these breakpoints are known to be involved in cell 
proliferation, cell death, or cell differentiation. These so-called "oncogenes" are critical 
components in the multifactorial pathway leading to the development of a malignancy. The 
more common aberrations have been associated with clinical characteristic, and are now 
being used as diagnostic and prognostic markers 43. Studying chromosome 
abnormalities/rearrangements in leukemia has been a very successful approach for 
identifying genes responsible for these disorders. Chromosomal rearrangements result in 
the rearrangement of genes at the location of the breakpoints. The identification of genes at 
the chromosomal breakpoints is performed by a variety of techniques including positional 
cloning which is aided by FISH (Fluorescence in situ hybridization) breakpoint mapping. 
By analyzing chromosomal abnormalities at the molecular level new genes that might play 
a role in AML can be identified. 
 
The genes and fusion genes identified at chromosomal translocation breakpoints in AML 
can also lead to the development of new treatment strategies. One of the first examples of 
"targeted leukemia therapy" is acute promyelocytic leukemia (APL). In this leukemia 
subtype the discovery that the RARα gene is involved in the gene rearrangement resulting 
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from the t(15;17) is very intriguing, given the clinical response of patients with APL to all-
trans retinoic acid 44. 
 
In the past few years, a number of studies have pointed to the dominant role of lineage-
specific transcription factors in normal hematopoietic differentiation 26,45,46. These studies 
predicted that the function of these transcription factors might be disrupted in AML. Recent 
studies have confirmed this hypothesis, showing that a number of cases of AML are 
associated with small mutations in the coding regions of these lineage-specific transcription 
factors or these factors are inhibited by direct protein-protein interactions 25,47-50. In 
addition, in many cases of chromosomal translocations the resulting translocation fusion 
proteins disrupt the expression and/or function of lineage-specific factors 50,51. In fact, the 
most common finding in AML and ALL is the aberrant expression of transcription factors 
or the production of an abnormal hybrid transcription factor 50-52. A selection of 
hematopoietic transcription factors often associated with AML is given in Table 3. 
 
Table 3: Transcription factors associated with AML 
Factor Subtype Mutation 
AML1 FAB M0 Often biallelic mutations 
AML1 FAB M2 t(8;21) AML1-ETO and 
AML1/EVI1 
GATA1 FAB M7 associated with 
Down’s syndrome 
Amino terminal mutations 
similar to those seen with 
C/EBPα 
PU.1 M0, M4, M5, M6 Mutations were generally 
heterozygous: DBD, PEST, 
and TAD domain of PU.1 
53. 
C/EBPα M1, M2 few M4 Mutation not associated 
with t(8;21); amino-terminal 
dominant negative 
C/EBPα M2 with t(8;21) No mutation; 
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downregulation of C/EBPα 
at the RNA level 
C/EBPα CML myeloid blast crisis No mutation; 
downregulation at the 
protein level 
C/EBPα APL No downregulation; loss of 
DNA binding in cell lines; 
C/EBPβ and C/EBPε 
mediate ATRA response in 
AML. 
CBFβ M4e Inversion of chromosome 
16 involving CBFβ,  which 
normally forms a 
heterodimer with AML1. 
Adapted from Nature Reviews, Cancer 2, Tenen, DG 
 
2.5 C/EBPα and Cancer 
C/EBPα-/- mice show a block in hematopoietic differentiation, with an accumulation of 
myeloblast and an absence of mature granulocytes, similar to what is observed in humans 
with AML 26. The expression of C/EBPα, on the other hand, in leukemic cell lines leads to 
granulocytic differentiation 14,26,50. Expression of C/EBPα is downregulated in patients with 
the t(8;21) AML1-ETO translocation 50. C/EBPα mutations are found in a significant 
number of AML patients with a normal karyotype 47,54,55. 
 
Furthermore, the roles of C/EBPα in HSCs and for stage- and lineage-specific decisions in 
granulopoiesis have suggested that C/EBPα might be a tumor suppressor gene. Recent 
results suggest that the exact expression level of such lineage-specific transcription factors 
might be of utmost importance. For example, reduction in the expression of the PU.1 gene 
to 20 % of normal levels in mice leads to the development of AML, whereas a 50 % or an 
absent expression of PU.1 will result in a different phenotype characterized by 
accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with 
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disruption of M-CSF and GM-CSF pathways 56. A similar strong association between 
leukemogenesis and hypomorphic transcription factor function may apply to C/EBPα as 
well, since C/EBPα mutations in AML patients do not occur as bi-allelic null mutations 
47,57. 
About 7.3% of AML samples carry heterozygous CEBPA mutations. In contrast to wild 
type C/EBPα, the mutant proteins cannot induce neutrophil differentiation when expressed 
in bipotential myeloid precursor cells 14,47. Interestingly, in cases with an N-terminal 
C/EBPα mutation, a dominant negative isoform of C/EBPα, the p30 protein, which lacks 
the N-terminal transactivation domain but retains the C-terminal DNA-binding domain, is 
still expressed from the mutated allele 58,59. The expression of truncated or other mutant 
C/EBPα proteins probably facilitates AML development by imposing a differentiation 
block and disrupting normal cell cycle exit. The hyperproliferating mutant cells may be at 
increased risk of acquiring other oncogenic mutations that are necessary for transformation 
and leukemogenesis 60. Knock-in mice with a targeted mutation in the C/EBPα basic region 
(C/EBPαBRM2 mutation) that specifically inhibits C/EBPα–E2F interaction showed 
increased capacity of bone marrow myeloid progenitors to proliferate. Furthermore the 
mice were predisposed to a granulocytic myeloproliferative disorder resulting in the 
transformation of the myeloid compartment of the bone marrow. This indicates that 
disrupting the cell cycle regulatory function of C/EBPα is sufficient to initiate AML-like 
transformation of the granulocytic lineage 61. 
 
C/EBPα function is impaired in specific subgroups of AML by either of the following: 
 
1) Mutations of the CEBPA gene in acute myeloid leukemia as described above. 
 
2) Transcriptional modulation of C/EBPα by AML1-ETO both in vitro and in vivo 50 or by 
FLT3/ITD signaling in vitro in 32D cells 62. Interestingly, other leukemic fusion proteins 
involving CBF family members such as the AML1–MDS1–EVI1 or the CBFB–MYH11 
fusion have not been shown to suppress C/EBPα mRNA 63,64. 
 
3) Epigenetic mechanisms: C/EBPα promoter hypermethylation has been reported in two 
out of 23 AML-M2 patients 65. Recently, the C/EBPα upstream region and not the core 
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promoter region has been shown to be hypermethylated in 12 out of 15 lung cancer cell 
lines and 81 out of 120 primary lung tumors associated with low or absent C/EBPα 
expression 66. 
 
4) Posttranscriptional regulation of C/EBPα: C/EBPα mutations are not found in CML but 
expression of C/EBPα protein is not detectable in primary cells from patients with CML 51. 
The C/EBPα mRNA is clearly present in CML samples. The expression of C/EBPα was 
found to be suppressed at the translational level by interaction of the poly(rC)-binding 
protein hnRNP E2 with C/EBPα mRNA 67. 
 
C/EBPα mRNA levels remain unchanged in AML with t(3;21) encoding the AML1–
MDS1–EVI1 fusion gene (AME) where the expression of AME regulates the rate of 
mRNA translation and suppresses C/EBPα protein in a conditional cell line model and in 
AML patient samples. Calreticulin, an RNA-binding protein which is strongly activated in 
AME patients interacts with stem loop structures of C/EBPα and C/EBPβ mRNAs. This 
leads to inhibition of translation of C/EBP proteins in vitro and in vivo 68. Furthermore, 
inhibition of calreticulin by siRNA restores C/EBPα levels 63,64. Interestingly, 
posttranscriptional suppression of C/EBPα by activated calreticulin was also observed by 
the CBFB–MYH11 leukemic fusion protein 64. These observations indicate that the down 
regulation of C/EBPα activity by one of several mechanisms is necessary for the decreased 
differentiation and increased proliferative capacity of cancer cells, specifically in those 
tissues where C/EBPα controls normal differentiation. 
 
5). Post translational modifications regulating C/EBPα activity: Phosphorylation of 
C/EBPα at serine 21 is mediated by extracellular signal-regulated kinases 1 or 2 (ERK1/2), 
which recognize serine 21 of C/EBPα as a substrate through an FXFP docking motif. This 
phosphorylation induces a conformational change in C/EBPα such that the transactivation 
domains of two C/EBPα molecules within a dimer move further apart and this favors 
monocyte differentiation by blocking granulopoiesis. Activated Ras appears to act on 
serine 248 of the C/EBPα transactivation domain 32. In liver tumor cells, the activation of 
the PI3K/Akt pathway blocks the growth inhibitory activity of C/EBPα through the PP2A-
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mediated dephosphorylation of C/EBPα on serine 193, leading to a failure of C/EBPα to 
interact with and inhibit cdks and E2F. Mutations of serine 193 abolish the ability of 
C/EBPα to cause growth arrest 69. Active JNK1 inhibits ubiquitination of C/EBPα possibly 
by phosphorylating its DBD and prolongs C/EBPα protein half-life 70. 
 
C/EBPα expression is known to be downregulated in lung cancer 71, hepatocarcinomas 10,72 
and squamous cell carcinomas 73,74. In addition to regulating terminal differentiation, 
C/EBPα can be induced by stress signals that inhibit cell proliferation during DNA repair, 
which could contribute to its role in tumor suppression 60. 
 
2.6 Importance of protein-protein interactions in AML: C/EBPα Network 
C/EBPα is part of a network of interacting proteins 
 
Proteins never act in isolation; instead, they combine to form multiprotein complexes that 
function as "molecular machines." In the last several years, a plethora of C/EBPα-
interacting proteins have been identified, which may explain the multitude of C/EBPα 
functions (Fig.5). 
 
TAD1 TAD2 BR LZ
1 286 306 317 34535870 97 127 200
cdk2 cdk4P300 PU.1
p21CBP E2F c-JUN
Rb NF-Y
E2F
SW1/SNF Pit-1
TBP/TFIIB
RUNX1
GATA.1JNK1  
 
Fig.5: Schematic representation of C/EBPα. TAD1 and TAD2: trans-activation domain 1 
and 2; BR: basic region; LZ: leucine zipper. Proteins known to physically interact with 
specific regions on C/EBPα are shown 45,70,75-85. 
 
Recently, we and other groups have shown that the activity of C/EBPα in various processes 
like growth arrest, differentiation and proliferation depends in part, upon the protein 
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partners interacting with C/EBPα. We have shown that C/EBPα functionally inactivates 
PU.1 by displacing c-Jun, the coactivator of PU.1. This leads to the inhibition of cell fates 
specified by PU.1 and directs cell development to the granulocyte lineage 81. C/EBPα 
downregulates c-Jun expression and its transactivation capacity to promote granulocytic 
differentiation 45. Furthermore, phosphorylation of serine 248 of C/EBPα via Ras signalling 
enhances the activity of C/EBPα to induce granulocytic differentiation 32. C/EBPα interacts 
directly with CDK2 and CDK4 and arrests cell proliferation by inhibiting these kinases 76. 
Aging switches the C/EBPα pathway of growth arrest in liver from cdk inhibition to 
repression of E2F transcription 86-88. The retinoblastoma protein interacts directly with 
C/EBPα 79. Ser193-dephosphorylated C/EBPα interacts with retinoblastoma protein (Rb) 
independently on E2Fs and sequesters Rb, leading to a reduction of E2F-Rb repressors and 
to an acceleration of proliferation. P300 acts as a co-activator of C/EBPα 77. C/EBPα has 
also been shown to interact with the SWI/SNF chromatin-remodeling complex during the 
regulation of differentiation-specific genes 84. C/EBPα fails to suppress proliferation in 
SWI/SNF-defective cell lines after knock-down of SWI/SNF core components or after 
deletion of the SWI/SNF interaction domain in C/EBPα. C/EBPα interacts directly with the 
E2 SUMO-conjugating enzyme Ubc9 and can be SUMOylated in vitro using purified 
recombinant components 89. C/EBPα recruits the coactivator CBP and triggers its 
phosphorylation 78. The t(8;21) fusion product, AML1-ETO, associates with C/EBPα, 
inhibits C/EBP-α-dependent transcription, and blocks granulocytic differentiation 50. 
C/EBPα interacts specifically with p21 82 and Cdk2 76 to directly inhibit the Cdk enzymatic 
activity required for cell cycle progression. Interaction of JNK1 with C/EBPα prolongs 
C/EBPα protein half-life leading to its enhanced transactivation and DNA-binding capacity 
70. 
 
All these findings demonstrate the crucial role of C/EBPα protein interactions in the 
myeloid differentiation program. Perturbations of interacting partners of a particular protein 
could contribute to the differentiation block in AML 90. In addition, post translational 
modification of C/EBPα might be important in both normal and leukemic hematopoiesis. 
Furthermore, factors regulating C/EBPα activity could become targets for therapeutic 
intervention. 
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2.7 Proteomics of interacting proteins 
The study of protein-protein interactions has provided an immense insight into human 
biology. A protein role is reflected in its interaction with other proteins. Therefore, the 
identification and analysis of multiprotein complexes is a mechanism to better understand 
protein function and cell regulation. Since errors in protein-protein interactions can 
manifest as human disease, the identification of protein-protein interactions holds great 
potential for the definition of new targets for therapeutic intervention 91. Protein 
interactions can be determined by a combination of methods that exploits the high affinity 
nature of protein-protein interactions to capture protein complexes and the application of 
ultrasensitive protein identification techniques. 
 
Interacting proteins can be identified by using methods like the yeast two hybrid screen 92, 
identification of affinity purified proteins by mass spectrometry, genetic interactions and 
phage display or by bioinformatic methods which are based on the assumption that 
homologous sequences interact with similar proteins 93. 
 
Affinity purification coupled with mass spectrometry 
 
The emergence of matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 
mass spectrometry within the past decade has greatly simplified the ability to identify 
proteins using an approach termed proteomics. Proteomics generally involves separating a 
mixture of proteins in a given system using techniques such as 2D gel electrophoresis (here 
proteins are separated by isoelectric point focusing in the first dimension and subsequently 
by their molecular weight in the second dimension) followed by staining to detect protein 
bands. These bands are then excised, digested in-gel with a protease (Trypsin), and 
subjected to mass spectrometry. Each protein exhibits a specific digestion pattern, which is 
manifested on MALDI as a specific mass fingerprint. This allows the identification of 
unknown proteins by comparing their digestion pattern to a database containing the 
proteolytic masses of known proteins. A variety of databases and algorithms have been 
constructed and developed to search for corresponding fragments within an organism's 
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genome 94. These techniques lead to the identification of protein complexes directly on a 
proteome-wide scale. 
 
A key contribution to the identification of interacting proteins in stable complexes in 
cellular systems is provided by affinity-based approaches. The basic idea is to express the 
protein of interest with a suitable tag (such as the Glutathione S-transferase) to be used as a 
bait to fish its specific partners out of cellular extracts 95. Individual components within the 
multi-protein complex can then be identified by mass spectrometry. Using a combination of 
affinity purification with two-dimensional and/or one-dimensional electrophoresis followed 
by mass spectrometry-based identification, we reported novel interacting partners of 
C/EBPα as shown in Fig. 6. 
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Fig 6: The proteomics approach employed to detect interacting proteins of the myeloid 
transcription factor C/EBPα. 
 
2.8 Protein identification 
2.8.1 By peptide mass fingerprinting (PMF) 
In this technique, the mass of peptides from a tryptic-digested protein are determined using 
MALDI-TOF mass spectrometry. Here, no information about peptide sequence is 
22 
 
generated but the set of measured peptides for that protein is characterized and can serve as 
a fingerprint that enables its identification 96. Proteins are identified by a statistically 
significant overlap between the experimentally determined and theoretically predicted 
peptide masses. Peptide mass fingerprinting works by the statistical rationale that although 
a single peptide mass might correspond to many different peptides in many different 
proteins, it is extremely unlikely that the same set of peptide masses would be found in a 
number of different (random) proteins by chance. The advantages of the technique are that 
it is experimentally simple to perform, very sensitive, fast and that the results are usually 
straightforward to interpret. The downsides are the statistical limitations imposed by the 
method. These include the requirement that the majority of the coding sequence (> 80%) of 
a protein has to be present in a database and that a sufficiently high number of peptides 
must be detected in the experiment. For the analysis of protein complexes, this means that 
PMF can only be used in conjunction with 1D or 2D gels as an initial protein separation 
step 97. 
 
2.8.2 By tandem mass spectrometry 
An alternative approach that overcomes some of the limitations of peptide mass 
fingerprinting (PMF) uses a combination of partial peptide sequence and mass information 
for protein identification (tandem MS or MS/MS). In this technique, the mass of a 
particular peptide is measured first, and then the peptide is isolated from the mixture 
(within the mass spectrometer) and subjected to collisions with inert gas molecules. These 
collisions result in cleavage of the peptide along the peptide backbone and create a set of 
fragments that differ in length by one amino acid each. The masses of the fragments can 
again be measured within the mass spectrometer to produce a series of signals which 
correspond in mass to adjacent amino-acid residues in the sequence. Quite often, only a 
part of the sequence can be read from the sequence. However, this stretch of consecutive 
sequence is locked within the peptide by the masses of the fragments that define the 
beginning and the end of the determined sequence. Information on peptide sequence, 
peptide mass and fragment mass can be queried simultaneously against a database in which 
the fragmentation patterns of all peptides derived from all proteins in that database are 
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computed and compared to the experimentally determined spectrum in order to identify the 
underlying protein 98,99. Each analyzed peptide independently identifies a given protein 
provided that this peptide sequence is unique. Analysis of many peptides of the digested 
protein can confirm the identification of a protein or identify a different protein that 
happens to be part of the mixture. Even a consecutive sequence read of three or four amino 
acids from a single partially sequenced peptide can be sufficient for protein identification. 
 
We have combined tandem mass spectrometry with nano-LC (liquid chromatography) 
peptide separation 100. NanoLC-MS is much more amenable to automation, provides 
enhanced sequence coverage of a protein (for example, analysis of post-translational 
modifications) and generally allows more efficient handling of complex mixtures 
especially if the relative quantities of proteins in the sample are very different. NanoLC-
MS provides a sufficient dynamic range to allow the identification of proteins that 
constitute as little as 2–5% of the total protein mixture 97. 
 
The above described strategies were applied to the identification of the protein partners of 
C/EBPα. Since C/EBPα plays a critical role in the activation of multiple signaling 
pathways, determination of its interacting proteins and those that form the complex of 
proteins within its 'interactome' may provide novel insights into its function, as well as 
reveal potential targets for novel therapies. Moreover, the identification of protein partners 
interacting with a given protein will lead to the description of cellular mechanisms at the 
molecular level. 
 
2.9 TIP60 
It has become increasingly evident that the regulation of gene expression and hence cellular 
differentiation involve a fine balance of histone acetylation and deacetylation mediated by 
transcription factors 101. Reports have suggested that C/EBPα uses these mechanisms for 
transcriptional regulation 77,102. In our efforts to identify interacting partners of C/EBPα, we 
identified the histone acetyltransferase TIP60. The identification of TIP60 as a novel 
interacting partner of C/EBPα is intriguing because TIP60 has been shown to be an 
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interacting partner of MYC and E2F. In these interactions, TIP60 is recruited by MYC and 
E2F to the promoter of target genes 103,104.  In addition, TIP60 is known both as a 
coactivator 105 and corepressor 106 for a number of different transcription factors. 
Furthermore, TIP60 is part of the NuA4 DNA repair complex 107. Based on these findings, 
we selected the C/EBPα - TIP60 interaction for further characterization. 
2.10 MCM5 
Among others, we also identified the cell cycle regulator protein MCM5 as an interacting 
protein of C/EBPα. MCM5 is a member of the minichromosome maintenance (MCM) 
family of proteins. Initiation of DNA replication requires the function of MCM gene 
products, which participate in ensuring that DNA replication occurs only once during the 
cell cycle. MCM5 has been found to be upregulated in a human leukemia cell line that is 
resistant to doxorubicin, an anthracycline anticancer agent 108. 
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 3 MATERIALS 
 
3.1 Biological material 
3.1.1 Bacteria 
• Escherichia coli DH5α 
• Escherichia coli BL21 
3.1.2 Patient samples 
Leukemia patient samples analysed by microarray were referred to the Laboratory for 
Leukemia Diagnostics, Department of Internal Medicine III, Hospital Grosshadern, for 
routine cytomorphologic and cytogenetic analyses. All samples were from the time of 
diagnosis and selected for mononuclear cells by Ficoll gradient separation. Microarray 
analysis was performed as described 109. 
3.1.3 Mammalian Cell lines 
• 293T (human embryonic kidney fibroblast cell line) 
• U937 (human myeloid cell line) 
• K562 C/EBPα-ER (β-estradiol inducible C/EBPα, Kind gift from D G Tenen) 
 
3.2 Cell culture media 
50 ml heat-inactivated FBS (56ºC, 30 min), sterile filtered. 
5 ml penicillin/streptomycin solution (10,000 U penicillin/ml, 10 mg/ml, respectively) 
RPMI 1640 or DMEM to complete 500 ml volume  
 
3.3 Chemicals, Commercial solutions 
Table 4a: 
Reagents Suppliers 
β-Estradiol Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
26 
 
2,5-Dihydroxy-Benzoic Acid Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
2-Hydroxy-5-Methoxy-Benzoic Acid Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Acetic Acid Merck, Darmstadt, Germany 
Acetonitrile Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Acetyl Co A Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ammonium bicarbonate Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ammonium persulfate Fluka-Sigma Chemie GmbH, Steinheim, Germany 
Ampicillin sodium salt Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Amplify solution Amersham Biosciences, U.K. 
Aprotinin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Boric acid Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Bradford assay buffer Biorad Laboratories, Germany 
Bromophenol blue Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Cesium chloride  MP Biomedicals Inc., Ohio, USA 
Chloroform Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Chymostatin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Colloidal Commassie Blue G-250 Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Deoxycholate sodium salt  Merck, Darmstadt, Germany 
Deoxynucleotide Triphosphates (dNTPs) Promega Corporation, Madison, USA 
Deoxyribonuclease I, Amplification grade Invitrogen Life Technologies, Karlsruhe, Germany 
Dialysis bag Carl Roth GmbH, Karlsruhe, Germany 
Dimethyl Sulfoxide Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Dithioerythritol (DTE) Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Merck, Darmstadt, Germany 
DNA fish sperm SERVA Electrophoresis GmbH, Heidelberg, Germany 
ECL detection kit Amersham Biosciences, Uppsala, Sweden 
ECL hyperfilm Amersham Biosciences, Uppsala, Sweden 
Ethanol Merck, Darmstadt, Germany 
Ethylene Glycol bis (2-aminoethyl ether)-
N,N,N'N'-Tetra acetic Acid 
Merck, Darmstadt, Germany 
Ethylenediamine Tetra-Acetic Acid (EDTA) Merck, Darmstadt, Germany 
Fetal Bovine Serum Gibco BRL, Life Technologies. Paisley, Scotland 
Formaldehyde Merck, Darmstadt, Germany 
Giemsa’s solution Merck, Darmstadt, Germany 
Glass beads, 150-212 μm Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
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Glycerol MP Biomedicals Inc., Ohio, USA 
Glycine ICN Biomedicals GmbH, Eschwege, Germany 
Glycogen Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
GST sepharose beads 4B Amersham Biosciences, Uppsala, Sweden 
HEPES Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
IGEPAL® CA-630  Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Immobilin dry strips (IPG strips, pH 3-10) Amersham Biosciences, Uppsala, Sweden 
Immobilon-P, PVDF (0.45µm) Millipore. Billerica, Massachusetts, USA 
Isopropyl-beta-D-thiogalactopyranoside (IPTG) Biomol GmbH, Hamburg, Germany 
Leupeptin hydrochloride Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Lipofactamine™ transfection reagent Invitrogen Life Technologies, Karlsruhe, Germany 
Lithium Chloride Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Luria Agar Gibco-BRL, Paisley, Scotland 
Luria Broth Base Gibco-BRL, Paisley, Scotland 
Lysozyme Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
May-Grünwald’s eosine-methylene blue solution 
modified 
Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 
Milk powder Merck, Darmstadt, Germany 
Nonidet® P 40 (NP40) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Orange G MP Biomedicals Inc., Ohio, USA 
P81 Phosphocellulose squares Upstate, Biomol GmbH, Hamburg, Germany 
Penicilin/Streptomycin PAN Biotech GmbH, Aidenbach, Germany 
Pepstatin A Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Phenol-chloroform  Carl Roth GmbH, Karlsruhe, Germany 
Phenylmethanesulfonyl fluoride  (PMSF) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Phosphatase inhibitor Cocktail I Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Phosphatase inhibitor Cocktail II Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
PLUS™ reagent Invitrogen Life Technologies, Karlsruhe, Germany 
PolyFect® Transfection Reagent Qiagen GmbH, Hilden, Germany 
Ponceau S  Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Potassium ferricyanide Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Propidium iodide Calbiochem, San Diego, USA 
Protease Inhibitor Cocktail Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Protein agarose beads  A/G Roche Molecular Diagnostics, Germany 
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Proteinase K Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Puromycin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Puromycin Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
QIAshredder™  Qiagen GmbH, Saint Louis, USA 
Resolyte buffer (Rehydration buffer) Amersham Biosciences, Uppsala, Sweden 
Restriction enzymes and buffers New England Biolabs, Frankfurt, Germany 
Retionic acid (ATRA) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Rnasein Promega, Mannhein, Germamy 
Rotiphorese® Gel 30 (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
Rotiphorese® NF-Acrylamid/Bis 40 % (19:1) Carl Roth GmbH, Karlsruhe, Germany 
RPMI 1640 PAN Biotech GmbH, Aidenbach, Germany 
S.O.C. Medium Invitrogen Life Technologies, Karlsruhe, Germany 
SeeBlue®Plus Invitrogen life technologies, Karlsruhe, Germany 
Silver nitrate Merck, Darmstadt, Germany 
Sodium acetate Sigma-Aldrich, Steinheim, Germany 
Sodium azide Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium carbonate Merck, Darmstadt, Germany 
Sodium chloride Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium Dodecyl Sulphate (SDS) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium fluoride Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium hydroxide Merck, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium pyrophosphate tetrabasic decahydrate Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Sodium thiosulfate Merck, Darmstadt, Germany 
Taq DNA Polymerase New England Biolabs, Frankfurt, Germany 
Taq DNA Polymerase Qiagen GmbH, Hilden, Germany 
TEMED Carl Roth GmbH, Karlsruhe, Germany 
Trifluoroacetic acid  Merck, Darmstadt, Germany 
Trifluoroacetic Acid (TFA) Merck, Darmstadt, Germany 
TRIS – (hydroxymethl)-aminomethane ICN Biomedicals GmbH, Eschwege, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypan Blue solution Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Trypsin Gold, Mass Spectrometry Grade Promega Corporation, Madison, USA 
Trypsin/EDTA PAN Biotech GmbH, Aidenbach, Germany 
Tween®20 Carl Roth GmbH, Karlsruhe, Germany 
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Tween-20 Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Urea Plus Amersham Biosciences, Uppsala, Sweden 
α-cyano-5-hydroxy cinnamic acid (4-HCCA) 
matrix 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
 
3.4 Kits 
Table 4b: 
Kits Suppliers 
Cell Line Nucleofector Kit V AMAXA GmbH, Cologne, Germany 
Dual-Luciferase® Reporter Assay System Promega Corporation, Madison, USA 
Endofree®Plasmid Maxi Kit Qiagen GmbH, Hilden, Germany 
HiSpeed Plasmid Maxi Kit Qiagen GmbH, Hilden, Germany 
MALDI Plate Cleaning Kit Amersham Biosciences, Uppsala, Sweden 
QIAprep Spin Miniprep Kit Qiagen GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit  Qiagen GmbH, Hilden, Germany 
ThermoScript™ RT PCR System Plus Platinum® 
Taq DNA Polymerase  
Invitrogen Life Technologies, Karlsruhe, Germany 
TNT® T7/SP6 Coupled Reticulocyte Lysate 
System 
Promega Corporation, Madison, USA  
TRIzol® Reagent  Invitrogen Life Technologies, Karlsruhe, Germany 
ZipTip with 0.2 µL C18 resin Millipore. Billerica, Massachusetts, USA 
 
3.5 Radioactive Substances 
Table 4c: 
Radioactive Substances Suppliers 
[3H] Acetyl coenzyme A MP Biomedicals Inc. Irvine, USA 
L-35S Methionine MP Biomedicals Inc. Irvine, USA  
α-32P-dCTP Amersham Biosciences, Braunschweig, Germany 
 
3.6 Markers/Ladders 
Table 4d: 
Markers/Ladders Suppliers 
DNA 100bp ladder  New England Biolabs, Frankfurt, Germany 
DNA 1kb ladder Invitrogen Life Technologies, Karlsruhe, Germany 
DNA PCR marker New England Biolabs, Frankfurt, Germany 
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Protein marker Amersham Biosciences Braunschweig, Germany 
 
 
3.7 Labwares 
Table 4e: 
Labwares Suppliers 
2-D gel apparatus Bio-rad, Germany 
Blotting paper Schleicher and Schüll, Stuttgart, Germany 
Cell culture material Costar, Cell star, Nunc, Sarstedt, Greiner 
Filters Millipore 
IPGphore  Amersham Biosciences Braunschweig, Germany 
Nunc Cryotube™ vials Nalge Nunc International, Denmark 
Pipette Tipps Star Labs (K &K labordarf), Munich, Germany 
Plastic matreial (tubes etc) Eppendorf, Greiner, Falcon, Munich, Germany 
Reaction tubes Eppendorf, Costar, Germany 
Ultra centrifuge tubes Beckman 
X-ray films Kodak (Biomax) 
Automatic Gel-stainer  Hoefer Hoefer Pharmacia Biotech, San Francisco, USA 
 
3.8 Antibodies 
Table 5. 
Antibody Isotype Supplier 
C/EBPα (14aa) Rabbit Polyclonal IgG; Primary Santa Cruz Biotechnology 
TIP60 (K-17) Goat Polyclonal IgG; Primary Santa Cruz Biotechnology 
TIP60 (N-17) Goat Polyclonal IgG; Primary Santa Cruz Biotechnology 
Anti-GFP Rabbit Polyclonal IgG; Primary Invitrogen, Molecular Probes 
Pan-Acetyl (C2) Goat Polyclonal IgG; Primary Santa Cruz Biotechnology 
Normal IgG  Goat Santa Cruz Biotechnology 
Normal IgG  Rabbit Santa Cruz Biotechnology 
Anti-acetyl Histone H3 Rabbit Polyclonal IgG Upstate, Biomol GmbH 
Anti-acetyl Histone H4 Rabbit antiserum  Upstate, Biomol GmbH 
MCM5 Rat Monoclonal IgG; Primary Alloys Scheppers, GSF, Munich 
PU.1 Rabbit Polyclonal IgG; Primary Santa Cruz Biotechnology 
β-tubulin (H-235) Rabbit IgG Santa Cruz Biotechnology 
Anti-human CD11b (Mac-1) Mouse Monoclonal IgG1; APC BD Pharmingen 
Anti-human CD11b (Mac-1) Mouse Monoclonal IgG1; PE BD Pharmingen 
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Anti Goat IgG Donkey IgG; HRP conjugated; Secondary Santa Cruz Biotechnology 
Anti Rat IgG Goat IgG; HRP conjugated; Secondary Santa Cruz Biotechnology 
Anti Rabbit IgG Goat IgG; HRP conjugated; Secondary Santa Cruz Biotechnology 
Anti Rabbit IgG Donkey IgG; HRP conjugated; Secondary Amersham Biosciences 
 
 
3.9 Plasmid Constructs 
In this article we used GST (pGEX4T, expressing a GST fusion protein in bacteria, 
Amersham, UK), GST-DBD, GST-C/EBPα (kind gift from Dr. Claus Nerlov); pCDNA3-
human C/EBPα was previously described 47, GST-TIP60, YFP-N1-TIP60 (pEYFP-N1, 
expressing a yellow fluorescence fusion protein in mammalian cells, Clontech, USA), YFP 
N1-TIP60 (-HAT), pCDNA3 TIP60, p(C/EBP)2TK (luciferase reporter plasmid with two 
CCAAT binding sites), pTK (luciferase reporter plasmid, Promega, USA), pRL null, 
pGAL4 luc, pC/EBPα GAL4DBD (vector expressing a GAL4DNA activation domain 
fusion protein , Clontech, USA), GAL4 VP16 (yeast activator GAL4 fused to a highly 
acidic portion of the herpes simplex virus protein VP16 and is potent transcriptional 
activator on pGAL4 luc promoter), and PCMV5 (Stratagene, USA) 
 
3.10 Buffers 
 
Buffers provided with the kits were used in the case of plasmid isolation, protein 
expression, RNA isolation, and polymerase chain reaction. The other buffers used are listed 
below. 
 
 
Electrophoresis buffer (SDS-PAGE)  25 mM Tris/HCl, [pH 8.3] 
      250 mM Glycine 
      0.1 % SDS 
 
Gel fixer solution    50 % Methanol 
      10 % Acetic acid 
 
Staining solution    30 % Methanol 
      10 % Acetic acid 
      0.25 % Coomassie-Blue R-250 
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Destaining solution    30 % Methanol 
      10 % Acetic acid 
 
Gel fixer solution (2-D)   50 % Methanol 
      12 % Acetic acid 
      500 µl formaldehyde (37%)/l 
 
Washing solution (2-D)   50 % Ethanol (three times, 20 min each) 
 
Sensitizinng solution (2-D)   200 mg/ml Sodium thiosulphate (1 min) 
 
Staining solution (2-D) 2 g/l Silver nitrate, 500 µl formaldehyde (37 
%)/l 
      (20 min) 
 
Destaining solution (2-D)   50 % Methanol 
      12 % Acetic acid 
 
Storage solution (2-D)   1 % Acetic acid 
 
Electrophoresis buffer (Tris-Glycine) 250 mM Tris/HCl, [pH 8.3] 
      1.9 M Glycine 
      10 mM EDTA 
 
Tris-Borate buffer    0.89 M Tris 
      0.89 M Boric acid 
      0.5 M EDTA 
 
SDS-PAGE gel loading dye (2×)  125 mM Tris/HCl, [pH 6.8] 
      4 % SDS 
      10 % ß-Mercaptoethanol 
      30 % Glycerol 
      0.004 % Bromophenol blue 
 
Western Stripping solution   0.1 M ß Mercaptoethanol 
      2 % SDS 
      1 M Tris, [pH 6.8] 
 
TE buffer     50 mM Tris/HCl, [pH 8.0] 
      1 mM EDTA 
 
10× Orange G dye     40 % Sucrose 
      0.2 % Orange G 
 
RIPA lysis buffer    50 mM Tris, [pH 8.0] 
      150 mM NaCl 
33 
 
      5 mM EDTA 
      1.0 % NP40 
      0.5 % Na-deoxycholate 
Protease-phosphatase inhibitors (freshly 
added) 
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 4 METHODS 
 
4.1 Cell Culture Techniques 
4.1.1 Mammalian Cell Culture 
Adherent human embyronic kidney fibroblast cells 293T were cultured in DMEM and 
suspension U937, human myeloid cell line, monoblastic cells were cultured in RPMI 
(PAA, Cölbe, Germany). Both supplied with 10% FBS (Invitrogen/GIBCO, Germany) and 
antibiotics (Penicillin/Streptomycin, GIBCO,Germany). Cells were culturd at 37ºC in a 
10% CO2 humid atmosphere. K562 ER-C/EBPα (Erythroleukemia cells stably transfected 
with a C/EBPα-ER fusion vector) were grown in RPMI without Phenol red (PAA, Cölbe, 
Germany) supplemented with 10% Charcoal treated FBS (Hyclone, Greiner, Nürtingen, 
Germany) with Puromycin (10 µg/ml) as a selection marker. 
 
4.1.2 Transient Transfection of 293T Cells 
Cells plated in 24 well plates (for luciferase assay) and in 10 cm plates (for protein lysate) 
at 70- 80% confluence were transfected with 1.2 µg (24 well) to 10 µg (protein lysate) of 
total plasmid using Polyfect transfection reagent (Qiagen) or Lipofactamine-PLUS reagent 
(Invitrogen), respectively, according to manufacturers' instructions. Cells were harvested 
24 h after transfection. 
 
4.1.3 Transient Transfection of U937 Cells 
Cells were grown at density 1 ×105 cells/ml a day before transfection. Cells were 
transfected with total 1 µg plasmid DNA using Nucleofactor Kit V according to the 
manufacturer's protocol (AMAXA). Cells were harvested after 24 h. 
 
 
 
35 
 
4.1.4 Treatment of U937 with Retionic acid 
U937 cells were induced to differentiate at 1 × 105 cells/ml by incubation with 1 μM all-
trans retinoic acid for 60 h. 
 
4.1.5 K562 ER-C/EBPα treatment with β-estradiol 
Cells were induced to differentiate at 5 × 105 cells/ml by incubation with 5 μM β-estradiol. 
 
4.2 Firefly and Renilla Luciferase Reporter Gene Assays 
Two different reporter systems were used. One for analyzing the transcriptional properties 
of proteins and protein domains which were fused to the GAL4 DNA binding domain 
(DBD). Here, the reporter plasmid pGAL4TK Luc, which contains 5 GAL4 DBD binding 
sites and a TK (Herpes simplex virus thymidine kinase) minimal promoter followed by the 
firefly luciferase reporter gene, was used. The other reporter system used a reporter plasmid 
with two C/EBPα binding sites upstream of the firefly luciferase gene p(C/EBP)2TK. To 
control for transfection efficiency, the pRL-null plasmid, which encodes the Renilla 
luciferase under the control of a minimal promoter, was used. In order to analyze the 
significance of protein-protein interactions on the transcriptional activity of C/EBPα, 
reporter gene assays were performed in which C/EBPα or C/EBPα GAL4DBD were 
cotransfected with TIP60 and/or its HAT mutant in HEK 293T cells. 293T cells were 
transfected using Polyfect (Qiagen) and U937 cells using nucleofactor Kit V (AMAXA) 
according to the manufacturer's instructions. Firefly luciferase activities from the constructs 
pGal4-luc, pTK, and p(C/EBP)2TK and Renilla luciferase activity from the internal control 
plasmid pRL-null were determined 24 h after the initiation of the transfection protocols 
using the dual-luciferase reporter assay system (Promega). Firefly luciferase activities were 
normalized to the Renilla luciferase values 110. The DNA concentrations of the reporter 
constructs and expression plasmids used for Polyfect transfections were 0.1 µg of pGal4-
luc, pTK, or p(C/EBP)2TK, 0.01 µg of the internal control plasmid pRL-null, 0.1 µg of the 
expression plasmids for C/EBPα and 0.05 µg, 0.1 µg, 0.25 µg for pYFP-N1-TIP60(w), 
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pYFP-N1-TIP60(-HAT) and 0.1 µg, 0.2 µg, 0.3 µg for C/EBPα-GAL4DBD. The same 
concentrations of the empty expression vectors were used as controls. 
 
4.3 Immunoblotting 
SDS PAGE (Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis) was carried 
out according to standard procedures. Proteins were transferred to PVDF membranes 
(Millipore) at 110 V for 90 min. Membranes were incubated in blocking solution (TBS, 0.1 
% Tween-20, 5 % w/v milk powder) for at least 1 hour, followed by incubation in blocking 
solution containing the appropriate antibody (see Materials) for at least 1 hour at RT or 
overnight at 4ºC. After washing 3 times for 10 min at RT with TBS containing 0.1 % 
Tween-20 and 2.5 % w/v milk powder, the membranes were incubated in blocking solution 
containing the appropriate, HRP-conjugated secondary antibody for at least 1 h. After 
washing 3 times for 15 min at RT with TBS containing 0.1 % Tween-20, protein bands 
were detected by enhanced chemoluminescence (ECL; Amersham) according to the 
manufacturer’s protocol. 
 
4.4 Preparation of Nuclear Extracts 
Cells were washed with PBS and then subjected to lysed with Buffer A (20 mM Tris/HCl 
[pH 8.0], 10 mM NaCl, 3 mM MgCl2, 0.1 % NP40, 10 % glyceol, 0.2 mM EDTA, 1 mM 
DTT and proteases-phosphatase inhibitors cocktail) for 15 min on ice with occasional 
mixing. Nuclei were pelleted by centrifugation in a tabletop centrifuge at 2,000 rpm for 5 
min at 4°C. The proteins were then extracted from the nuclei by incubation at 4°C with 
snap freeze-thawing three times in buffer C (20 mM Tris/HCl [pH 8.0], 400 mM NaCl, 20 
% glyceol, 0.2 mM EDTA, 1 mM DTT, and proteases-phosphatase inhibitors cocktail). 
Nuclear debris was pelleted by centrifugation at 14,000 × g for 15 min at 4°C, and the 
supernatant extract was aliquoted, snap frozen, and stored at -70°C or used directly for the 
experiments. 
 
4.5 GST-Pull Down 
For the pull down experiments the U937 cell line ws used. These cells can be induced to 
differentiate from their immature state to cells resembling more morphologically and 
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functionally mature monocytes, macrophages, and granulocytes. Nuclear extract from 
U937 cells was prepared as described above. Equal amounts of bacterially purified proteins 
were incubated with 1 mg of nuclear extract (volume made up to 1 ml with NETN buffer) 
for 3 h at 4°C. After pull down, protein bound beads were washed 3 times with NETN 
buffer at 10 rpm on a rotating shaker for 5 minutes at 4°C. Beads were lysed in urea lysis 
buffer (66 % Urea plus one, 1 % DTE, 4 % CHAPS, 2.5 mM EDTA, 2.5 mM EGTA) to 
completely denature the interacting proteins which were then applied for 1-D and 2-D 
separation in a pH range of 3-10. In addition, S35-Methionine labelled in-vitro translated 
C/EBPα was pulled down with GST-fusion protein TIP60 by incubating for 3 hours, 
separated on 12 % SDS PAGE and detected by autoradiography using Kodak films. 
 
4.6 Co-Immunoprecipitation 
Co-immunoprecipitation is an in-vitro biochemical assay which was used to detect in-vivo 
interactions. For TIP60, 293T cells were transfected at a density of 1× 106 cells in 10 cm 
plates. The cells were transfected with Polyfect with expression plasmids of human 
C/EBP  and pYFP-N1-TIP60. 24 h after transfection, cells were scraped off with a cell 
scraper. Cells were washed with PBS and then subjected to lysis for nuclear extracts as 
described above. 300 µg nuclear extracts was incubated with 40 µl of 50 % protein G 
agarose beads slurry and precleared using a goat isotype IgG antibody (2 µg) with mild 
agitation at 4°C. The supernatants were then added to the Protein G agarose beads 
preincubated with antibodies against TIP60 protein (Santa Cruz; sc-5725 [N-terminal] and 
sc-5727 [C-terminal], 1 µg each, mixed together, as we observed only weak precipitation 
using only one antibody) for 4 h followed by extensive washes in coimmunoprecipitation 
buffer (50 mM Tris/HCl [pH 7.5], 150 mM NaCl, 0.5 % NP-40, 0.25% sodium 
deoxycholate, and proteinase-phosphatases inhibitor cocktail). The corresponding IgG goat 
served as a control. Immunoprecipitated proteins were heated at 56°C for 90 min in 2× 
SDS loading buffer and then boiled at 95°C for 5 minutes before being loaded on the SDS 
PAGE. Western blot analysis was performed with a rabbit anti-C/EBPα polyclonal 
antibody and a rabbit anti-GFP monoclonal antibody. 
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In order to immunoprecipitate MCM5, U937 cells were lysed in RIPA buffer. 600µg of 
U937 lysate were used to co-immunoprecipitate MCM5 using an C/EBPα antibody in the 
Co-IP buffer (50 mM Tris/HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 5 % glycerol, 0.25 
% NP-40, and proteinase inhibitor cocktail). Incubation was for overnight at 4ºC followed 
by extensive washes in Co-IP buffer. We used 5 0 µl slurry of protein A agarose beads and 
2 µg of the anti C/EBPα antibody. Denatured proteins were subsequently separated on 12 
% SDS PAGE and immunoblotted with rat monoclonal anti-MCM5 and anti C/EBPα 
antibody. 
 
4.7 GST-Purification 
Full length C/EBPα and TIP60 were cloned is in frame with the Glutathione-S-Transferase 
(GST) in the pGEX bacterial expression vector (Amersham Biosciences, Germany). Fusion 
proteins were expressed in the BL21 E. coli bacterial strain after 0.5 mM IPTG induction 
for 2 hours. The bacterial pellet was lysed in NETN buffer (150 mM NaCl, 20 mM 
Tris/HCl [pH 8.0], 1 mM EDTA [pH 8.0], 0.1 % NP40 and protease inhibitors cocktail) 
and sonicated, followed by protein purification using immobilised Glutathione Sepharose 
4B beads (Amersham Biosciences, USA). Sepharose beads bound with GST proteins were 
washed 4 times with NETN buffer on a rotating shaker at 4°C for 10 minutes each and then 
lysed in 2× SDS sample loading buffer (125 mM Tris [pH 6.8], 4 % SDS, 20 % glycerol, 
10 % 2 β-mercaptoethanol and 0.03 % bromophenol blue). Subsequently proteins were 
separated on 12 % SDS PAGE  and visualised by Coomassie blue staining. 
 
4.8 Interaction assay with radiolabelled proteins 
C/EBPα was in vitro transcribed and translated in the presence of [35S] methionine by using 
the T7 coupled reticulocyte lysate system (Promega) according to the manufacturer's 
instructions. GST purification for TIP60 was performed as described above. 
 
4.9 Histone Acetyltransferase (HAT) Assay 
HAT assays were performed similarly to previously published protocols 111. Cell culture 
and GST protein purification was performed as described above. For the filter binding 
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assay, acetylation reactions contained 1 μg of recombinant Drosophila histones (Kind gift 
from Axel Imhof) or GST-C/EBPα, 0.25 μCi of [3H] acetyl-CoA, (Amersham; e.g. 0.2 to 
0.4 μl of 2-10 Ci/mmol) with 100 ng (1 μl) GST-TIP60 in 10 mM Tris [pH 8.0], 0.1 mM 
EDTA, 1 mM DTT, 1 mM PMSF, 10 mM sodium butyrate, and 5 % glycerol in a total 50 
μl volume. The yeast Hat1 protein (kind gift from Axel Imhof) was used as positive control 
for the acetylation reactions. Reactions were incubated at 37°C for 30 min, spotted onto 
phosphocellullose p81 filters and allowed to air dry. Purified histones (provided by Axel 
Imhof) were used as positive control for acetylation reaction by GST-TIP60 and by yeast 
Hat1 protein. Dry filters were washed three times for 5 min at RT with 50 mM sodium 
carbonate/bicarbonate buffer (Na2CO3/NaHCO3 ) [pH 9.2], and then rinsed in acetone to 
remove unincorporated radioactive acetyl-CoA. The filters were air dried. The filters were 
then placed in scintillation vials, and 2 mls of scintillation fluid was added. After 
incubating the vials at RT for 10 min, the amount of incorporated radioactivity was 
determined using a liquid scintillation counter. 
For non-radiaoactive acetylation experiments, 5 μM non-radioactive acetyl-CoA was used. 
In the Western blot acetylation assays, reactions were separated by 10 % SDS-PAGE, 
proteins were transferred onto a PVDF (0.22 μM pore size) and then probed with 
antibodies specific to acetylated lysines (Pan acetyl, Santa Cruz Biotechnology, USA). 
4.10 Determination of DNA concentration 
The DNA concentration was determined either by spectrophotometry or by comparing 
different dilutions of DNA with a standard amount of DNA in an agarose gel. 
4.11 FACS (Florescence activated cell sorting) analysis 
U937 cells were induces with retinoic acid for 60 h, followed by FACS analysis. For each 
flow cytometry analysis, 4×106 cells were washed twice in washing buffer (plain RPMI, 1 
% FBS) and resuspended in 100 µl of washing buffer with 6 µl of the Cd11b APC or PE 
labelled antibody. Incubation was performed at 4ºC for 30 min. Cells were washed and 
resuspended in washing buffer with PI (propidium iodide, 0.1 %) and were analyzed by 
flow cytometry on a BD FACS Calibur System (BD Biosciences, Palo Alto, CA). 
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 4.12 Semi-quantitative RT-PCR 
Expression of TIP60, CEBPA and CEBPE were assayed by RT-PCR in induced (U937 + 
RA, 1 µM, CD11b+) and uninduced (U937, C11b-) flow-sorted cells (BD FACSVantage SE 
System; BD Biosciences, Palo Alto, CA). Total RNA was isolated using Trizol reagent 
(GIBCO BRL) and treated with DNase I (amp grade) to remove contaminating genomic 
DNA. First strand cDNA was synthesized from 1 μg total RNA using the thermoScript RT-
PCR system (all reagents from Invitrogen GmbH, Karlsruhe, Germany). Equal amounts of 
cDNA originating from 50 ng starting RNA were loaded on to an Ethidium bromide gel to 
quantitate the RNA before amplification. The annealing temperature was 60°C for CEBPA 
and CEBPE and 52°C for TIP60. The number of PCR cycles for each gene was chosen to 
stop the reaction in the logarithmic phase of amplification (22 cycles for β-tubulin, 30 
cycles for TIP60, CEBPA and CEBPE).  
Primer sequence for TIP60: 
TIP60_Ex7_Sense  5'- CACATCGTGGGCTACTTCT-3' 
TIP60_Ex9_ASsense  5'- TGTTTTCCCTTCCACTTTGG -3' 
Expected size: 150 bp 
Primer sequence for CEBPA 112 
CEBPA_Sense  5'- AAGGTGCTGGAGCTGACCAG -3' 
CEBPA_ASense  5'- AATCTCCTAGTCCTGGCTCG -3' 
Expected size: 255 bp 
Primer sequence for CEBPE 112 
CEBPE_Sense   5'- AGTCTGGGGAAGAGCAGCTTC -3' 
CEBPE_ASense   5'- ACAGTGTGCCACTTGGTACTG -3' 
Expected size: 305 bp 
Primer sequence for β-tubulin: 
41 
 
β-actin _Sense   5'-CTTCAACACCCCAGCCAT-3' 
β-actin _ΑSense   5'-TAATGTCACGCACGATTTCC-3' 
Expected size: 285 bp 
 
4.13 Expression analysis of TIP60 and C/ΕΒPα in leukemia samples 
Total mRNA was isolated from patient samples, processed and analyzed on the Affymetrix 
HG-U133A and HG-U133B chips as described before 109. The .CEL file data from the 
samples used in the comparison were normalized together according to the procedure 
described by Huber et al., 113. Normalized expression data were then analyzed with the R 
software package and the "boxplot" function (www.r-project.org). Expression signal 
intensities are given on a logarithmic scale. Ten samples from each leukemic subgroup as 
well as ten normal bone marrow samples were included in the analysis. The leukemic 
subgroups were: chronic myeloid leukemia (CML), AML with the CBF/MYH11 fusion 
gene (AML_M4), with the PML/RARA fusion gene (AML_M3), and AML with the 
AML1/ETO fusion gene (AML_M2). 
 
4.14 Chromatin Immunoprecipitation (ChIP Assay) 
The ChIP assay is a technique used to map the location of modified histones and other 
DNA interactiong proteins in the genome. In these experiments antibodies are used that 
recognise and bind to the protein of interest, not only in free solution, but also when 
contained in chromatin. The ChIP assay is composed of two steps — first, in vivo 
formaldehyde cross-linking of whole cells which stabilizes protein-protein and protein-
DNA interactions, followed by immunoprecipitation of protein-DNA complexes with 
specific antibodies from sonicated extracts followed by a reversal of the cross-linking, and 
amplification of precipitated DNA (Fig. 7). 
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Fig 7: General principle of Chromatin ImmunoPrecipitation assay 
 
Suspension cultures of human K562 C/EBPα-ER cells induced with β-estradiol (5 µM, 6 h) 
were used to prepare cross-linked extracts. Formaldehyde (37 %) was added directly to the 
cultured cells (approx. 5×105 cells/ml, 150 ml medium), i.e. four confluent flasks of K562 
ER-C/EBPα cells per time-out for ChIP (triplicates) to a final concentration of 1 % . Then 
the cells were gently fixed at RT for 9 min on a roller. Fixation was stopped by the addition 
of glycine to final concentration of 0.125 M, and the cells were then immediately 
transferred on ice. Cells were rinsed twice with PBS at 4ºC. PBS was aspirated completely, 
and the harvested cells were either stored at -80ºC or used directly for lysis in 10 ml of 
sonication buffer (Buffer A: 50 mM HEPES-KOH [pH 7.9], 140 mM NaCl, 1 mM EDTA 
[pH 8.0], 1% Triton, 0.1% Sodium deoxycholate, 1 mM PMSF) with the addition of glass 
beads. Cross linked material was sonicated (Branson Sonifer) in an ice-ethanol bath to an 
average DNA length of 500-1000 bp (4 min total time, 0.5 sec on, 1 sec off, 30% 
amplitude). Samples were centrifuged for 10 min at 3500 rpm to remove glass beads. 
Lysates were collected and adjust to 0.5 % sarcosyl and 1.42 g/cm3 CsCl and run on a CsCl 
gradient (Beckman SW 41 swinginng bucket rotor) at 38,000 rpm for 36 h at 18ºC as 
described previously 114. After centrifugation, the centrifuge tube was punctured at the 
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bottom with a syringe and fractions of 500-800 µl were collected. An aliquot from these 
fractions were adjusted to NaCl concentration 500 mM and incubated for 2 h at 65ºC to 
remove cross-links and were checked on a eithidum bromide stained 0.8% agarose gel for 
DNA size. Fractions in the size range of 500 - 1.5 kb were pooled and dialysed overnight 
against buffer D (Dialysis buffer: 5% glycerol, 1 mM EDTA, 10 mM Tris/HCl [pH 8.0], 1 
mM PMF, 4ºC). The optical density (O.D.) of the samples was measured, and then the 
samples were stored at -80ºC. These fractions represent the cross linked whole cell extracts 
ready for immunoprecipitation. OD 1.5 fraction (1.5 A260) was adjusted to buffer A in a 
total volume of 1 ml. As a pre clearing step, 120 µl of slurry (equilibrated with buffer A, 30 
µl of protein G sephrose, 500 ng/ml BSA, and salmon sperm DNA [sonicated to an average 
size of 2-5kb] 10 µg/ml) was added and incubated for 2 h at 4ºC. Protein G sephrose was 
removed by centrifugation at 2000 rpm. Precleared lysates were then used for 
immunoprecipitation with the appropriate antibodies (10 µg of C/EBPα, TIP 60 [K-17]. 
IgG Goat, IgG Rabbit and 4 µl of anti-acetylated histone H3 and anti acetylated histone 
H4). After immuno-precipitation (8 h), antibody bound complexes were isolated by adding 
protein G. Washed two times, 1 ml each with buffer A, (with 500 mM NaCl for anti-
acetylated histone H3 and anti acetylated histone H4 antibodies; 350 mM for C/EBPα and 
TIP60 antibodies), buffer B (10 mM Tris/HCl [pH 8.0], 250 mM LiCl, 0.5 % IGEPAL CA-
630, 0.5 % Sodium deoxycholate, 1 mM EDTA), TE buffer (10 mM Tris/HCl [pH 8.0], 1 
mM EDTA) and finally with buffer E (1 %SDS, 0.1 M NaHCO3). After extensive washing, 
complexes were eluted from the beads, cross-links were reversed. It is important to revert 
the cross-linked from a certain volume (usually 10% of that used for immunoprecipitation) 
after the the optical density determineation. This will be needed as the input control. 
Samples were adjusted to 500 mM NaCl and incubated for overnight at 65ºC to reverse the 
cross-links 6 µg of proteinase K was added and samples were adjusted to 100 mM Tris/HCl 
[pH 6.8], 50 mM EDTA, and incubated at 56ºC for 1 h. DNA was extracted by phenol-
chloroform extraction and precipitated. The samples were finally resuspended in 30 µl of 
ddH20. For the detection of immunoprecipitated C/EBPα promoter region, and as a 
control the C/EBPα coding region, PCR reactions (27 cycles) were performed with 4 µl of 
resuspended DNA in the presence of 1 µCi α32-dCTP and separated on PAGE. Primers 
used for ChIP were described previously 115. 
44 
 
 CEBPA_Prom_F  5’ ACTTCGG TACCGCTACCGACCACGTGGGCG 3’ 
CEBPA_Prom_R  5’ GTGAACTCGAGC ACCTCCGGGTCGCGAATGG 3’ 
CEBPA_cds_F  5’ATTCACTCGAGGATCCCCATGAGCGCGCTGAAGGG 
GCTG 3’ 
CEBPA_cds_R  5’ GTGAACT CGAGGTACCTCACGCGCAGTTGCCCAT 3’ 
 
4.15 2D-Gel Electrophoresis 
GST and GST-C/EBPα were incubated with nuclear extracts of the myelomonocytic cell 
line U937 in NETN buffer as described above in the GST purification section. Beads with 
their associated proteins from nuclear extract were lysed in urea lysis buffer for 1h at RT 
on a rotating shaker. Lysed beads were passed through an RNA qiashredder (Quiagen, 
Germany), and resulting supernatant containing dissolved proteins was centrifuged for 50 
minutes at 50,000 rpm at 22°C to remove DNA and other cellular debris. For the first 
dimension, 350 µl of dissolved proteins were separated on an immobilineTM dry strip pH 3-
10 by isoelectric focusing (IEF). The reduction and alkylation of separated proteins was 
carried out in urea buffer containing 2 % DTE and 2.5 % iodoacetamide. Failure in 
maintaining the proteins in a reduced state can lead to artefactual spots and/or streaking due 
to the formation of disulphide bridges 116. In many cases, streaking in the basic gradient is a 
consequence of cysteine oxidation. Artefactual modification of proteins during sample 
preparation and 2-D can mask functionally significant events within the cell and can hinder 
protein identification by MS. Several types of protein modifications have been reported to 
occur during electrophoretic separation, and among them alkylation seems to occur most 
often. Alkylation of different amino acid residues (most often of cysteine) can be caused by 
free immobiline monomers, free unpolymerised acrylamide, N-substituted acrylamide in 
the acrylamide gel or cross-linkers 117. An attractive alternative to reducing the cysteine 
residues and a possible solution to the described problems is to covalently block these 
residues either irreversibly, by alkylation, or reversibly, by oxidation to mixed disulphides 
118. After reduction and alkylation of 1D strips, proteins were separated in the second 
dimension using 12 % SDS PAGE on the basis of their size (relative molecular weight). 2D 
gels were silver stained to visualise the protein spots. In silver staining, treatment with 
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glutaraldehyde (cross-linking and sensitizing agent) was omitted. Instead the gel was 
sensitized by sodium thiosulfate. 
 
4.16 1D SDS-PAGE 
1-D SDS-PAGE of the GST pull down samples (pull down were carried as described 
before) with 1 mg of U937 nuclear extracts was carried out according to the Laemmli 
method. The beads were dissolved in a modified Laemmli buffer (3 % SDS, 10 % glycerol, 
0.1 % bromophenol blue, 100 mM Tris-HCl, [pH 6.8]. Proteins were denatured by 
incubation at 100ºC for 5 min, and were separated on a 12 % bis-tris polyacrylamide gel. 
Protein lanes were visualised by Coomassie R- 250 staining. 
 
4.17 Destaining protocol for Trypsin in-gel digestion 
To promote efficient enzymatic cleavage and to reduce the background for subsequent 
mass spectrometric analysis, any excessive stain must be carefully removed. Differentially 
expressed silver stained protein spots from 2-D gel electrophoresis were excised with cut 
pipette tip and were transferred to a 0.65 ml polypropylene Eppendorf tube. Excess water 
was removed and samples were washed briefly with 100 mM NH4HCO3. For destaining, a 
volume of destaining solution (0.2 g potassium ferricyanide [K3Fe(CN)6] in 100 ml of 100 
mg/l sodium thiosulphate) was added sufficient to cover the gel pieces and incubated on a 
shaker until the gel was completely destained, typically 15-30 min. The gel pieces turned 
bright yellow and were washed twice with 100 mM NH4HCO3, for 10 minutes and twice 
with milli-Q water for 5 min, until the yellow color was no longer visible. Excess liquid 
was removed, and the gel was washed for 5 min with 50 % acetonitrile (ACN)/ 50 % 50 
mM NH4HCO3, and then 5 min with ACN for dehydration. Tubes were vortexed during 
incubation. The ACN was removed and the samples were air dried for 10 min or put into a 
speedvac for 1 min at RT. 
 
The protein lanes from the Coomassie stained gel was excised and thencut into small pieces 
with a scalpel on a glass plate. The gel pieces were transferred to a 0.65 ml polypropylene 
eppendorf tube and were washed briefly with 100 mM NH4HCO3 to adjust the pH. 50 % 
acetonitrile (ACN)/ 50 % 50 mM NH4HCO3 were added and the tubes were incubated in a 
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vortexer for 10 min. The liquid was replaced several times until the gel pieces appeared 
colourless. Excess liquid was then removed and the gel pieces were incubated with 100 % 
ACN for dehydration. Finally, the ACN was removed, and the samples were either air dried 
or evaporated briefly in a speedvac. The gel pieces were then processed for reduction and 
alkylation. The gel pieces were covered with 150 µl 10 mM DTT in 100 mM NH4HCO3, 
vortexed, spun briefly and incubated for 1 h at 56ºC. The tubes were cooled to room 
temperature and the DTT solution was removed and replaced with 150 µl of 50 mM of 
idoacetamide in 100 mM NH4HCO3. Tubes were vortexed, spun briefly, and incubated for 
45 min in a dark place at room temperature. The idoacetamide was then removed. Gel 
pieces were washed with 100 mM NH4HCO3 for 5 min and then twice with 50 % ACN/ 50 
% 50 mM NH4HCO3 for 5 minutes with vortexing. The gel pieces were dehydrated with 
ACN for 5 min. The ACN was removed and the gel pieces were dried in a speedvac. After 
this procedure, the gel pieces were noticeably shrunken and appeared white. 
 
4.18 Trypsin In-Gel Digestion protocol for MALDI-TOF, TOF/TOF and for 
LC-MS/MS 
The gel pieces were swollen in digestion buffer containing 12.5 ng/µl trypsin (Promega) in 
50 mM NH4HCO3 in an ice-cold bath. After 45 min, the supernatant was removed and 
replaced with 5-10 µl of the same buffer but without trypsin to keep the gel pieces wet 
during enzymatic cleavage (37ºC overnight). Peptides were extracted with 10-15 µl of 20 
mM NH4HCO3. Samples were spun down, sonicated for 5 min in a water bath. Peptide 
enriched supernatant was collected. Gel pieces were washed three times with 2 % formic 
acid in 50 % ACN (incubated for 20 min each time) at room temperature. Supernatant were 
collected and dried down in speedvac. For LC-MS/MS lyophilized peptides were dissolved 
in 20 % acetonitrile (ACN) and 0.1 % trifluoroacetic acid (TFA). 
 
4.19 Separation of Peptides by 1D nano-LC 
Peptide separations were performed on a nano-HPLC system (UltiMate, LC Packings, 
Sunnyvale, USA). A 20 ml aliquot of each sample was injected into a C18 RP trapping 
column (300 mm×65 mm, flow rate 30 ml/min) using a Famos autosampler. After elution 
onto a nano-RP column (C18, 75 mm×615 cm, flow rate 200 nl/min), the peptides were 
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separated with a gradient from 5 to 80 % ACN in 0.1 % TFA in 120 min. Fractions were 
collected at 30-s intervals directly on a 192-well MALDI target plate using a spotting robot 
(Probot, LC Packings). The eluent from the capillary column was mixed with a matrix 
solution consisting of 2 mg/ml α-Cyano-4-hydroxycinnamic acid (CHCA) matrix. 
 
4.20 Sample Preparation for Mass Spectrometry 
α-Cyano-4-hydroxycinnamic acid (CHCA) matrix preparation for MALDI-TOF: CHCA 
saturated  solution (8 mg) was mixed in 200 µl of solvent solution (50 % ACN and 0.1 % 
TFA). This mixture was vortexed for 5-10 min, spun down, and one part of this CHCA 
saturated supernatant was mixed with three part of solvent solution. This constituted the 
matrix solution. 0.5 µl of matrix solution together with 0.5 µl of the sample was applied 
onto anchorChip plate (Bruker Daltonics, Leipzig, Germany) and samples were air dried 
and used for mass spectrometry. 
 
4.21 Mass Spectrometry 
Mass spectra were obtained on a Bruker REFLEX III mass spectrometer (Bruker Daltonics, 
Leipzig, Germany). MALDI peptide spectra were calibrated using several matrix ion peaks 
(or standard keratin peaks) as internal standards. Proteins were identified by a MASCOT 
database search (Matrix Sciences). Mass spectra of some spots were also analysed by an 
AB4700 MALDI-TOF/TOF (Applied Biosystems, Darmstadt, Germany) operating in 
reflectron mode with an ion source pressure of 0.5 µ torr. After a 400-ns time-delayed ion 
extraction period, the ions were accelerated to 20ºkV for TOF mass spectrometric analysis. 
A total of 600–1000 laser shots were acquired and signal averaged for MS/MS analysis and 
data were analyzed by the GPS explorer software (AB 4700 Inc., USA) using a Swiss/Prot 
protein database for Mascot search assuming (1) monoisotopic peptide masses, (2) cysteine 
carbamidomethylation, (3) variable oxidation of methionine, (4) a maximum of one missed 
trypsin cleavage and (5) a mass accuracy of 60 ppm. or better. The four highest intensity 
peaks were selected in a range between m/z 1500 and 2500 for MS-MS peptide sequencing 
in an interpretation method. A molecular weight search (MOWSE) score > 53 was assumed 
to indicate a significant match. 
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The GPS Explorer 2 software reports two different scores: the MASCOT best ion score, the 
highest score of a single peptide, and a total ion score, the sum of all peptide scores of one 
protein. The significance level for a peptide score should usually be higher than 20 and for 
a protein score higher than 40–50. Because different database searches have different 
MASCOT significance levels due to different database sizes and different numbers of 
masses submitted for a search, scores cannot be compared directly. For this reason, the 
software calculates a confidence interval from MASCOT protein scores or ion scores, and 
the MASCOT significance level for each search is defined as the 95 % confidence level. 
Therefore, the total ion score confidence level is also a reliable and comparable parameter 
for the significance of a database search as shown in Table 7 of nanoLC coupled with 
MALDI-TOF/TOF. 
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5 AIM OF THE STUDY 
 
Mechanisms underlying the inactivation of C/EBPα function in acute myeloid leukemia are 
poorly understood. Recent findings suggest that protein-protein interactions play a pivotal 
role in normal functioning of lineage-specific factors. Hence, the objective of the present 
study is to identify and characterize interacting proteins of C/EBPα which might modulate 
C/EBPα protein function. For this purpose we used the GST fused C/EBPα and performed 
GST-pull down assays for isolating the interacting proteins and further identifying them by 
mass spectrometry. 
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6 RESULTS 
 
6.1 Purification of GST-tagged proteins 
 
C/EBPα−interacting proteins were identified using co-purification of complexes with GST 
affinity tags, coupled with protein identification by mass spectrometry. A GST-C/EBPα 
fusion protein and a GST only control were used in this study. The Coomassie blue stained 
gel shows the expression and purification of GST-C/EBPα and GST (Fig. 8). The 
functionality of the GST-C/EBPα fusion protein was assayed by pulling down the known 
C/EBPα interacting protein PU.1 using the same buffer condition that were later used in the 
pull down experiments for the identification of unknown proteins in nuclear extracts. 
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Fig 8: Coomassie-stained gel showing the expression of GST-C/EBPα (lane 1, 2) and the 
GST protein (lane 4). Known amount of BSA were loaded in lane 5 (0.5 µg), lane 6 (0.1 
µg), and lane 7 (5 µg) to show the relative expression of the purified tagged proteins. 
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6.2 Screening for C/EBPα interacting proteins in the myeloid cell line 
U937 
 
6.2.1 2-D gel electrophoresis of interacting proteins 
 
The selection of an appropriate cell system is crucial for studies on C/EBPα which is an 
important transcription factor in the myeloid compartment. The U937 myeloid cell line has 
been successfully used to investigate C/EBPα and/or myeloid development. These cells are 
committed precursors and can give rise to granulocytic cells. Putative protein interacting 
partners of C/EBPα were identified by using a pull-down assay in which a GST-tagged 
C/EBPα fusion protein was incubated with lysates containing nuclear proteins (1 mg) from 
the myeloid U937 cell line (Fig. 9). Equal amounts of GST and GST-C/EBPα were used 
for the pull down. Protein spots that were specific for the GST-C/EBPα fusion protein were 
analyzed by 2-D gel electrophoresis, and identified by matrix-assisted laser 
desorption/ionization time of flight mass spectrometry/MALDI-TOF (Bruker), or MALDI-
TOF/TOF (Applied Biosystems, Darmstadt, Germany). 
pH3 10
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Fig 9: 2D gel electrophoresis for the identification of C/EBPα interacting proteins. U937 
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nuclear extracts were incubated with GST or the GST-C/EBPα fusion protein. Arrows in 
the silver stained 2D gel on the right (pH 3-10, 12 % SDS PAGE) indicate proteins 
specifically interacting with C/EBPα. 
 
6.2.2 1D SDS PAGE of differentially interacting proteins 
After thet GST pull down the samples were also directly subjected to 12 % SDS-PAGE 
(without 2-D gel electrophoresis) and stained with Coomassie blue. The complete lanes 
containing the interacting proteins were trypsin digested and peptides were separated by 
reverse-phase nano liquid chromatography and identified by MALDI-TOF/TOF. 
Using the 2D gel approach, 19 potentially interacting proteins were identified: 7 with the 
MALDI-TOF (Bruker) machine and 12 with a MALDI-TOF/TOF (Applied Biosystems) 
(Table 6). We identified 11 additional proteins using the 1-D nano-LC approach (Table 7). 
In summary, we identified a total of 30 potential C/EBPα interacting proteins of which 
4 were known previously as a binding partner of C/EBPα. Among these known 
interacting partners of C/EBPα are pRB (retinoblastoma susceptibility protein), hnRNP, 
E2F4, and C/EBPα itself (Table 6 and 7). Because the identified proteins included most 
reported C/EBPα interacting proteins, the reliability and efficiency of this approach appears 
quite high. 
6.3 List of C/EBPα interacting proteins identified by 2D SDS PAGE and MS or MS/MS 
Table 6:  
Spot 
No. 
Accession 
No. 
Mr. 
(kD) Score Gene name Description 
1 Q92993 60.0 62 HTATIP HIV-1 Tat interactive protein 60kDa; TIP60 
2 Q13696 62.3 77 ACF7 Actin cross linking family protein 
3 Q9UKD2 27.5 74 MRT4 mRNA turnover protein 4 homolog 
4 Q96FE8 68.3 62 EWSR1 Similar to Erwing Sarcoma protein 
5 Q01844 68.4 70 EWS RNA-binding protein EWS 
6 Q9HB58 78.5 59 SP110 Transcriptional Coactivator sp110 
7# AAA82555 40.9 66 RB1 Retinoblastoma Suspectibility Protein fragment 
8* P62995 33.6 92 SFRS10 Arginine/serine-rich splicing factor 10; TRA2B 
9* Q9BZG1 29.0 61 RAB34 Ras related protein Rab 34 
10* Q9Y6K8 22.0 57 AK5 Adenylate kinase isoenzyme; KAD5 
11* P18669 28.6 261 PGAM1 Phosphoglycerate mutase 1 
12* P33992 82.2 63 MCM 5 DNA replication licensing factor; CDC46 homolog 
13* P61812 48.5 69 TGFB 2 Transforming growth factor beta-2 
14* Q14683 143.2 64 SMC1L1 Structural maintenance of chromosome 1-like protein; SMC1A 
15#* P07910 33.6 135 HNRPC Heterogeneous nuclear ribo-nucleoproteins; hnRNPC1/C2 
16* P23246 76.1 129 SFPQ Polyprimidine tract binding protein  associated splice factor; PSF 
17* P14136 49.8 71 GFAP Glial fibrillary acidic protein 
18* Q14168 64.5 54 MPP2 MAGUK p55 subfamily member 2 
19* Q6N069 101.4 55 NARG1L NMDA receptor-regulated 1-like protein; NARGL 
*Mass spectra were acquired using a Proteomics Analyzer 4700 (MALDI-TOF/TOF) mass spectrometer 
# Same protein or family members were previously shown as an interacting partner of C/EBPαΧ 
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6.4 List of C/EBPα interacting proteins identified by the 1D nano-LC-MS/MS method 
Table 7:  
 
No. Accession No. 
Mr. 
(kD) 
Peptide 
count 
Total ion 
score 
confidence 
level*, % 
Gene name Description 
1# P49715 37.7 1 99.95 CEBPA CCAAT/enhancer-binding protein alpha; C/EBPα 
2 Q99583 62.3 2 99.86 MNT Max-binding protein MNT; ROX  
3 Q8TCU5 126.6 2 99.73 GRIN3A Glutamate [NMDA] receptor subunit 3A; NMD3A   
4 Q16513 104.7 3 98.66 PKN2 Protein-kinase C related kinase 2  
5 Q99996 455.7 2 97.777 AKAP9 A-kinase anchor protein 9   
6 Q8IXJ9 165.4 3 97.47 ASXL1 Putative Polycomb group protein  
7 P17655 80.6 1 95.91 CAN2 Calpain-2 catalytic subunit; M-calpain  
8 Q9GZS1 53.9 1 95.83 PRAF1 DNA-directed RNA polymerase I-associated factor 53kDa subunit; RPF53  
9 Q15906 40.7 1 95.52 VPS72 Component of the NuA4 histone acetyltransferase  complex which contains catalytic subunit TIP60  
10 P49792 358.1 2 95.38 RANBP2 Nuclear pore complex protein Nup358; RBP2  
11# Q16254 44.2 1 95.37 E2F4 Transcription factor E2F4  
*MASCOT significance level for each search is defined as the 95% confidence level. 
# Known interacting partners of C/EBPα 
 
 
 
6.5 Detailed Analysis of the Interaction of C/EBPα with Selected Putative 
Partner Proteins. 
 
6.5.1 MCM5 interacts with C/EBPα in vivo 
To confirm the interaction between C/EBPα and MCM5, co-immunoprecipitation and 
GST pulldown experiments were performed. Endogenous MCM5 could be co-
immunoprecipitated with C/EBPα antibodies from U937 RIPA lysates. The membrane 
was then stripped and immunoblotted with a C/EBPα antibody showing the 
immunoprecipitated C/EBPα (Fig. 10 A). Additionally, a GST pull down experiment was 
performed with U937 nuclear extracts using GST-C/EBPα and GST only as a control. 
Immunoblotting with an MCM5 antibody showed that GST-C/EBPα beads selectively 
retained MCM5 (Fig. 10 B). 
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Fig 10: C/EBPα physically interacts with MCM5: Coimmunoprecipitation of 
endogenous MCM5 and C/EBPα from U937 RIPA lysates with C/EBPα antibody and 
control IgG. Western blot analysis was performed using an anti-MCM5 (upper panel) and 
an anti C/EBPα antibody (lower panel) for the same membrane. B. A GST pull-down 
assay was performed with U937 nuclear extracts (Input) incubated with equal amounts of 
bacterially expressed GST alone as a control (lane 1) and GST-C/EBPα (lane 2). Western 
blot analysis was performed by using anti-MCM5 antibody. 
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 6.5.2 TIP60 interacts with C/EBPα directly 
To confirm the physical interaction between C/EBPα and the proteins identified in our 
initial pull-down assay, we conducted co-immunoprecipitation and an in vitro GST pull-
down assay for the histone aceyltransferase TIP60. To show Tip60 interaction with 
C/EBPα, GST-TIP60 was incubated with in vitro translated [35S] methionine labelled 
C/EBPα. GST-TIP60 was able to retain C/EBPα (Fig. 11 A, Lane 5). In vitro translated 
C/EBPα did not bind to GST beads alone (Fig. 11 A, Lane 3). Unprogrammed 
reticulocyte lysate with [35S] methionine incubated with GST-TIP60 served as a further 
control (Fig. 11 A, Lane 4). We next asked if the interaction between TIP60 and C/EBPα 
occurs in vivo. 293T cells were transfected with expression plasmids for C/EBPα and 
YFP-tagged TIP60. The lysates of the transfected cells were immunoprecipitated with 
two TIP60-specific antibodies. Then immunoblotting of the precipitate with C/EBPα and 
GFP antibodies was performed (Fig. 11 B). C/EBPα was specifically co-
immunoprecipitated with TIP60-specific antibodies but not with the IgG control (Fig. 11 
B, panel-I). Detection of YFP-TIP60 under these conditions using an anti-GFP antibody 
served as a control (Fig. 11 B, panel-II). 
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Fig 11: C/EBPα physically interacts with TIP60 in vitro and in vivo: A GST pull-
down assay was performed with [35S]-methionine-labelled in vitro-translated C/EBPα and 
bacterially expressed GST-TIP60. Equal amounts of bacterially expressed GST-TIP60 
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(lane 5) or GST alone (lane 3) were incubated with in vitro translated C/EBPα. Only 
GST-TIP60 (lane 5) was able to retain C/EBPα. B. Coimmunoprecipitation of C/EBPα 
and TIP60 from nuclear extracts of transiently transfected 293T cells with TIP60 
antibodies and an IgG control. Western blot analysis was performed by using anti-
C/EBPα (panel I) and with anti-GFP antibody (panel II) on the same membrane. 
 
6.6 TIP60 increases the transactivation capacity of C/EBPα 
Transient transfection assays were performed in the HEK293T and U937 cell lines using 
a luciferase reporter plasmid with a minimal TK promoter containing two CCAAT sites 
to test the ability of TIP60 to modulate C/EBPα-mediated transcriptional activation. 
Reporter gene expression was determined 24 h after transfection. Transfection of a TIP60 
expression construct significantly enhanced the ability of C/EBPα to transactivate the 
reporter plasmid up to 25-fold in a dose-dependent manner (Fig. 12 A). In control 
experiments, no effect of TIP60 on C/EBPα activity was observed when a reporter 
plasmid without CCAAT sites was used. While C/EBPα alone was able to transactivate 
the CCAAT site containing reporter up to 5-fold, TIP60 alone (without coexpression of 
C/EBPα) had no effect on luciferase activity, indicating that TIP60 specifically mediates 
up-regulation of the reporter through interaction with C/EBPα. Similar results were 
obtained in the myeloid U937 cell line (Fig. 12 B). Thus, the association of C/EBPα with 
TIP60 potentiates the transactivation activity of C/EBPα. 
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Fig 12: TIP60 enhances the transactivation capacity of C/EBPα. Transient 
transfection of 293T (A) and U937 cells (B) were performed with a reporter construct 
containing a minimal TK promoter with two CEBP binding sites p(CEBP)2TK or a 
reporter without CEBP sites (pTK) and expression plasmids for C/EBPα and YFP-
TIP60. The four different amounts of YFP-TIP60 transfected in A were 0.05 µg, 0.1 
µg, or 0.25 µg. The activity obtained for the p(CEPB)2TK plasmid without C/EBPα 
transfection was set as one and fold changes of normalized relative firefly luciferase 
activities are shown. 
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6.7 A functioning TIP60 HAT domain is required for the co-operativity 
with C/EBPα 
TIP60 is a histone aceyltransferase (HAT). Therefore, we asked if the histone 
aceyltransferase activity of TIP60 is required for increasing the transcriptional 
activity of C/EBPα. To address this, we used site-directed mutagenesis to alter three 
critical amino acids in the acetyl co-enzyme A binding domain of the TIP60 HAT 
domain which resulted in a TIP60 protein lacking histone acetyltransferase activity; 
TIP60(-HAT) (Fig. 13 A) 106. While YFP-TIP60 cotransfected with C/EBPα was able 
to increase luciferase activity 5-fold compared to C/EBPα alone, cotransfection of the 
YFP TIP60 (-HAT) expression plasmid with C/EBPα resulted in no change in 
transativation capacity compared to C/EBPα transfected alone (Fig. 13 B). Increasing 
the concentration of the YFP TIP60(-HAT) was unable to change the transactivation 
potential of C/EBPα. YFP TIP60(-HAT) alone had no effect on the CCAAT binding 
site-containing reporter plasmid. These results demonstrate that the acetyl transferase 
activity of TIP60 is required for increasing the transcriptional activity of C/EBPα. 
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Fig 13: TIP60(-HAT) does not enhances the transactivation capacity of C/EBPα. 
A. Amino acid sequence of the core acetyl transferase domain of TIP60 with the 
mutated amino acids highlighted, and bar diagram of TIP60 with conserved protein 
domains. B. Transient transfection of 293T cells with the p(CEBP)2TK reporter 
construct and expression plasmids for C/EBPα, YFP-TIP60, and YFP-TIP60(-HAT). 
The four different amounts of YFP-TIP60(-HAT) transfected were 0.05 µg, 0.1 µg, 
0.2 or 0.25 µg.  The activity obtained for the p(CEPB)2TK plasmid without C/EBPα 
transfection was set as one and fold changes  of normalized relative firefly luciferase 
activities are shown. YFP-TIP60 increases the transactivation up to 5 fold in a dose 
dependent manner while YFP-TIP60(-HAT) has no effect on C/EBPα transactivation. 
 
6.8 The TIP60 HAT domain mutant protein is expressed at similar levels 
compared to wild type TIP60 in 293T 
We have shown that a functioning HAT domain of TIP60 is required for the co-
operativity with C/EBPα on the CCAAT binding site containing reporter plasmid. 
However, the lack of increased transactivation after transfection of the HAT domain 
mutant TIP60 expression plasmid could be due to low expression of the YFP-TIP60(-
HAT) protein. We therefore compared the levels of protein expression of the YFP-
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TIP60 (wild) and YFP-TIP60(-HAT) plasmids transfected in 293T cells. There was 
no difference in the expression of these two proteins when detected with an anti-GFP 
antibody (Fig. 14). The same membrane was also blotted with an anti-β-tubulin 
antibody as a loading control (Fig. 14). 
 
Transfection: 293T
YFP-TIP60 + -
Blot:
anti-β tubulin
anti-GFP 86 kD
50 kD
-
YFP-TIP60 (-HAT) - -+
1 2 3  
Fig 14: Western blot showing equal expression of YFP-TIP60 (lane 1), and YFP-
TIP60(-HAT) (lane 2) in 293T cells.  
 
6.9 Coactivation by TIP60 depends on the DNA binding domain of 
C/EBPα 
The DNA binding of C/EBPα is required for its transactivation potential 47,119 and we 
showed that the HAT activity of TIP60 is crucial for increasing the transactivation 
activity of C/EBPα (Fig. 13). We therefore asked if TIP60-mediated increased 
transactivation potential is specific to C/EBPα or whether it is a general effect of 
TIP60 overexpression. To address this, we used the C/EBPα-Gal4DBD construct, in 
which the Gal4-DNA binding domain is fused to the transcriptional activation domain 
1 and 2 (TAD1 and TAD2) of C/EBPα and replaces the DNA binding domain of 
C/EBPα (basic region/leucine zipper domain) (Fig. 15 A) 120. C/EBPα-Gal4DBD 
transactivates a Gal4-UAS-luciferase reporter plasmid 33.5 fold as expected (Fig. 15 
B). However, cotransfection of TIP60 does not lead to an increased transactivation. 
These results indicate that the coactivator function of TIP60 requires the C/EBPα 
DNA binding domain. We, then performed a pull down assay with GST-C/EBPα, 
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GST-DBD (of C/EBPα), and GST alone with the nuclear extracts of 293T cells 
transfected with YFP-TIP60. Our results indicate that GST-DBD and GST-C/EBPα 
interact with TIP60 (Fig. 15 C, Lane 1, 2). However, no interaction was observed 
when the GST protein only was incubated with nuclear extracts of YFP-TIP60 
expressing cells (Fig. 15 C, Lane 3). 
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Fig 15: Co-activation by TIP60 depends on the DNA binding domain of C/EBPα. 
A) Diagram of the protein domain structure of C/EBPα and the C/EBPα-GAL4DBD 
construct, in which the basic region and leucine zipper of C/EBPα are replaced by the 
DNA binding domain of the yeast transcription factor GAL4. B) Transient 
transfection of 293T cells using a luciferase reporter plasmid containing Gal4DNA-
binding sites only (pGal4-luc). The C/EBPαGAL4DBD is able to transactivate the 
reporter plasmid. However, coexpression of YFP-TIP60 does not lead to increased 
activation. GAL4-VP16 was used as a positive transactivation control. The 
normalized firefly luciferase activity obtained for the pGal4-luc plasmid without 
C/EBPαGAL4DBD transfection was set as one and fold changes are shown. C) GST 
pulldown showing physical interaction between YFP-TIP60 and GST-C/EBPα and 
GST-DBD (the DNA binding domain of C/EBPα fused to GST). YFP-TIP60 was 
transiently expressed in 293T cells. YFP-TIP60 was detected with an anti-GFP 
antibody after the pulldown experiment and in the cell lysate. GST-DBD and GST-
C/EBPα interact with YFP-TIP60 (lane 1 and 2). GST alone does not retain YFP-
TIP60 (lane 3).  
 
6.10 TIP60 is found at the endogenous C/EBPα promoter in vivo 
Since the TIP60 and C/EBPα interaction could be shown to greatly change the 
transcriptional activation potential of C/EBPα, we examined whether this interaction 
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also occurs in vivo at the endogenous C/EBPα promoter. To this end, chromatin 
immunoprecipitation (ChIP) 121 experiments were performed (Fig. 16). Chromatin 
was extracted from K562ER-C/EBPα cells and subjected to immunoprecipitation 
with antibodies directed against C/EBPα and TIP60. C/EBPα activation (nuclear 
translocation) can be induced in K562ER-C/EBPα cells with β-estradiol. The 
presence of the C/EBPα promoter DNA fragment, which contains the C/EBPα 
binding sites, in the immunoprecipitated chromatin fraction was detected by PCR 
amplification of a 280 bp region from the human C/EBPα promoter 122. Our results 
revealed that even in uninduced conditions some endogenous TIP60 and C/EBPα are 
present at the C/EBPα promoter (Fig. 16 Panel I Lane 7, 8). This is a first report 
showing the occupancy of the C/EBPα promoter by TIP60 in vivo. Since K56ER-
C/EBPα cells can form granulocytes after induction with β-estradiol, we examined if 
induction of differentiation affects the C/EBPα and/or TIP60 binding at the 
C/EBPα promoter. After induction with β-estradiol both precipitation with anti TIP60 
and anti C/EBPα antibodies led to a stronger amplification of the C/EBPα promoter 
amplicon (Fig. 16 Panel II Lane 7, 8). Immunoprecipitation using an isotype-
matched IgG was used as a negative control (Fig. 16 Lane 4, 5). No amplification of 
an amplicon from the C/EBPα coding was found after using C/EBPα and TIP60 
antibodies in the ChIP experiment (negative control) (Fig. 16 Lane 10, 11). The 
induction of differentiation by β-estradiol was verified by analyzing the expression of 
CD11b, a marker of myeloid differentiation. Thus, C/EBPα and TIP60 associate in 
vivo in the context of chromatin and are more abundant on the C/EBPα promoter 
when cells are induced towards granulocytic differentiation. 
 
TIP60 is known to acetylate histones H3 and H4 and C/EBPα has been shown to alter 
the acetylation of histone H3 123. We therefore examined whether the histone 
acetylation at the C/EBPα promoter would change upon C/EBPα-TIP60 recruitment. 
Antibodies against acetylated histones H3 and H4 were used to precipitate the cross-
linked chromatin derived from uninduced and induced cells. Abundant levels of 
acetylated H3 and H4 histones were found to be present at the C/EBPα promoter after 
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induction with β-estradiol (Fig. 16 Panel II Lane 1, 2). Whereas no H3 or H4 
acetylation at the C/EBPα promoter was found in the uninduced conditions (Fig. 16 
Panel I Lane 1, 2). These data strongly suggest that TIP60 is involved in histone 
acetylation at the human C/EBPα promoter. 
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Fig 16: TIP60 is recruited to the human C/EBPα promoter in vivo with 
concomitant increase in histone H3 and histone H4 acetylation after induction of 
granulocyte differentiation in K562ER-C/EBPα cells. ChIP assay was performed 
on logarithmically-growing uninduced and β−estradiol induced K562ER-C/EBPα 
cells (6 hr after induction). An increase in the acetylation of H3 and H4 histones 
(Lane 1, 2) and an increase in C/EBPα and TIP60 binding at the C/EBPα promoter 
were observed in induced K562ER-C/EBPα cells (Lane 7, 8). Input (Lane 6): PCR 
performed on total chromatin. Immunoprecipitations with antibody isotype controls 
are shown in lane 4 and 5. PCR performed on chromatin immunoprecipitated using 
C/EBPα and TIP60 antibodies with primers for an amplicon in the C/EBPα coding 
region served as a control (Lane 9, 10, 11). 
6.11 C/EBPα becomes acetylated in vivo and in vitro 
C/EBPα interacts with a number of histone aceyltransferases. However, acetylation of 
C/EBPα has not been reported so far. We inquired whether C/EBPα is subject to 
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acetylation. 293T cells were transfected with C/EBPα expression plasmid and nuclear 
extracts were prepared in the presence of the HDAC (Histone deacetylase) inhibitor, 
TSA (10 mM). Immunoprecipitation was carried out using C/EBPα antibody and 
blotted with Pan acetyl antibody (Santa cruz biotechnology). The same membrane 
was stripped and blotted with an anti C/EBPα antibody to demonstrate the 
immunoprecipiated C/EBPα (Fig. 17 A). This is, to our knowledge, the first report 
showing C/EBPα can become acetylated. Furthermore, a non-radioactive in vitro 
acetylation reaction was performed to analyze whether TIP60 would be capable of 
acetylating C/EBPα. GST-TIP60 was incubated with GST-C/EBPα and GST as 
control with non-radioactive acetyl CoA, followed by SDS PAGE and probed with 
anti-acetyl antibody. These experiments clearly showed that C/EBPα becomes 
acetylated by TIP60 in vitro (Fig. 17 B). However, in a P81 filter binding HAT assay, 
we observed no acetylation of GST-C/EBPα (Fig. 17 C) in the preseence of GST-
TIP60. 
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Fig 17: C/EBPα acetylation: A. Co-immunoprecipitation of C/EBPα from nuclear 
extracts of transiently transfected 293T cells with C/EBPα antibody and an IgG 
control. Western blot analysis was performed using an anti-acetyl antibody (upper 
panel) and an anti-C/EBPα antibody (lower panel) on the same membrane. B. An in 
vitro non-radioactive acetylation assay was performed with GST-TIP60 incubated 
with decreasing amounts of GST-C/EBPα and GST as control. Only GST-C/EBPα 
and not GST became acetylated in the presence of GST-TIP60. Western blot analysis 
was performed using an anti-acetyl antibody. C. HAT activity was monitored in the 
radioactive P81-filter binding assay: Yeast acetyl transferase (YAT) with histone H3 
was used as a positive control. TIP60 is known to acetylate histone H4. GST-TIP60 
alone was used as a negative control. 
 
 
6.12 TIP60 expression in AML 
6.12.1 TIP60 mRNA expression is higher in differentiated U937 cells 
TIP60 expression was analyzed by a semi quantitative RT-PCR assay in RNA 
isolated from FACS-sorted differentiated CD11b+ U937 cells after 60 hours of 
treatment with retinoic acid. Higher TIP60 mRNA expression was found in 
committed granulocytic cells compared to undifferentiated CD11b- U937 cells. 
C/EBPα and C/EBPε transcript levels were used as positive controls for the induction 
of differentiation and β-tubulin levels were used as RNA quality controls (Fig. 18 A). 
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 6.12.2 TIP60 and C/EBPα expression levels correlate in different leukemia subtypes 
To obtain a first glimpse of what the role of TIP60 in the development of AML might 
be, we analyzed the TIP60 mRNA expression in a microarray dataset from AML 
patients with defined leukemia subtypes (Fig. 18 B). Our data suggest that there is a 
correlation between the expression levels of C/EBPα and TIP60 in normal bone 
marrow, CML and AML subtypes with the AML1/ETO (AML_M2), the 
CBFB/MYH11 (AML_M4) and the PML/RARA (AML_M3) fusion genes. 
 
A.
U
ni
nd
.
In
du
ce
d*
U
ni
nd
.
In
du
ce
d*
H
20
+RT -RT
Cycles
22
30
28
30
30TIP60
C/EBPα
C/EBPε
β-tubulin
β-tubulin
U937
* U937 + RA (1µM) CD11b+
U
ni
nd
.
In
du
ce
d*
U
ni
nd
.
In
du
ce
d*
H
20
U
ni
nd
.
In
du
ce
d*
U
ni
nd
.
In
du
ce
d*
H
20
U
ni
nd
.
In
du
ce
d*
U
ni
nd
.
In
du
ce
d*
H
20
 
 
69 
 
B.
CEBPA mRNA expression
(micro array signal intensity)
TIP60 mRNA expression
(micro array signal intensity)  
Fig 18: TIP60 mRNA expression in differentiated cells and in AML subtypes. A. 
Expression of TIP60, C/EBPα, C/EBPε analysed by semiquantitative RT PCR in 
CD11b-negative, retinoic acid untreated U937 cells and in retinoic acid treated, 
CD11b-positive U937 cells. B. Boxplots of mRNA expression levels (micro array 
signal intensity values) of C/EBPα and TIP60 in normal bone marrow, CML and 3 
AML subtypes (AML_M4: AML with CBFB/MYH11 fusion; AML_M3: AML with 
PML/RARA fusion; AML_M2: AML with AML1/ETO fusion). The normalized and 
variance-stabilized expression values are shown on a logarithmic scale 
(approximately log 2). Dark bar represents median, boxes give the 25 to 75 % 
quantile range (inter quantile range: IQR), whiskers represent the 1.5 fold IQR, small 
circles represent outlier. If the "notches" of two distributions do not overlap, it is 
considered strong evidence that their medians differ. 
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7 DISCUSSION 
 
7.1 C/EBPα interacting proteins 
The C/EBPα protein is of great interest because of its involvement in myeloid 
differentiation and leukemia. C/EBPα is abundant in early myeloid cells where it binds to 
the promoters of key myeloid target genes 124, including its own promoter 29. Ectopic 
C/EBPα expression induces granulocytic differentiation and blocks erythroid 
differentiation of human CD34+ cells 21. The identification of novel interacting partners 
of C/EBPα might lead to novel therapeutic approaches that specifically target 
leukemogenic mechanisms which depend on C/EBPα loss of function mutations 125. 
C/EBPα interacting proteins have previously been identified by 1-D SDS PAGE coupled 
with mass spectrometry in prostate cancer cell lines 126 , using GST-C/EBP-DBD in 
myeloid cell line 70 and by yeast two hybrid screens 127. Here, we describe two 
approaches, one based on 2-D gel electrophoresis and the other on 1-SDS PAGE/nano 
LC, to identify novel C/EBPα interacting proteins which will help in elucidating the 
complicated protein interaction network underlying normal C/EBPα function. 
Several novel C/EBPα interacting proteins were identified by this approach (Table 6 and 
7). These are proteins involved in DNA repair and cell cycle: SMC1, MCM5; Proteins 
involved in chromatin modification and remodeling VPS72 (which is a part of NuA4 
complex containing TIP60), TIP60 and ASXL1; the Ras superfamily member RAB34; 
the MAX binding protein MNT; the nuclear pore complex protein RANBP2; the splice 
factors SFPQ and TRA2B; metabolic enzymes like KAD5 and PGAM1 and many other 
proteins including proteins like hnRNP, RB, E2F4, and C/EBPα, which had already been 
shown to interact with C/EBPα directly 51,80,86. To confirm the protein interaction results 
found by mass spectrometry, we have confirmed the interaction between C/EBPα and 
MCM5 and TIP60 and further characterized the functional significance of the interaction 
between C/EBPα and TIP60. 
 
71 
 
Our two approaches, the 2-D and the 1-D/nano LC, revealed different C/EBPα 
interacting protein. This result is most likely due to the inherent differences in these two 
approaches which affect the coverage and the confidence of the protein identification 
procedure. In the 2-D gel approach, complex protein samples were separated over a larger 
defined pH range, increasing the resolution for each protein when compared to a 1-D 
SDS-PAGE gel. Furthermore, in contrast to the 2-D analyses, where differentially 
expressed spots were visually identified and manually excised, the identification of 
proteins from the 1-D gel was independent of their visualization and allowed for the 
identification of proteins with high isoelectric points. 
Using these two approaches we identified a large number of known and novel C/EBPα 
interacting proteins. We could confirm the interaction of C/EBPα and two other proteins, 
namely MCM5 and TIP60, by alternative methods. Furthermore, we concentrated our 
efforts on analyzing the functional significance the interaction between C/EBPα and 
TIP60. 
The identification of TIP60 as a novel interacting partner of C/EBPα was intriguing 
because TIP60 has been shown to be an interacting partner of a numbr of other 
transcription factors in mammalian cells and has been shown to function as a coactivator 
or a corepressor. TIP60-mediated repression might be effected through the recruitment of 
histone deacetylase HDAC7 128 or independent of HAT activity 106,129. TIP60-mediated 
activation is generally thought to require the HAT activity of TIP60, in particular through 
the acetylation of histones on target promoters. Transcription factors themselves might be 
substrates for TIP60-mediated acetylation 130. 
TIP60 is also a very interesting protein because it might affect higher-order chromatin 
structure. The eukaryotic chromatin structure is very complex, highly dynamic and 
regulates virtually all DNA-associated processes, like transcription, replication and DNA 
repair 131. Chromatin is also the basis of epigenetic inheritance, by which the differential 
expression state of genes can be transmitted through successive cellular generations 132. 
There are two known broad classes of enzymes that regulate chromatin 133,134. First the 
chromatin remodeling enzymes that uses ATP hydrolysis to modify the histone 
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composition or positioning of nucleosomes, without introducing covalent modifications 
of histones. Second, histone-modifying enzymes modify chromatin by covalently adding 
a variety of chemical moieties to specific histone residues. These enzymes are highly 
specifc and belong to a variety of protein families like histone acetyltransferases (HATs), 
deacetylases (HDACs), methyltransferases, demethylases, kinases, ubiquitin ligases and 
others. Chromatin–modifying enzymes exist as a part of large macromolecular complexes 
that exercise various functions like enzymatic activity, substrate specificity, chromatin 
association, and site specific recruitment by DNA-bound transcription factors. TIP60 is a 
HAT and is recruited by many transcription factors to a number of target promoters, 
where it participates in histone acetylation and transcriptional activation. It is interesting 
to note that members of the MYST domain histone acetyltransferase family are also 
involved in long lasting modifications of chromatin functions such as dosage 
compensation of the Drosophila X chromosome and therefore might play a special role in 
more long lasting epigenetic modifications which might be associated with permanent 
lineage decisions in the hematopoietic differentiation program. This is the first report of 
the interaction of the transcription factor C/EBPα interacting with a MYST family 
member protein. 
 
7.2 Structure and function of the histone acetyltransferase TIP60 
 
Acetyltransferases are enzymes that catalyse the transfer of acetyl groups from acetyl 
coenzyme A to either the α-amino group of N-terminal amino acids or the -amino group 
of internal lysine residues. Lysine acetyltransferases fall into several categories, one of 
which is the MYST family, named after its founding members: MOZ, Ybf2/Sas3, Sas2 
and TIP60. MYST family members function in a broad range of biological processes, 
such as gene regulation, dosage compensation of the Drosopila X chromosome, DNA 
damage repair and tumourigenesis 135. Although MYST proteins seem to have diverse 
cellular roles, all family members are characterised by the highly conserved MYST 
acetyltransferase domain and most MYST enzymes exist as the catalytic subunits of 
multiprotein complexes. 
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Fig 19: Schematic diagram of TIP60 protein domains: ZF (Zinc finger), HAT (Histone 
acetyltransferase domain), MYST (MOZ, Ybf2/Sas3, Sas2 and TIP60). Proteins known 
to interact physically with TIP60 are shown. 
 
TIP60 was originally isolated as a HIV-1 Tat interactive protein 136 (Fig. 19). The 
HTATIP gene encoding TIP60 is located at 11q13.1 and consists of 14 exons. Alternative 
splicing results in the expression of at least three splice variants, TIP60 isoform 1, TIP60 
isoform 2 (TIP60α) and TIP60 isoform 3 (TIP60β, PLA2 interacting protein, PLIP). The 
best characterised splice variant is isoform 2. Isoform 1 arises from translation of intron 1 
and encodes for a protein with potentially distinct functions  from isoform 2 137. Isoform 
3 (TIP60β) results from the exclusion of exon 5 that encodes a proline-rich region 138 and 
appears to have similar properties as TIP60α 139. TIP60 isoforms are expressed at 
relatively low levels in a broad variety of tissues and cells and exhibit cell type specific 
functions 129. HTATIP homologues have been identified in various organisms, including 
G. gallus, M. musculus and D. melanogaster, which encode proteins that share 
considerable homology with human TIP60 (57–99 %) 140-142. 
The TIP60 isoform 2 (TIP60α) is a 513 amino acid protein (58 kDa), which contains an 
N-terminal chromodomain and a C-terminal conserved MYST domain (Fig. 19) 
Chromodomains are present in many chromatin regulatory proteins and are thought to 
mediate interactions with methylated histone lysines or RNA molecules, although in the 
case of TIP60 the chromodomain may have yet unidentified functions 135,143. The MYST 
domain is the catalytic domain and contains a short sequence (residues 335–404, 
‘conserved HAT domain’), which binds to acetyl coenzyme A and the substrate and 
which is structurally conserved in other acetyltransferase families. The MYST domain 
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also contains a characteristic Cys-Cys-His-Cys zinc finger, which is essential for 
acetyltransferase activity and is required for protein–protein interactions 128,129,144. 
Shortly after its discovery, it became evident that TIP60 possesses histone 
acetyltransferase (HAT) activity. Recombinant TIP60 acetylates core the histones H2A 
(Lys5), H3 (Lys14) and H4 (Lys5, Lys8, Lys12 and Lys16) in vitro; 145,146. As part of a 
stable multiprotein complex, TIP60 can also modify histones assembled into nucleosomes 
in vitro; in this case, TIP60 selectively targets nucleosomal H2A and H4 147. Recent 
evidence from D. melanogaster indicates that TIP60 can also acetylate modified histone 
variants, such as phospho-H2Av at Lys5 140. TIP60 functions as transcriptional 
coactivator or corepressor, connecting a number of different factors to the basal 
transcriptional machinery. 
Apart from histones, cellular TIP60 can acetylate transcription factors, such as androgen 
receptor (AR), the upstream binding transcription factor (UBF), the myelocytomatosis 
oncogene c (CMYC) 130,148,149 and the kinase Ataxia Telangiectasia mutated (ATM) 150. 
 
7.3 Reported functions of TIP60 
Nuclear receptor coactivation and involvement in prostate cancer: 
 
TIP60 predominantly coactivates and interacts with class I nuclear recpetors (NR) 151, 
although there have been reports of TIP60-dependent NR corepression 152. TIP60 directly 
acetylates the androgen receptor (AR) and this acetylation is essential for TIP60-
dependent AR coactivation. TIP60 forms a trimeric complex with histone deacetylase 1 
(HDAC1) and AR on AR-responsive promoters and competes with HDAC1 most likely 
by inducing changes in AR acetylation status 148. 
AR signalling is central to normal prostate development and carcinogenesis. The fact that 
TIP60 is involved in AR signalling suggests that it may be important for prostate cancer 
development. In metastatic prostate cancer cells, this function of TIP60 is lost, expression 
of TIP60 protein is decreased and TIP60 localisation is more diffuse 153. 
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Involvement of TIP60 in MYC function: 
 
The TRRAP–TIP60 complex acts as a dual cofactor for the MYC transcription factor: 
The recruitment of the acetyltransferase complex TRRAP-TIP60 is important for the 
ability of CMYC to regulate promoters and enhance MYC transactivation efficiency 
independently of MYC acetylation 103 In addition, TIP60 can directly acetylate MYC 
which results in increased stability of the MYC protein 130. 
 
TIP60 and amyloid-β precursor protein signaling and NF-κB signaling 
 
Although subcellular localization data show that TIP60 is mainly a nuclear protein, there 
is also some evidence that suggests that TIP60 might have a role in signal transduction in 
the cytoplasm. TIP60 forms a protein complex in the cytoplasm with the intracellular tail 
fragment of the amyloid-beta precursor protein (APP) and the nuclear adapter protein 
Fe65. APP is a widely expressed cell surface protein involved in the pathophysiology of 
Alzheimer's disease 154-157. This complex stimulates histone acetylation 158 and 
coactivates gene promoters which are linked to apoptosis and neurotoxicity 159. However, 
recent evidence have cast doubt on the exact role of TIP60 in this complex as, in some 
cases, TIP60 appears to be redundant or even acts as a Fe65 corepressor 156,160. 
The transcription factor nuclear factor kappa light chain gene enhancer in B cells (NF-
κB) is a homo- or heterodimeric transcription factor that consists of members of the Rel 
family (Rel-A/p65, REL-B, c-Rel, p50 and p52) and controls processes, such as 
immunity, inflammation, proliferation and apoptosis. TIP60 acts as a coactivator of 
certain NF-κB-regulated genes like KAI1 161,162. 
 
Involvement of TIP60 in E2F-mediated transcription: 
 
E2F proteins can either activate or repress transcription. E2F1 recruits the TIP60 complex 
(Tip60, TRRAP, p400, Tip48, and Tip49) to target promoters in vivo. This recruitment is 
responsible for the H4 acetylation observed in several E2F responsive genes 104. In 
addition, E2F, in cooperation with the transcription factors specificity protein 1/3 (Sp1 
and Sp3), recruits TIP60 to the MYCN promoter 163. 
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 Involvement of TIP60 in other transcriptional processes: 
 
Tip60 was first identified as an interaction partner for the HIV-1 Tat protein and was 
shown to increase Tat transactivation of the HIV-1 promoter 136. TIP60 has subsequently 
been reported to coregulate several other transcription factors. UBF, a ribosomal specific 
transcription factor actively involved in ribosomal gene transcription, is acetylated by 
Tip60 and coactivated by TIP60 within the nucleolus at sites of active rDNA transcription 
149. Jade-1 has two zing finger motifs called plant homeodomains (PHD). It is involved in 
renal cancer. TIP60 interacts with Jade-1 and is believed to be responsible for Jade-1-
dependent H4 acetylation 164. TIP60 is also reported to coactivate transactivation of the 
serum response factor (SRF) gene by the T-Box 2 and 5 (Tbx2 and Tbx5) transcription 
factors in cardiac cells thus modulating the expression of SRF-dependent cardic genes 165. 
 
TIP60 as a corepressor of transcription: 
 
TIP60 has not only been shown to be a transcriptional co-activator, but also been shown 
to be a transcriptional co-repressor depending on the proteins that it interacts with. TIP60 
functions as a transcriptional coactivator for androgen receptor 148,166, NF- B 161, UBF 149 
and c-Myc 103 but also as co-repressor for ETV6 144 and STAT3 128. This co-repressor 
function of TIP60 can be further enhanced by co-transfection of HDAC7. TIP60 usually 
induces gene repression via the recruitment of other complexes, for example, 
deacetylases. Another example of a transcription factors corepressed by TIP60 are the 
cAMP response element binding protein (CREB) 106,128. CREB is a transcriptional 
activator stimulated by hormone and growth factor dependent phosphorylation by protein 
kinase A (PKA). TIP60 corepresses CREB by direct binding to CREB and repressing 
CREB stimulation by PKA 106. STAT3 activity is modulated by a TIP60/HDAC7 
complex 128. Furthermore, TIP60 represses gene expression by cooperating with 
transcriptional repressors. Zinc finger E box (ZEB) binding protein is a repressor that 
associates with TIP60 and whose repressor activity is stimulated by TIP60 in certain cell 
types 129. The translocation E26 transforming-specific leukaemia gene (TEL, ETV6) is a 
putative tumour suppressor gene and transcriptional repressor disrupted by a number of 
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chromosomal translocations in haematological malignancies 167. TIP60 directly interacts 
with ETV6 and function as corepressor in ETV6-mediated transcription repression., 
possibly by stimulating the interaction between ETV6 and its corepressor Switch 
independent 3 (Sin3) and Silencing Mediator for retinoid and thyroid Receptor 
(SMRT)/NCoR 144. 
 
TIP60 is involved in DNA repair and apoptosis 
 
The TIP60 histone aceyltransferase complex also exhibits ATPase, DNA helicase, and 
structural DNA binding activities. Ectopic expression of mutated TIP60 lacking the 
histone acetyltransferase activity in HeLa cells results in cells with defective double 
stranded DNA break repair. Furthermore, the mutated TIP60 expressing cells were 
resistant to apoptosis 147. 
 
7.4 C/EBPα and TIP60 interaction 
The direct physical interaction between C/EBPα and TIP60 was demonstrated by a GST 
pull down assay. The C/EBPα-TIP60 interaction was shown to occur in vivo by co 
immunoprecipitation and chromatin immunoprecipitation assay (Fig. 11 A and Fig. 16). 
In reporter gene assays C/EBPα and TIP60 synergistically cooperated to stimulate 
transcription from a C/EBPα responsive promoter in a dose dependent manner (Fig. 12). 
It could also been shown that the acetyltransferase activity of the MYST domain of 
TIP60 is essential for this co-activation activity. An acetyltransferase dead mutant of 
TIP60 showed no co-activation and was unable to cooperate with C/EBPα in enhancing 
the transcription of the luciferase reporter gene (Fig. 13, A, B). These findings imply that 
TIP60 is directly responsible for the transcriptional coactivation observed and that this is 
not due to the recruitment of other activators by TIP60 to the promoter complex. 
Replacement of the DNA binding domain of C/EBPα with the yeast Gal4 DNA binding 
domain leads to a loss of TIP60 coactivator function with respect to C/EBPα (Fig. 15 A, 
B). The DNA binding domain of C/EBPα interacts directly with TIP60 (Fig. 15 C) 
suggesting that the basic region/leucine zipper domain of C/EBPα is critical for TIP60 
recruitment. 
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Acetylation of transcription factors is a widely known phenomenon. Dynamic acetylation 
of non-histone proteins has multiple effects on cellular function. Acetylation increases the 
DNA binding affinity (GATA-2 acetylation by P300 and GCN5 168) or decreases the 
DNA binding affinity (acetylation of transcription factor YY1 by P300 and PCAF 169). 
Acetylation increases (androgen receptor by TIP60 148) or decreases (Hypoxia-inducible 
factor 1, HIF-1, by arrest defective 1 protein, ARD1 170) the transcriptional activation. It 
might increase the protein stability (MYC acetylation by TIP60 130) or decrease the 
protein stability (HIF-1 acetylation by ARD1 170); might promote protein-protein 
interaction (STAT3 acetylation by P300/CBP 171) or disrupts protein-protein interactions 
(Hsp90 hyperacetylation, results its dissociation from an essential cochaperone p23 172. 
TIP60 is known to acetylate non histone proteins such as UBF 149, MYC 130 and ATM 150. 
Acetylation of C/EBPα by TIP60 has not been shown so far. To determine whether TIP60 
has a role in C/EBPα acetylation, in vitro HAT assays were performed followed by 
Western blot. Evidence of acetylation was provided by sole use of acetylated-lysine-
specific antibody (Fig 17 A, B). However, we were unable to confirm that C/EBPα is 
directly acetylated by TIP60.by other methods like 3H in vitro HAT assays. Thus our 
results did not show conclusively that C/EBPα is acetylated. However our data do not 
rule out the possibility that C/EBPα is acetylated by TIP60. Alternative strategies to 
demonstrate C/EBPα acetylation by TIP60 such as HAT assays with cleaved the GST tag 
cleaved off from fusion protein, in vivo labeling or mass spectrometry are required to 
confirm our findings. 
7.5 C/EBPα recruits TIP60 to chromatin 
C/EBPα is known to bind and cooperate with numerous chromatin modifying coactivators 
to stimulate transcription. It is also known that C/EBPα stimulates the acetylation of 
nucleosomal histones by CBP 102. DNA binding of C/EBPα in adipocytes is associated 
with the recruitment of the coactivators CBP and p300 and abundant acetylation of 
histones 173. C/EBPα also interacts with the SWI/SNF complex to induce proliferation 
arrest through the regulation of differentiation-specific genes 174. Furthermore, expression 
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of C/EBPα led to the enhanced acetylation of histone H3 at peri-centromeric chromatin 
123. 
The association of TIP60 with the C/EBPα promoter in vivo under physiological 
conditions, and the recruitment of C/EBPα and TIP60 to the C/EBPα promoter during 
granulocytic differentiation indicates that the formation of a CEBPα-TIP60 complex on 
the C/EBPα promoter might be a key event during granulocytic differentiation. Our 
results showed that TIP60 and C/EBPα interact in vivo at the C/EBPα promoter 
concomitant with an increase in H3 and H4 acetylation (Fig. 16). It could very well be 
that the primary targets of TIP60 acetylation in this context are the histones in the 
promoter regions of C/EBPα regulated genes. We do not know whether histone 
acetylation is a prerequisite or a consequence of the C/EBPα-TIP60 interaction. So far, 
this is the first report showing occupancy of the C/EBPα promoter by TIP60 in vivo. 
Whether TIP60 functions as a tumor suppressor gene or oncogene is unknown at the 
present time and might be highly context dependent. TIP60 could influence tumor 
progression either positively or negatively, depending on whether we consider it as a 
coactivator for TFs that promote (e.g. Myc, E2F) or suppress tumorigenesis (e.g. p53, 
C/EBPα). In addition, competition or sequestration of TIP60 by various transcription 
factors such as MYC may constitute a mechanism of negative cross talk between 
different signaling pathways. 
TIP60 is a part of the TRRAP complex 133. It is thus very likely that other members of the 
TIP60 complex are also recruited to the C/EBPα promoter. TIP60 may therefore serve as 
a platform for the assembly of multiprotein complexes. The role of signaling pathways 
that control the association of TIP60 with C/EBPα might be equally important in 
controlling tumor progression. 
 
7.6 C/EBPα and TIP60 m RNA expression in AML 
Higher expression levels of TIP60 mRNA in retinoic acid induced differentiated U937 
CD11b+ cells compared to undifferentiated U937 CD11b- cells suggest that higher TIP60 
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expression is associated with myeloid differentiation similar to what is observed for 
C/EBPα expression (Fig. 18 A). In order to get a first glimpse at the role of TIP60 in the 
pathogenesis of AML, we examined TIP60 and C/EBPα mRNA expression in a 
microarray data set from AML patients with defined leukemia subtypes. Interestingly, 
TIP60 and C/EBPα showed high expression levels in CML compared to normal bone 
marrow and similar expression trends in three AML subtypes (Fig. 18 B). The 
significance of these observations for the development of AML and for granulocytic 
differentiation has to be analyzed in future experiments. 
Interestingly, TIP60 and two other MYST domain HATs (MOZ and MORF) have been 
shown to interact with other leukemia-relevant proteins like ETV6 144,175 or to participate 
in leukemia-associated chromosomal translocations (e.g. the MOZ/TIF2, MOZ/P300 and 
MORF/CBP) 176-178. All MYST family members share a region of similarity of 
approximately 240 amino acids in length containing the canonical acetyl CoA binding 
site found in most acetyl transferases 179. MYST family members are also implicated in 
transcriptional silencing in yeast (SAS2 and YBF2/SAS3), and in dosage compensation 
in Drosophila (MOF). A novel gene product, hMOF, which exhibits significant similarity 
to the Drosophila dosage compensation regulator Mof (males absent of the first) has been 
found in humans 180. MYST acetyltransferase proteins differ from other acetyltransferase: 
1). Involvement in DNA repair 2). Long lasting changes for dosage compensation. The 
presence of MYST homologs in organisms as diverse as yeast and humans suggests that 
these proteins function in one or more important cellular processes. 
These observations and findings further confirm the functional synergism between 
C/EBPα and TIP60 and suggest that TIP60 might be an important player in 
leukemogenesis. It is now well known that changes in chromatin structure, which 
corresponds to the epigenetic memory of a cell, play an essential role in cellular 
differentiation processes and lineage choices. The findings here give a glimpse of the 
complex and intricate network of interactions between TIP60 and transcription factor that 
regulate myeloid cell development. It is therefore tempting to speculate that the MYST 
domain histone acetyltransferase TIP60 is crucial in converting the transcriptional 
decisions initiated by C/EBPα into long-lasting epigenetic chromatin changes. In 
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summary, our findings that TIP60 interacts both physically and functionally with the 
myeloid transcription factor C/EBPα (Fig. 20) will lead to further studies to define the 
role of TIP60 protein complexes in the process of hematopoietic cell differentiation and 
leukemogenesis. 
 
C/EBPα
TIP60
CCAAT
Ac 
Ac Ac Ac
Co-activators
 
Fig 20: MODEL Direct recruitment of TIP60 by C/EBPα may serve to modulate 
C/EBPα transactivation potential by aiding disruption of local chromatin structure 
thereby facilitating C/EBPα access to its CCAAT DNA binding sites and providing easier 
access for other transcription factors at the promoters of target genes. 
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 8 SUMMARY 
 
The transcription factor C/EBPα is a key player in granulopoiesis and leukemogenesis. In 
the present study, we sought to identify C/EBPα interacting proteins. A glutathione-S-
transferase-C/EBPα fusion protein was used to pull down interacting proteins from U937 
nuclear extracts. These proteins were analyzed by 2-D gel electrophoresis or 1-D nano 
LC and identified by mass spectrometry. The interaction between C/EBPα and two novel 
interacting partners, the cell cycle regulator protein MCM5 and the MYST domain 
histone aceyltransferase TIP60, was confirmed by using pull-down and co-
immunoprecipitation experiments. TIP60 was able to markedly enhance C/EBPα 
mediated transcriptional activation in reporter gene assays, suggesting that TIP60 is a co-
activator of C/EBPα. This co-activator function of TIP60 was dependent on its intact 
histone aceyltransferase domain and on the C/EBPα DNA binding domain. TIP60 was 
found to be associated with the human C/EBPα promoter in vivo in a chromatin 
immunoprecipitation assay with a concomitant increase in histone H3 and H4 acetylation. 
Furthermore, we observed a lower expression of TIP60 mRNA in undifferentiated U937 
CD11b- cells compared to retinoic acid induced differentiated U937 CD11b+ cells 
suggesting that higher TIP60 expression is associated with myeloid differentiation. 
Correlated expression between C/EBPα and TIP60 was also observed in certain leukemia 
subtypes. These findings point to a functional synergism between C/EBPα and TIP60 in 
myeloid differentiation and suggests that TIP60 might be an important player in 
leukemogenesis. 
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9 ZUSAMMENFASSUNG 
 
Der Transkriptionsfaktor C/EBPα spielt eine wichtige Rolle bei der Entwicklung von 
Granulozyten sowie bei der Leukämieentstehung. Das Ziel dieser Arbeit war, Proteine zu 
identifizieren, die mit C/EBPα interagieren. Ein Glutathione-S-Transferase-C/EBPα- 
Fusionsprotein wurde verwendet, um interagierende Proteine aus Extrakten der Zelllinie 
U937 zu binden. Diese Proteine wurden mittels 2-D Gelelektrophorese oder 
chromatographisch getrennt und anschließend im Massenspektrometer identifiziert. Die 
Interaktion von C/EBPα  mit zwei neuen Interaktionspartnern, dem Zell-Zyklus- 
Regulator MCM5 sowie der MYST Domänen Histon-Acetyltransferase TIP60, wurde mit 
Hilfe von Pull-down- und Koimmunpräzipitations-Experimenten bestätigt. TIP60 konnte 
die Transkriptions-Aktivierung eines Reportergens durch C/EBPα  deutlich verstärken, 
was darauf hinweist, dass TIP60 ein Co-Aktivator von C/EBPα ist. Für diese Co-
Aktivation werden eine intakte Histon-Acetyltransferasedomäne von TIP60 sowie die 
DNA-Bindungsdomäne von C/EBPα benötigt. Nach Chromatin Immunpräzipitation war 
TIP60 mit dem humanen C/EBPα Promotor in vivo assoziiert, wobei gleichzeitig die 
Histone H3 und H4 eine erhöhte Acetylierung aufwiesen. Darüber hinaus fand sich eine 
verminderte Expression der TIP60 mRNA in undifferenzierten U937 CD11b- Zellen im 
Vergleich zu U937 CD11b+ Zellen, deren Differenzierung mit Retinolsäure induziert 
wurde, was auf einen Zusammenhang zwischen der Expression von TIP60 und der 
myeloiden Differenzierung hinweist. Es wurde auch eine Korrelation der 
Expressionshöhen von C/EBPα und TIP60 in bestimmten Formen von Leukämie 
beobachtet. Zusammengefasst weißen die Ergebnisse auf einen funktionellen 
Synergismus zwischen C/EBPα und TIP60 während der myeloiden Differenzierung hin, 
was den Schluss zuläßt, dass TIP60 eine wichtige Rolle bei der Leukämieentstehung 
spielen könnte. 
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ORIGINAL ARTICLE
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP)
as a co-activator of the myeloid transcription factor C/EBPa
D Bararia1, AK Trivedi2, AA Peer Zada2, PA Greif1, MA Mulaw1, M Christopeit2, W Hiddemann1, SK Bohlander1,3 and G Behre2,3
1Department of Medicine III, University of Munich and Clinical Cooperative Group, HelmholtzZentrum ‘German Research Center
for Environmental Health’, Munich, Germany and 2Bone Marrow Transplantation Section, Department of Hematology and
Oncology, Martin-Luther-University Halle-Wittenberg, Halle, Germany
The transcription factor C/EBPa (CEBPA) is a key player in
granulopoiesis and leukemogenesis. We have previously re-
ported the interaction of C/EBPa with other proteins (utilizing
mass spectrometry) in transcriptional regulation. In the present
study, we characterized the association of the MYST domain
histone acetyltransferase Tat-interactive protein (TIP) 60 (HTA-
TIP) with C/EBPa. We show in pull-down and co-precipitation
experiments that C/EBPa and HTATIP interact. A chromatin
immunoprecipitation (ChIP) and a confirmatory Re-ChIP assay
revealed in vivo occupancy of the C/EBPa and GCSF-R promoter
by HTATIP. Reporter gene assays showed that HTATIP is a co-
activator of C/EBPa. The co-activator function of HTATIP is
dependent on its intact histone acetyltransferase (HAT) domain
and on the C/EBPa DNA-binding domain. The resulting balance
between histone acetylation and deacetylation at the C/EBPa
promoter might represent an important mechanism of C/EBPa
action. We observed a lower expression of HTATIP mRNA in
undifferentiated U937 cells compared to retinoic acid-induced
differentiated U937 cells, and correlated expression of CEBPA
and HTATIP mRNA levels were observed in leukemia samples.
These findings point to a functional synergism between C/EBPa
and HTATIP in myeloid differentiation and suggest that HTATIP
might be an important player in leukemogenesis.
Leukemia advance online publication, 31 January 2008;
doi:10.1038/sj.leu.2405101
Keywords: C/EBPa; HTATIP; mass spectrometry; AML
Introduction
Transcription factors strongly influence cellular lineage commit-
ment during hematopoiesis, and the enforced expression of
some transcription factors can alter the fate of developing
hematopoietic progenitor cells.1 The CCAAT/enhancer-binding
protein alpha (C/EBPa, CEBPA) is a tissue-specific transcription
factor expressed in the liver, differentiating adipocytes and
myelomonocytic cells that was shown to regulate hematopoietic
activity.2,3 C/EBPa-knockout mice have a block in granulocyte
differentiation in the fetal liver and in newborns.4 C/EBPa acts as
a tumor suppressor gene in acute myeloid leukemia (AML).5
Inactivation of C/EBPa is an important event in AML and
overexpression of C/EBPa leads to differentiation and growth
arrest in AML.6 Thus, C/EBPa has essential functions in the
regulation of cell proliferation and differentiation. Recent data
from our laboratory indicated that the differentiation and
proliferation functions of C/EBPa involve direct protein–protein
interactions.7–10 Furthermore, C/EBPa is known to cooperate
with the histone acetyltransferases (HATs) p300 and CREB-
binding protein (CBP) to activate transcription.11,12
Thus, C/EBPa functions within a large network consisting of
different protein–protein interactions to regulate gene expres-
sion and hence cellular differentiation by maintaining a fine
balance between histone acetylation and deacetylation. How-
ever, in-depth studies involving protein–protein interactions of
C/EBPa with HATs are lacking.11,13
In our efforts to identify interacting partners of C/EBPa
utilizing mass spectrometry-based proteomics,7,8 we identified
TIP60 (HTATIP; Tat-interactive protein, 60 kDa), a MYST family
HAT. The identification of TIP60 as a C/EBPa interacting partner
is intriguing because of the role of TIP60 in transcriptional
activation, DNA repair and histone acetylation. TIP60 functions
as a co-activator of many key cellular proteins such as nuclear
hormone receptors, b-catenin and nuclear factor-kB.14
In the present study, we provide evidence for the physical
association of TIP60 with C/EBPa and the consequences of this
association for the transcriptional function of C/EBPa, and for
the correlated expression between C/EBPa and TIP60 in certain
subtypes of leukemia and during differentiation of U937 cell
line. Our data might provide a useful framework for elucidating
the role of TIP60 in the biology of leukemia in general and in
novel C/EBPa functions in particular.
Materials and methods
Cell culture, plasmids and reporter constructs
The HEK293T, U937 and K562 C/EBPa-ER (estrogen receptor)
cell lines were cultured as described previously.7 The pEYFP
(yellow fluorescent protein)-N1-TIP60 and pEYFP-N1-TIP60
(-HAT) plasmids have been described.15 TIP60 was subcloned
from pcDNA3-TIP60 to obtain the pGEX-4T3-TIP60 (GST-TIP60)
expression plasmid. The pcDNA3-C/EBPa, pcDNA6-C/EBPa-
His6, pTK, p(C/EBP)2TK, pGAL4-luc and pGAL4DBD-VP16
plasmids were described previously.7,9 As an internal control
plasmid for co-transfection assays, the pRL-TK (thymidine
kinase) construct driving a Renilla luciferase gene (Promega,
Madison, WI, USA) was used. The C/EBPa-GAL4DBD expres-
sion plasmid was kindly provided by A Friedman. GST, GST-C/
EBPa and GST-C/EBPa DBD (the basic region and the leucine
zipper of C/EBPa; amino acid 270–358, fused to GST) plasmids
were kind gifts from C Nerlov. GST-C/EBPa 1–97 (fragment
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containing transactivation domain 1) and GST-C/EBPa 98–262
(fragment containing transactivation domain 2) of C/EBPa were
constructed by PCR amplification from C/EBPa-His6 and cloned
into the EcoRI/XhoI sites of pGEX4 T.1 (Amersham Biosciences,
GE Healthcare, Uppsala, Sweden). Details of plasmid construc-
tion are available upon request.
Reporter gene assays
Reporter assays using transient transfection of 293T cells have
been described before.7 The DNA amount of the reporter
constructs and expression plasmids used for transfections were
0.1 mg for pTK, p(CEBP)2TK and pGAL4-luc; 0.01 mg for pRL-TK;
0.1 mg for the expression plasmids for C/EBPa and 0.05, 0.1, 0.2
or 0.3 mg for pEYFP-N1-TIP60 (or pcDNA3-TIP60) or pEYFP-N1-
TIP60(-HAT) and 0.1, 0.2 or 0.3mg for C/EBPa-GAL4DBD. The
total DNA amount of pre-transfection was normalized with the
corresponding empty expression vectors.
Glutathione S-transferase pull down, gel electrophoresis
and mass spectrometry
The proteomics methodology was used essentially as described
recently by our group.7,8 The separation of peptides by one-
dimensional nano reverse-phase liquid chromatography and
their identification by matrix-assisted laser desorption/ionization
time of flight mass spectrometry (MALDI-TOF/TOF), including
the use of the GPS Explorer software for protein identification,
were performed as described.16
Co-precipitation
293T cells were transfected with expression plasmids for
YFP-TIP60, YFP-EV (empty vector) and His6-tagged C/EBPa as
described.17 For co-immunoprecipitation, nuclear extracts were
prepared from 293T cells transfected with C/EBPa and
YFP-TIP60 expression plasmids and were used for pull down
with antibodies against TIP60 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; sc-5725 (N terminal) and sc-5727 (C terminal),
1 mg each, mixed together). The protocol used for co-immuno-
precipitation was described before.8 The following antibodies
were used for subsequent immunodetection: rabbit anti-C/EBPa
polyclonal antibody (sc-61; Santa Cruz), rabbit anti-green
fluorescent protein (GFP) monoclonal antibody (Invitrogen,
Molecular Probes, Karlsruhe, Germany) and mouse anti-His6
(1 922 416, Roche, Indianapolis, IN, USA).
Chromatin immunoprecipitation (ChIP) assay, Re-ChIP,
real-time PCR quantification of genomic DNA ChIP, cell sorting,
semiquantitative reverse transcriptase-PCR and expression
analysis of HTATIP/CEBPA in leukemia samples are described
in detail in the Supplementary Information.
Results
Proteomic identification of TIP60 as an interacting
partner of C/EBPa
We have previously reported the use of mass spectrometry-based
proteomics in identifying C/EBPa-interacting proteins in vitro as
well as in vivo.7,8 In the present study, we extended our
approach to include full-length C/EBPa. A glutathione
S-transferase (GST) C/EBPa fusion protein was used to pull down
C/EBPa-interacting proteins from nuclear extracts of the myeloid
cell line U937 prepared under similar experimental conditions as
described previously7 (Supplementary Figure 1a). Protein spots
specific for the GST-C/EBPa pull down (Figure 1a) were excised
from the gels and identified by MALDI-TOF/TOF. Additionally,
pre-purified GST pull-down samples (pre-cleared with GST
protein) were incubated with the GST-C/EBPa bait and subjected
to 12% SDS-polyacrylamide gel electrophoresis (PAGE) followed
by nano reverse-phase liquid chromatography and subsequent
peptide identification by MALDI-TOF/TOF (Figure 1b). Twenty-
nine candidate interacting proteins were identified using these
approaches (Supplementary Table 1). No major overlap was
found among the proteins identified by the two approaches used,
probably reflecting the differences in the separation techniques
used and the fact that only a subset of potential interactors was
identified by either approach. However, confirming the validity
of these approaches several known C/EBPa interacting partners,
such as pRB (retinoblastoma susceptibility protein), hnRNP, E2F4
and C/EBPa itself, were among the proteins identified.
TIP60 was identified as one of the interacting partners of
C/EBPa. Because of its function as a HAT involved in many
biological processes, we chose to concentrate on the analysis of
the TIP60–C/EBPa interaction.
Confirmation of C/EBPa and TIP60 interaction
To confirm the interaction of TIP60 with C/EBPa, we performed
co-precipitation and GST pull-down assays. The GST-TIP60
fusion protein was able to retain in vitro-translated [35S]methio-
nine-labeled C/EBPa (Figure 2a, lane 5), whereas GST alone was
not (Figure 2a, lane 3). We next sought to characterize this
potential interaction in a myeloid cell line. As previously
reported, endogenous TIP60 could not be immunodetected by
available TIP60 antibodies. Therefore, 293T cells transfected
with expression constructs for His6-tagged C/EBPa and YFP-
TIP60 or YFP alone were followed by a Nickel-NTA (Ni2þ -
nitrilotriacetate) Agarose purification of the His-tagged C/EBPa
protein and western blotting using anti-GFP and anti-His
antibodies. This experiment showed that YFP-TIP60 but not
YFP was recovered with C/EBPa (Figure 2b, compare lanes
3 and 4). Similarly, co-immunoprecipitation assays revealed that
C/EBPa co-immunoprecipitates with TIP60 antibodies but not
with immunoglobulin G control (Supplementary Figure 1b).
Confocal microscopy also revealed colocalization of TIP60 and
C/EBPa in the nucleus (data not shown). Taken together, these
experiments showed that C/EBPa and TIP60 do interact,
confirming the result of the proteomic interaction screen.
TIP60 increases the ability of C/EBPa to transactivate a
minimal TK promoter
To test the ability of TIP60 to modulate C/EBPa-mediated
transcriptional activation, transient transfection assays were
performed in the HEK293T cell line using a luciferase reporter
plasmid with a minimal TK promoter containing two CCAAT
sites.8 Co-transfection of a TIP60 expression construct enhanced
the ability of C/EBPa to transactivate the reporter plasmid
fivefold compared to C/EBPa alone in a dose-dependent manner
(Figure 2c). In control experiments, no effect of TIP60 on C/EBPa
activity was observed when a reporter plasmid without CCAAT
sites was used. TIP60 alone had no effect on luciferase activity,
indicating that TIP60 specifically mediates upregulation of the
reporter through its interaction with C/EBPa.
HAT activity of TIP60 is required for its cooperativity
with C/EBPa
We next investigated whether the HAT activity of TIP60 is
required to increase the transcriptional activation capacity of
HTATIP is a co-activator of CEBPA
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C/EBPa. While YFP-TIP60 co-transfected with C/EBPa is able to
increase the luciferase activity fivefold compared to C/EBPa
alone, co-transfection of the YFP-TIP60(-HAT) expression
plasmid failed to affect the transactivation capacity of C/EBPa
(Figure 2d). YFP-TIP60 and YFP-TIP60(-HAT) were expressed
at equal levels (Figure 2e). Furthermore, we show that
co-transfection of C/EBPa with TIP60 does not alter the C/EBPa
protein levels to rule out an increase in the reporter gene activity
due to increased C/EBPa protein levels (Figure 2f).
Co-activation by TIP60 depends on the DNA-binding
domain of C/EBPa on a GAL4-responsive promoter
The DNA-binding domain (DBD) of C/EBPa is required for its
transactivation potential.18 To investigate whether the TIP60-
mediated increase in the transactivation capacity of C/EBPa
requires the DBD of C/EBPa, a C/EBPa-Gal4DBD construct was
used, in which the DBD of C/EBPa is replaced by the Gal4-
DBD. C/EBPa-Gal4DBD transactivates a Gal4-UAS5 (penta-
meric upstream-activating sequence) luciferase reporter plasmid
35-fold (Figure 3a). However, co-transfection of TIP60 did not
lead to increased transactivation. Gal4DBD-VP16 was used as a
positive control in these experiments. These results indicate that
the co-activator function of TIP60 requires the C/EBPa-DBD.
To investigate the protein domains involved in the C/EBPa–
TIP60 interaction, we performed GST pull-down experiments
using GST-tagged C/EBPa DBD and C/EBPa 1–97. 293T cells
were transfected with pcDNA-TIP60 and 24 h after transfection,
nuclear extracts were incubated with the GST-tagged proteins as
shown in Figure 3b (upper panel). Immunoblot analysis using
TIP60 antibody revealed that TIP60 interacts with GST-C/EBPa,
GST-C/EBPa DBD and GST-C/EBPa 1–97. Equal amounts of
GST-tagged proteins were used in these experiments (Figure 3b,
lower panel, Supplementary Figure 1c). Taken together, we
conclude that both the DBD and the fragment containing the
transactivation domain of C/EBPa are sufficient on their own for
interaction with TIP60.
TIP60 occupies the endogenous C/EBPa and GCSFR
promoters in vivo
We next investigated whether the C/EBPa–TIP60 interaction also
occurs in vivo at the C/EBPa promoter and the GCSFR promoter,
which is known to be a target of C/EBPa.19,20 To address this, we
performed quantitative radioactive and non-radioactive ChIP
experiments in K562 cells that express conditionally active
C/EBPa-ER chimaera (Figure 4). These cells undergo granulo-
cytic differentiation when treated with b-estradiol (data not
Figure 1 Mass spectrometry-based proteomics identifies putative proteins of the C/EBPamultiprotein complex. (a) Silver-stained two-dimensional
gel showing differentially expressed proteins after glutathione S-transferase (GST) pull down from nuclear extracts of U937; protein spots that were
excised and subsequently analyzed by mass spectrometry are marked with arrows. (b) Coomassie-stained SDS-polyacrylamide gel electrophoresis
(PAGE) gels after GST pull down from U937 nuclear extracts using GST-C/EBPa. Nuclear extracts were pre-cleared thrice by incubation with GST
protein that retained all the proteins unspecifically interacting with both matrix and the GST protein. The pre-cleared extract was then incubated
with the GST-C/EBPa bait. After several wash steps to remove unbound proteins, the complex components were eluted from the beads, separated
by two-dimensional SDS-PAGE and stained with colloidal Coomassie; proteins identified are listed in Supplementary Table 1.
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shown). Antibodies against TIP60 and C/EBPa were used to
precipitate the crosslinked chromatin. Our results showed that
even in the uninduced condition (0 h) some endogenous TIP60
and C/EBPa are present at the C/EBPa promoter (Figures 4a and
b). After induction with b-estradiol, immunoprecipitation with
anti-TIP60 antibodies (N/C terminal) led to a strong enrichment
of the GCSFR promoter amplicon and a significant enrichment
for the CEBPA promoter amplicon (Figure 4a). Immunoprecipi-
tation using the C/EBPa antibody led to stronger amplification of
the GCSFR and CEBPA promoter amplicons (Figure 4b). The
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Figure 2 C/EBPa interacts with TIP60. (a) Glutathione S-transferase (GST) pull-down assay was performed with [35S]methionine-labeled in vitro-
translated C/EBPa and bacterially expressed GST-TIP60. Only GST-TIP60 (lane 5) was able to retain C/EBPa. (b) 293T cells were transfected with
C/EBPa-His6 and yellow fluorescent protein-empty vector (YFP-EV) or YFP-TIP60 as indicated and then harvested in co-immunoprecipitation buffer
and incubated with Nickel-NTA agarose beads to precipitate His-tagged C/EBPa protein. Eluted proteins were analyzed by western blotting. The
upper half of the western blot was probed with a green fluorescent protein (GFP) antibody and the bottom half with a His antibody as indicated.
Western blot analysis was performed on the same membrane. (c) TIP60 increases the ability of C/EBPa to transactivate a minimal p(CEBP)2TK
promoter. Luciferase assays were performed in 293T cells lacking endogenous C/EBPa. Cells were transiently transfected with a reporter construct
containing a minimal thymidine kinase (TK) promoter with two CEBP-binding sites p(CEBP)2TK or a reporter without CEBP sites (pTK) and
expression plasmids for C/EBPa and YFP-TIP60 (or pcDNA-TIP60). The activity obtained for the p(CEPB)2TK plasmid without C/EBPa transfection
was set as one and fold changes are shown. (d) The increase in the C/EBPa transactivation activity depends on the histone acetyltransferase (HAT)
domain of TIP60: Transient transfections were performed in 293T cells with the p(CEBP)2TK reporter construct and expression plasmids for
C/EBPa, YFP-TIP60 and YFP-TIP60(-HAT). The activity obtained for the p(CEPB)2TK plasmid without C/EBPa transfection was set as one and fold
changes are shown. The pRL-TK Renilla luciferase construct was co-transfected to normalize for transfection efficiency. Experiments were
performed in triplicate and luciferase activity was measured in duplicate for each experiment. Error bars represent s.d. (e) Western blot showing
equal expression of YFP-TIP60 (lane 1) and YFP-TIP60(-HAT) (lane 2) in 293T cells. (f) TIP60 co-transfection does not alter C/EBPa protein level:
293T cells were transfected with expression plasmids for C/EBPa-His6 and YFP-TIP60. C/EBPa levels were determined by western blotting. Cells
transfected with C/EBPa in the absence of TIP60 (lane 2) served as the source for determining the C/EBPa level.
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specificity of the binding of TIP60 and C/EBPa to the promoter
region of C/EBPa could be demonstrated by a no-antibody
control and by the fact that an amplicon from the C/EBPa coding
region could not be amplified after precipitation (Supplementary
Figure 1d). Thus, C/EBPa and TIP60 associate in vivo in
the context of chromatin and are more abundant on the
C/EBPa promoter when cells are induced toward granulocytic
differentiation.
Differentiation induction leads to increased histone
acetylation at the C/EBPa and GCSFR promoters in vivo
concomitant with TIP60 recruitment
Our results indicated TIP60 occupancy at the C/EBPa promoter.
Therefore, we hypothesized that histone acetylation at the
C/EBPa promoter might be influenced by TIP60 recruitment to
chromatin. We therefore performed a ChIP experiment using
antibodies against acetylated histones H3 and H4 to precipitate
the crosslinked chromatin derived from uninduced and induced
K562 C/EBPa-ER cells. As measured by quantitative PCR,
abundant levels of acetylated H4 and H3 histones were found
to be present at the C/EBPa and GCSFR promoter loci in K562
C/EBPa-ER cells 6 h after the addition of b-estradiol (Figures
4c and d). Immunoprecipitation using an isotype-matched
immunoglobulin G was also used to serve as a negative control
(data not shown).
To verify the TIP60–C/EBPa interaction at the GCSFR
promoter amplicon, a Re-ChIP experiment was performed. After
b-estradiol treatment, crosslinked nuclear lysates were first
immunoprecipitated with anti-C/EBPa, and then the immuno-
precipitate was subjected to a second immunoprecipitation with
anti-TIP60 antibodies. The amount of GCSFR promoter DNA
was then assayed by quantitative real-time PCR. The second
immunoprecipitation showed an enrichment of over 100-fold of
the GCSFR promoter compared to the uninduced samples
(Figure 4e). This clearly shows a strong increase of TIP60 at the
GCSFR promoter when the cells are induced toward granulo-
cytic differentiation. In summary, we conclude that TIP60 might
play an important role in the regulation of histone acetylation
and deacetylation at the C/EBPa promoter.
HTATIP and CEBPA expression levels correlate in
retinoic acid-induced myeloid differentiation in U937
cells as well as in certain leukemia subtypes
To analyze the level of TIP60 mRNA upon granulocytic
differentiation, we used the myelomonocytic U937 cell line
that can be induced to differentiate toward more mature
granulocyte cells by retinoic acid treatment as assessed by the
expression of the cell surface differentiation marker CD11b and
morphology (data not shown). TIP60 expression was analyzed
by a semiquantitative reverse transcriptase-PCR assay on RNA
isolated from differentiated CD11bþ U937 cells by fluores-
cence-activated cell sorting after 60 h of treatment with retinoic
acid. Compared to undifferentiated CD11b U937 cells, higher
TIP60 mRNA expression was observed in differentiated U937
cells. As expected, C/EBPa and C/EBPe transcript levels were
increased upon myeloid differentiation. b-actin levels were used
for RNA quality control (Figure 5a).
To obtain a preliminary assessment whether this correlated
expression would also be found in myeloid leukemias, we
analyzed the mRNA expression of TIP60 and CEBPA in a
microarray data set from a small cohort of patients with defined
leukemia subtypes (CML: chronic myeloid leukemia; AML_M2:
AML-M2 with the AML1/ETO fusion; AML_M3: AML-M3 with
the PML/RARA fusion; AML_M4: AML-M4eo with the CBFB/
MYH11 fusion) and from normal bone marrow samples
(Figure 5b). A Pearson’s two-tailed correlation analysis showed
that there was a significant positive correlation between the
expression levels of HTATIP and CEBPA when considering all
samples (n¼ 50) together (r¼ 0.606, P¼ 0.00000314). In view
of the low sample number (n¼ 10) in the individual subgroups,
this correlation reached significance at the 95% confidence
interval only in the group with the AML1/ETO fusion gene
(AML_M2) (r¼ 0.703, P¼ 0.023). Studies in larger patient
cohorts are expected to clarify this issue.
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represent s.d. (b) (Upper panel) GST pull down showing physical interaction between pcDNA-TIP60 and GST-C/EBPa, GST-C/EBPa-DBD and
GST-C/EBPa 1–97. GST-C/EBPa, GST-C/EBPa-DBD and GST-C/EBPa 1–97 interact with TIP60 (lanes 1–3). GST does not retain TIP60 (lane 4).
(Lower panel) Coomassie-stained gel showing bacterially expressed and purified GST-C/EBPa, GST-C/EBPa-DBD, GST-C/EBPa 1–97 and GST
proteins; bovine serum albumin was used for quantification.
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Discussion
Protein–protein interactions play key roles in all cellular
processes and functions. Identifying and characterizing such
protein interactions is therefore required to understand these
processes at a molecular level. To our knowledge, TIP60 is the
first MYST domain family member identified as an interaction
partner of C/EBPa. This finding might be of potential importance
with regard to the functions of C/EBPa, in particular since there
are sparse data regarding C/EBPa and histone acetylation.
While we were partially successful in finding known C/EBPa
interaction partners using different proteomic approaches (two-
dimensional gels vs SDS-PAGE LC-MS/MS), we also identified
several novel putative C/EBPa-interacting proteins, thereby
giving new dimensions to C/EBPa functions. Future technologi-
cal advances in the proteomics field should overcome the
discrepancies found with the different proteomic approaches.
Nevertheless, we report several additional putative C/EBPa-
interacting proteins to be characterized in future studies
(Supplementary Table 1).
The TIP60–C/EBPa interaction is intriguing given the fact that
TIP60 is a MYST domain HAT. This family of HATs has been linked
to mediate long-lasting epigenetic changes of chromatin (for
example, mof in Drosophila is responsible for X chromosome
dosage compensation21). Additionally, the acetyl transferase
activity of TIP60 on nucleosomal histones in the presence of other
factors has been reported, and TIP60 can function both as a
transcriptional co-activator or as a co-repressor, connecting a
number of different factors to the basal transcriptional machinery.14
TIP60 is involved in oncogenesis and other disease processes.
Upregulation of TIP60 has been recently linked to the promotion
of epithelial tumorigenesis, Alzheimer’s disease and progression
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Figure 4 TIP60 associates with C/EBPa target loci. Chromatin immunoprecipitation (ChIP) analysis of quiescent (0 h) and stimulated (6 h) K562 C/
EBPa-ER cells using antibodies against TIP60 (a), C/EBPa (b), acetylated histone H4 (c) and acetylated histone H3 (d). Two promoters were
analyzed: GCSFR and CEBPA. (a, b) C/EBPa and TIP60 colocalize on the GCSFR and CEBPA loci when stimulated with b-estradiol. Ethidium
bromide-stained gels of conventional PCR products after ChIPs are shown in small insets. (e) Re-ChIP was carried out using the indicated
antibodies on extracts from the quiescent and stimulated (6 h) K562 C/EBPa-ER cells. The data are representative of three experiments with similar
results. Error bars represent s.d.
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of prostate cancer cells to hormone independence and
resistance to chemotherapy.14 Thus, it is possible that upregula-
tion of TIP60 in leukemia confers to the leukemic clone a
survival advantage. It should be noted that TIP60 and two other
MYST domain HATs (MOZ and MORF) have been shown to
interact with other leukemia-relevant proteins like ETV615,22 or
to participate in leukemia-associated chromosomal transloca-
tions (for example, the MOZ/TIF2, MOZ/P300 and MORF/
CBP).23 It was recently shown that TIP60 acts as a tumor
suppressor gene in a mouse model.24 However, we are unaware
of any reports of chromosomal aberrations or mutations that
directly target TIP60.
Interestingly, we observed that TIP60 can interact with the
DBD as well as with the transactivation domain containing
portions of C/EBPa (aa 1–97, Figure 3b; and aa 98–262, data not
shown). These fragments contain transactivation domains of
C/EBPa. Thus, TIP60 could be an important transcriptional
co-regulator for C/EBPa functions by acting in large multi-
protein complexes with other factors that also associate with
C/EBPa. This might be particularly true for proteins such as E2F,
which have been shown to interact with both TIP6025 and
C/EBPa.26
TIP60 can directly acetylate and stabilize non-histone
proteins.14 Our efforts to detect acetylation of C/EBPa by
TIP60 failed (data not shown). The fact that C/EBPa and TIP60
are recruited to the C/EBPa and GCSFR promoters during
granulocytic differentiation in vivo under physiological condi-
tions (Figure 4) suggests that TIP60 enhances the transactivation
capacity of C/EBPa on these promoters. This has been reported
for MYC.27 It is possible that the primary targets of TIP60
acetylation in this context are the histones at C/EBPa-dependent
genes. In fact, we show that there is increased histone
acetylation when the cells are induced toward granulocytic
differentiation concomitant with recruitment of C/EBPa and
TIP60 at the GCSFR promoter. However, at the moment it is not
clear whether histone acetylation is a prerequisite or a
consequence of the C/EBPa–TIP60 interaction or whether this
histone acetylation is a direct result of the TIP60 HAT activity.
The increase in expression of both C/EBPa and TIP60 during
retinoic acid-induced differentiation of U937 cells suggests a
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(a) Expression of TIP60 (HTATIP), C/EBPa and C/EBPe was analyzed by semiquantitative reverse transcriptase-PCR in CD11b, retinoic acid
untreated U937 cells and in retinoic acid treated, CD11bþ U937 cells by fluorescence-activated cell sorting after 60 h. (b) Boxplots of mRNA
expression levels (microarray signal intensity values) of C/EBPa and TIP60 in normal bone marrow, chronic myeloid leukemia (CML) and three
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(Pearson’s two-tailed correlation analysis) was found to be statistically significant at 95% confidence interval for AML_M2 subtype between CEBPA
and HTATIP (r¼ 0.703, P¼0.023).
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role for TIP60 in myeloid differentiation. Expression microarray
data from patients with defined leukemia subtypes showed an
overall significant positive correlation between TIP60 (HTATIP)
and C/EBPa mRNA levels (Figure 5b), suggesting the role of
TIP60 in leukemogenesis. However, the different levels of TIP60
expression in the AML subtypes could also be a reflection of the
differentiation status of the AML blasts rather than being
important for leukemogenesis. Nevertheless, TIP60 might be
critical in regulating the promoters of myeloid differentiation-
specific genes.
In summary, our observations and findings indicate a
functional synergism between two tumor suppressor proteins
involved in hematological malignancy. TIP60 may be an
integral part of multiprotein complexes, which convert the
transcriptional decisions initiated by C/EBPa into long-lasting
epigenetic chromatin changes. Finally, our data provide a
framework for investigating the mechanisms and signaling
pathways that control the interaction of TIP60 with C/EBPa,
for example, by examining the phenotype of mice with tissue-
specific knockouts of these two genes.
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Proteomic identiﬁcation of C/EBP-DBD multiprotein complex: JNK1
activates stem cell regulator C/EBPa by inhibiting its ubiquitination
AK Trivedi1, D Bararia1, M Christopeit1, AA PeerZada1, SM Singh1, A Kieser2, W Hiddemann3,
HM Behre4 and G Behre1
1Bone Marrow Transplantation Section, Department of Internal Medicine IV – Hematology and Oncology, State Center for Cell and
Gene Therapy, Martin-Luther-University Halle-Wittenberg, Halle, SA, Germany; 2Department of Gene Vectors, GSF-National
Research Center for Environment and Health, Munich, Germany; 3Department of Internal Medicine III Grosshadern, University of
Munich, Munich, Germany and 4Andrology Section, Martin-Luther-University Halle-Wittenberg, Halle, Germany
Functional inactivation of transcription factors in hema-
topoietic stem cell development is involved in the
pathogenesis of acute myeloid leukemia (AML). Stem
cell regulator C/enhancer binding protein (EBP)a is
among such transcription factors known to be inactive in
AML. This is either due to mutations or inhibition by
protein–protein interactions. Here, we applied a mass
spectrometry-based proteomic approach to systematically
identify putative co-activator proteins interacting with the
DNA-binding domain (DBD) of C/EBP transcription
factors. In our proteomic screen, we identiﬁed c-Jun
N-terminal kinase (JNK) 1 among others such as PAK6,
MADP-1, calmodulin-like skin proteins and ZNF45 as
proteins interacting with DBD of C/EBPs from nuclear
extract of myelomonocytic U937 cells. We show that
kinase JNK1 physically interacts with DBD of C/EBPa
in vitro and in vivo. Furthermore, we show that active
JNK1 inhibits ubiquitination of C/EBPa possibly by
phosphorylating in its DBD. Consequently, JNK1 pro-
longs C/EBPa protein half-life leading to its enhanced
transactivation and DNA-binding capacity. In certain
AML patients, however, the JNK1 mRNA expression and
its kinase activity is decreased which suggests a possible
reason for C/EBPa inactivation in AML. Thus, we report
the ﬁrst proteomic screen of C/EBP-interacting proteins,
which identiﬁes JNK1 as positive regulator of C/EBPa.
Oncogene (2007) 26, 1789–1801. doi:10.1038/sj.onc.1209964;
published online 18 September 2006
Keywords: JNK1; C/EBPa; ubiquitination; AML and
proteomics
Introduction
C/enhancer binding protein (EBP)a belongs to a family
of transcription factors that homo- and hetero-dimerize
via their conserved C-terminal leucine zipper domains
and bind DNA as dimers through the adjacent basic
regions (b-Zip) (Landschulz et al., 1989). C/EBPa and
PU.1 are two major regulators of hematopoietic stem
cell development. Unlike PU.1, which governs trans-
cription of a wide spectrum of myeloid-speciﬁc genes,
C/EBPa has a more speciﬁc function in granulopoietic
stem cell development (Scott et al., 1992; Muller et al.,
1995). C/EBPa/ knockout mice show no mature
granulocytes, whereas other hematopoietic lineages are
not affected (Zhang et al., 1997). Recent ﬁndings have
demonstrated a direct link between myeloid leukemo-
genesis and certain transcription factors including
C/EBPa.
Mutations in C/EBPa leading to its disruption have
recently been shown in acute myeloid leukemia (AML)
(Pabst et al., 2001b; Gombart et al., 2002; Frohling
et al., 2004; Perrotti et al., 2004). In a recent study,
Smith et al. (2004) have shown a C/EBPa mutation in
inherited AML, where multiple members were affected
by AML associated with an identical mutation in
CEBPA. Several studies have emphasized that protein–
protein interactions of transcription factors may con-
tribute to leukemogenesis (Westendorf et al., 1998;
Pabst et al., 2001a; Reddy et al., 2002; Tenen, 2003;
Vangala et al., 2003). Modiﬁed properties of a multi-
protein complex resulting from variable interacting
partners are likely to be involved with all three
hematopoietic checkpoints: cell proliferation, differen-
tiation and apoptosis; impairment of each of which may
induce leukemia. Hence, an important emerging concept
is that not only relative expression of transcription
factors is important, but that protein–protein interac-
tions among various transcription factors are crucial
(Sieweke and Graf, 1998). Potential antagonistic protein
interactions leading to a block in C/EBPa function in
AML have been well implicated in recent ﬁndings (Pabst
et al., 2001a; Vangala et al., 2003; Zheng et al., 2004).
Interestingly, C/EBPa also functions via direct protein–
protein interactions in normal stem cell development
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(Behre et al., 2002a; D’Alo et al., 2003; Muller
et al., 2004); PU.1 and c-Jun inactivation (Rangatia et al.,
2002; Reddy et al., 2002), E2F repression (Porse et al.,
2001), and cdk2 and cdk4 inhibition (Wang et al., 2001) by
C/EBPa are all accompanied by direct protein–protein
interactions. Moreover, different protein partners of
C/EBPa in young and old mice livers itself demonstrate
the importance of protein–protein interactions during
ageing (Iakova et al., 2003).
Owing to its role in differentiation, anti-proliferation
and apoptosis, functional inactivation of C/EBPa is
central to the pathogenesis of AML. However, mole-
cular mechanisms behind this are poorly understood
except for some cases (Pabst et al., 2001b; Perrotti et al.,
2002; Zheng et al., 2004). Recent advances in mass
spectrometry have revolutionized the analysis of the
proteome of a cell by simplifying the analytical protocol
and increasing the sensitivity of detection by several
orders of magnitude. Global high throughput mass
spectrometry-based functional proteomic approaches
could lead to new insights into the network of C/
EBPa-interacting proteins relevant for stem cell deve-
lopment and AML therapeutics (Mann et al., 2001;
Cristea et al., 2004; Balkhi et al., 2006). Therefore, to
evaluate the signiﬁcance and role of proteins interacting
with C/EBPa and modulating its activity, we analysed
the C/EBPa multiprotein complex using mass spectro-
metry-based proteomics.
Results
Proteomic identiﬁcation of the C/EBP-DBD multiprotein
complex by 2D gel electrophoresis
In order to identify co-activator proteins interacting
with C/EBPa and modulating its activity in stem cell
development and AML, a mass spectrometry-based
proteomics approach was applied. The DBD of C/EBPs
contains a conserved leucine zipper region, which is
necessary for interaction with other proteins; there-
fore, we used glutathione-S-transferase (GST) fused
with DBD to identify C/EBP-interacting proteins.
Figure 1a depicts wild-type C/EBPa with conserved
domains of C/EBP family proteins and GST-fused
constructs, which we used for our investigation in this
study. We puriﬁed GST fusion proteins from bacterial
strain Escherichia coli after inducing with 0.5mM
isopropyl-thiogalactopyranoside (IPTG). The commas-
sie-stained gel picture shows expression of GST
fused with DNA-binding domain (DBD) of C/EBP
(GST-DBD), GST-C/EBPa and GST alone (Figure 1b);
Different amount of commercially available bovine
serum albumin was resolved together to quantify the
respective volume of GST fusion proteins to be used in
further assays. We conﬁrmed the physical activity of
bacterially puriﬁed fusion proteins by assessing their
interaction with in vitro-translated (ivt PU.1) and
endogenous PU.1 from U937 nuclear extract (NE);
PU.1 is known to interact with C/EBPa in its DBD
(Reddy et al., 2002) (Figure 1c–d). Next, we performed
GST pull down assay from NE of myelomonocytic cell
line U937. Proteins from NE bound with fusion proteins
on GST sepharose beads were lysed in sample buffer and
subsequently separated by isoelectric focussing (IEF) in
ﬁrst dimension followed by second-dimensional sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE). Silver staining was performed to visualize
differentially interacting proteins from 2D gels
(Figure 1e). Protein spots present only in GST-DBD gel
were excised and analysed by matrix-assisted laser
desorption/ionization–time of ﬂight (MALDI–TOF)
mass spectrometry for further identiﬁcation; as control
we identiﬁed GST as a common spot from both gels.
Identiﬁed protein spots interacting with the DBD region
of C/EBP are listed in Figure 1f. Note that for large
number of protein spots the mowse score was insigniﬁcant
and hence could not be identiﬁed. This is presumably due
to small spot size (protein amount), silver interference and
low sensitivity of mass spectrometer.
C/EBPa physically interacts with JNK1 in vitro and
in vivo
c-Jun N-terminal kinase (JNK) is an important member
of mitogen-activated protein kinase (MAPK) family
and regulates the activity of its physically associated
substrates (Fuchs et al., 1997). Therefore, we chose
JNK to study the biological relevance of its interac-
tion with C/EBPa. We conﬁrmed direct protein–protein
interaction between GST-DBD and JNK1 by incubating
GST-DBD with methionine-labelled ivt JNK1 for
90min. After stringent washing, interaction between
JNK1 and GST-DBD was observed (Figure 2a; lane 5).
We next examined whether JNK1 interacts with
full-length C/EBPa and performed GST pull down
assay using GST-DBD, GST-C/EBPa and GST alone
from 25 ng/ml anisomycin-induced (U937 radioimmu-
noprecipitation assay (RIPA*) and uninduced (U937
RIPA) cell lysates; anisomycin is a potent activator of
JNK which acts on upstream activators of JNK
(Bogoyevitch et al., 1995; Morton et al., 2003).
Immunoblot against JNK1 showed direct interaction
of JNK1 (Figure 2b; lanes 2, 6 and 8 with fast migrating
lanes) and phospho-JNK1 (pJNK) (Figure 2b; lanes 1, 5
and 7 with slow migrating bands as compared to
respective uninduced conditions) with GST-DBD and
GST-C/EBPa. The higher binding afﬁnity of GST-C/
EBPa with JNK could be owing to favorable conforma-
tion of full-length wild-type C/EBPa protein as com-
pared to shorter GST-DBD; GST-c-Jun served as
positive control (Figure 2b). Note that, bands below
35 kDa, GST or degraded GST-fusion proteins show
input in each lane. We also examined in vivo interaction
of C/EBPa and JNK1 by co-immunoprecipitation
of JNK1 from U937 RIPA lysates. Immunoblot against
JNK1 (upper panel) followed by C/EBPa (lower panel)
after stripping the same membrane conﬁrmed in vivo
interaction of JNK1 and C/EBPa in myeloid cells
(Figure 2c).
As JNK interacts with GST-DBD, we wished to map
down the region of C/EBPa interacting with JNK1 using
JNK1 activates C/EBPa
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previously reported C/EBP-DBD mutants (Landschulz
et al., 1989). 293T cells were transfected with different
C/EBP-DBD mutants described in Materials and
methods together with hemagglutinin (HA)-JNK; 24 h
post-transfection RIPA extracts were prepared and JNK
was immunoprecipitated using HA antibody. Immuno-
blot against HA and subsequently with C/EBPa
antibody after stripping the same membrane shows
JNK interaction with C/EBPa and various DBD
mutants with variable intensity (Figure 2d). Taken
together, this conﬁrms that JNK1 directly interacts with
DBD region of C/EBPa. Further studies using C/EBPa
basic region deletion mutant could further narrow down
the region of C/EBPa interacting with JNK1.
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Figure 1 2D proteomic identiﬁcation of the C/EBP-DBD multiprotein complex. (a) Schematic presentation of wild-type C/EBPa and
different GST fusion proteins. (b) Commassie-stained gel shows bacterially puriﬁed GST-C/EBPa, GST-DBD and GST proteins;
different amounts of commercially available puriﬁed bovine serum albumin was separated together to compare the equivalent amount
of bacterially puriﬁed proteins. (c, d) Immunoblot against PU.1 antibody after GST pull down of PU.1 from ivt PU.1 and U937 NE
shows interaction with GST-DBD; sepharose beads served as control. (e) Silver-stained 2D gel shows differentially expressed proteins
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Active JNK increases C/EBPa protein stability by
inhibiting its ubiquitination
JNK1 regulates ubiquitination and hence protein
stability of its physically associated substrates (Fuchs
et al., 1997). Considering that C/EBPa levels are
controlled post-translationally (Hattori et al., 2003;
Subramanian et al., 2003), we determined the effect of
JNK1 on the stability of former protein. Induced
activation of JNK in acute promyelocytic NB4 cells
with 25 ng/ml anisomycin signiﬁcantly increased the
expression of C/EBPa (Figure 3a.i, ivt C/EBPa-His,
46 kDa used as positive control; upper panel, lane 6)
which is consistent with JNK activation as shown by
phospho-c-Jun expression in a separate immunoblot of
same lysates after indicated time points (3a.ii). A similar
effect was observed with acute myelomonocytic HL60
cells when treated with 25 ng/ml of anisomycin
(Figure 3b); 25 ng/ml anisomycin signiﬁcantly activates
JNK1 in HL60 cells (Terrance A Stadheim, 2002). We
also assessed C/EBPa-inducible cell line K562C/EBPa-
ER for JNK-induced C/EBPa protein stabilization,
where C/EBPa-ER protein is active only when induced
with 1 mM b-estradiol but with accelerated degradation
(Cleaves et al., 2004). Immunoblot against C/EBPa
shows anisomycin induction together with b-estradiol
can reduce the degradation of C/EBPa-ER (Figure 3c).
Additionally, MEKK1 (an upstream member of MAPK
pathway that binds to JNK and thereby facilitates the
receipt of signals from upstream inputs to activate it (Xu
and Cobb, 1997)), with or without C/EBPa was
expressed in C/EBPa-null 293T cells and protein levels
were measured. MEKK1 transfection dramatically
increased the amount of C/EBPa (Figure 3d; lane 4),
an effect likely owing to JNK1 activation, as treatment
of MEKK1- and C/EBPa-transfected cells with 20 mM
JNK inhibitor SP600125 3 h post-transfection signiﬁ-
cantly reduced the amount of C/EBPa protein
(Figure 3d; lane 5); SP600125 functions by directly
inhibiting JNK (Han et al., 2001).
We next conﬁrmed that JNK affects C/EBPa
at protein level rather than its mRNA by treating
U937 cells with 50 mg/ml cycloheximide (a chemical
which inhibits new protein synthesis in eucaryotes
by inhibiting peptidyl transferase) before the addition
of 50 ng/ml anisomycin for different time points as
indicated. Immunoblot against C/EBPa after resolving
RIPA lysates on SDS–PAGE shows that C/EBPa
protein degradation is reduced when treated together
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Figure 2 C/EBPa physically interacts with JNK1 in vitro and in vivo. (a) GST pull down assay was performed from methionine-
labelled ivt JNK1 incubated with equal amounts of bacterially puriﬁed GST-DBD (lane 5), GST (lane 6) and GST sepharose beads
(lane 2); autoradiogram was developed after 36 h (b) Immunoblot against JNK1 after GST pull down of JNK1 from RIPA lysates of
anisomycin-induced (U937 RIPA*) and -uninduced U937 cells shows in vitro interaction of JNK1 with GST-C/EBPa, GST-DBD and
positive control GST-c-Jun. (c) C/EBPa and JNK1 interaction was conﬁrmed in vivo in myeloid cells by immunoprecipitation of JNK1
from U937 RIPA lysates and blotting against JNK1 and C/EBPa antibody, respectively. (d) JNK1 interacts with different C/EBP-
DBD mutants; GZ, (Leucine zipper replaced with leucine zipper of yeast GCN4 protein), point mutants BR3 (basic region mutant) and
L1,and 2 form leucine zipper mutated to valine. 293T cells were transfected together with above mutants and HA-JNK and cells were
harvested 24 h post-transfection. JNK1 was immunoprecipitated using an anti-HA antibody (upper panel), same membrane stripped
and blotted with C/EBPa (lower panel). Results are representative of three independent experiments.
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with anisomycin (Figure 3e). However, slow degrada-
tion of C/EBPa after 0 h may be attributed to
JNK activation by cycloheximide itself (Kyriakis and
Avruch, 1990). In addition, analysis of C/EBPa mRNA
expression in anisomycin-induced and -uninduced
U937 cells showed no increase in C/EBPa mRNA;
rather was marginally downregulated (Supplementary
Figure S1).
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Figure 3 Active JNK1 increases C/EBPa protein stability by inhibiting its ubiquitination. (a) Anisomycin-induced activation of JNK1
stabilizes C/EBPa protein; (i) NB4 cells were induced with 25 ng/ml anisomycin for different time points, RIPA lysates were resolved
on SDS–PAGE and blotted with C/EBPa and b-tubulin antibody. (ii) Same lysates were separated on different gel and probed for
pc-Jun as a measure of anisomycin-induced activation of JNK kinase and b-tubulin as loading control. (b) HL60 cells induced with
25ng/ml of anisomycin for different time points were resolved on SDS–PAGE. Immunoblot against C/EBPa shows signiﬁcant increase
in C/EBPa protein after 1 h as compared to uninduced cells. (c) b-Estradiol-inducible cell line K562C/EBPa-Er was treated with 25 ng/
ml anisomycin for different time points and lysed in RIPA buffer. Immunoblot against C/EBPa antibody shows that the rate of
degradation of C/EBPa is lower in anisomycin-induced cell lysates as compared to cells induced with b-estradiol alone; K562Er empty
vector (extreme left, upper panel) is used as control. (d) MEKK1 co-transfection in 293T cells accumulates C/EBPa protein; 293T cells
were transiently co-transfected with C/EBPa and MEKK1; 24 h post-transfection, cells were lysed and separated on SDS–PAGE.
Immunoblot with C/EBPa antibody shows signiﬁcant increase in C/EBPa protein (lane 4). MEKK1-induced increase in C/EBPa
protein drastically decreased when these cells were treated with 20mM JNK inhibitor SP600125 (lane 5). (e) JNK affects C/EBPa at
protein level; U937 cells were treated with cycloheximide before treatment with anisomycin; whole-cell extract was resolved and
immunoblotted with C/EBPa antibody. (f) In vivo HA-Ubi assay was performed as described in Materials and methods. Immunoblot
with HA antibody shows that C/EBPa is signiﬁcantly ubiquitinated (lane 4), whereas this ubiquitination was inhibited upon JNK
activation by co-transfection of MKK7 (Upper panel, lane 5). The membrane was stripped and reprobed for C/EBPa. (g) Like in
Figure 3f, in vivo HA-Ubi assay was performed by transfection of different plasmid constructs as indicated which shows that kinase-
dead JNK mutant (HA-JNK*; lane 6) enhances C/EBPa ubiquitination. Lower panel probed with C/EBPa. (h) Anisomycin-induced
JNK activation prolongs C/EBPa half-life; HL60 cells were labelled with methionine and chased with cold methionine for 0–6 h with or
without anisomycin treatment. C/EBPa was immunoprecipitated from 250mg protein, and analysed by autoradiography after
separating on SDS–PAGE. Pulse chase result was quantiﬁed using AIDA software (Raytest, Germany) depicted in graph, represents
values with error of o10%. Results are representative of three independent experiments. (i) pJNK interacts with C/EBPa in vivo;
pJNK and C/EBPa interaction was conﬁrmed in vivo in myeloid cells by immunoprecipitation of pJNK1 from anisomycin-induced and
-uninduced U937 RIPA lysates. Membrane was immunoblotted against pJNK1 and C/EBPa antibody, respectively.
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Further, as JNK activation stabilizes C/EBPa protein
expression, we determined if activation of JNK1 inhibits
JNK-targeted C/EBPa ubiquitination. Therefore, we
performed in vivo ubiquitination assay by transiently
transfecting 293T cells with HA-tagged Ubiquitin (HA-
Ubi) alone, together with C/EBPa, and with C/EBPa
and MKK7, respectively. Twenty-four hours post-
transfection, cells were harvested in RIPA buffer.
Immunoblot against HA after immunoprecipitation of
C/EBPa shows that C/EBPa is signiﬁcantly ubiquitinated
when co-transfected with HA-Ubi (Figure 3f; lane 4),
whereas this ubiquitination was inhibited in HA-Ubi-,
C/EBPa- and MKK7-co-transfected cells where JNK1 is
activated by MKK7 (Figure 3f; lane5). MKK7 directly
interacts with JNK1 and activates it by receiving signals
from upstream kinases (Moriguchi et al., 1997). Next,
we demonstrate that inactive JNK indeed leads
to enhanced C/EBPa ubiquitination; C/EBPa was
co-transfected with varying amount of MKK7
(Figure 3g; lanes 3, 4 and 5) and kinase-dead JNK
mutant (HA-JNK*; Figure 3g; lane 6) together with
HA-Ubi; 24 h post-transfection, RIPA extract was
prepared and separated on 10% SDS–PAGE. Immuno-
blot against HA antibody shows transfection of kinase-
dead JNK with C/EBPa was sufﬁcient to enhance
ubiquitination of later. Note that in a separate experi-
ment, activation of mutant JNK by co-transfection of
MKK7 could marginally inhibit C/EBPa ubiquitination
(Supplementary Figure S2).
Furthermore, if active JNK1 inhibits C/EBPa ubiqui-
tination, it should enhance C/EBPa protein half-life. To
answer this question, we performed pulse chase assay as
described in Materials and methods. Autoradiogram
developed after 2 days shows that C/EBPa protein half-
life is prolonged (from 100 to B160min) when induced
with anisomycin as compared to uninduced cells
(Figure 3h). Next, to investigate if phospho-JNK
interacts in vivo with C/EBPa to protect later from
ubiquitination, we performed co-immunoprecipitation
of phospho-JNK from anisomycin-induced and -unin-
duced RIPA lysates. Immunoblot against C/EBPa and
subsequent phospho-JNK antibody conﬁrms in vivo
interaction of phospho-JNK with C/EBPa (Figure 3i).
Alternatively, we also performed co-immunoprecipita-
tion of C/EBPa, immunoblot with pJNK and later with
C/EBPa after stripping the same membrane conﬁrmed
in vivo interaction of phsopho JNK and C/EBPa
(Supplementary Figure S3). Taken together, these data
suggest that under normal conditions, JNK1 interaction
with C/EBPa targets its ubiquitination which is inhibited
upon interaction of phospho-JNK with C/EBPa in
response to chemicals or stress. To our knowledge, this
is ﬁrst report of modulation of C/EBPa ubiquitination
by JNK1.
JNK1 phosphorylates C/EBPa
The mechanisms that modulate ubiquitination by stress
signals are: association with ancillary proteins, phos-
phorylation by speciﬁc kinases, and a combination of
two (Fuchs et al., 1998). JNK1 is a stress-regulated
kinase and C/EBPa is known to be post-translationally
modiﬁed by small ubiquitin-like modiﬁer, ubiquitin and
phosphorylation (Mahoney et al., 1992; Behre et al.,
2002b; Subramanian et al., 2003; Ross et al., 1999,
2004). Therefore, we hypothesized, under stress condi-
tions JNK1 physically associate, phosphorylates C/
EBPa and thereby inhibits its ubiquitination. To answer
this, in vitro kinase assay performed using GST-C/EBPa
as substrate and immunoprecipitated HA-JNK from
transiently co-transfected 293T with MEKK1 as kinase
shows JNK1 phosphorylates GST-C/EBPa (Figure 4a;
lane 1). Next, we assessed phosphomodiﬁcation of
immunopuriﬁed C/EBPa from mammalian cells. For
this, we again performed in vitro kinase assay using
immunoprecipitated C/EBPa from transiently trans-
fected 293T as substrate and immunoprecipitated
HA-JNK and kinase-dead HA-JNK (HA-JNK*) from
transiently co-transfected 293T together with MEKK1
as kinase. Wild-type JNK phosphorylated C/EBPa
(Figure 4b; lane 3) whereas HA-JNK* could partially
(Figure 4b; lane 5). GST-c-Jun was used as positive
control whereas pRK5 empty vector-transfected cells
were used as control for JNK immunoprecipitation
(lane 1). As JNK interacts with GST-DBD, we then
examined if JNK1 can also phosphorylate GST-DBD.
In vitro kinase assay using GST-DBD as substrate and
immunoprecipitated HA-JNK and HA-JNK*, respec-
tively as kinase from transiently co-transfected 293T
with MEKK1 shows GST-DBD can be phosphorylated
by JNK whereas there is little or no phosphory-
lation with mutant JNK (Figure 4c). Collectively,
these ﬁndings indicate that JNK1 does phosphorylate
C/EBPa in DBD region. However, future work will be
required to locate the amino-acid residue of C/EBPa
being phosphomodiﬁed by JNK.
JNK1-induced increase in C/EBPa protein expression
augments C/EBPa transactivation and DNA binding
To assess if active JNK-induced increase in C/EBPa
protein expression is also accompanied by an increase in
C/EBPa transactivation activity, we transiently trans-
fected 293T cells with a minimal thymidine kinase (TK)
promoter containing two C/EBP sites cloned upstream
of the luciferase reporter gene along with expression
plasmids for hC/EBPa and MEKK1. Expression of the
luciferase reporter gene was determined 24 h post-
transfection. Transfection of MEKK1 expression con-
struct signiﬁcantly enhanced the ability of C/EBPa
to transactivate a minimal C/EBP promoter almost
ﬁvefold, whereas this effect was drastically reduced to
1.5-fold when C/EBPa- and MEKK1-co-transfected
cells were treated with 10 mM JNK inhibitor
(SP600125) 3 h post-transfection. No signiﬁcant change
was observed in pTK-luc empty vector (Figure 5a).
Because JNK1 enhances C/EBPa protein expression and
its transactivation capacity, we next asked, if MEKK1-
mediated activation of JNK1 increases DNA-binding
capacity of C/EBPa. To investigate this, 293T cells were
transiently transfected with expression plasmids for hC/
EBPa and MEKK1 as indicated (Figure 5b). NE was
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prepared 24 h post-transfection and 10 mg of NE was
used in electrophoretic mobility shift assay (EMSA)
reaction together with labelled probe which is a 30-
nucleotide oligomer corresponding to the C/EBPa-
binding region on the granulocyte colony-stimulating
factor (G-CSF) receptor promoter (Behre et al., 2002b).
Signiﬁcant increase in C/EBPaDNA binding with probe
was observed when NE from co-transfection of C/EBPa
and MEKK1 was used as compared to NE from C/
EBPa-transfected cells alone. Super shift with C/EBPa
antibody was observed whereas no binding occurred
when 50-fold excess of unlabelled probe was used as
competitor. Figure 5c shows loading control for EMSA
experiment. Taken together, these data suggest that
active JNK-induced stabilization of C/EBPa protein
indeed contributes to enhanced C/EBPa function.
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Figure 4 JNK1 phosphorylates the DBD of C/EBPa. (a) JNK
phosphorylates GST-C/EBPa (lane 1) and positive control GST-
c-Jun in in vitro kinase assay (lane 3). Same membrane probed with
HA antibody shows presence of kinase in each lane (b) In vitro
kinase assay shows phosphorylation of wild-type C/EBPa (lane 3,
upper panel), whereas there is much less phosphorylation of
C/EBPa with HA-JNK1* (kinase-dead HA-JNK; lane 5, upper
panel); GST-c-Jun served as positive control. Same membrane was
immunoblotted with JNK1 antibody (lower panel). (c) In vitro
kinase assay shows phosphorylation of GST-DBD (lane 4, upper
panel), whereas much less with mutant JNK1 (HA-JNK* lane 6);
same membrane was stripped and probed with GST antibody to
conﬁrm the presence of substrate. GST-c-Jun (GST fused with 1–79
amino acids of c-Jun have mol wt. B35 kDa) was used as control.
Data are representative of three separate experiments.
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Figure 5 JNK1-induced increase in C/EBPa protein expression
augments C/EBPa trans-activation and DNA-binding activity:
(a) 293T cells were transiently transfected with various expression
plasmids as described in Materials and methods. MEKK1 enhances
C/EBPa transactivity almost ﬁvefold whereas JNK inhibitor
(JNKi; SP600125) treatment under these conditions reduces it to
1.5-fold. (b) EMSA analysis using radiolabelled probe and 10mg of
NE from 293T cells transiently transfected with C/EBPa and
MEKK1 (lane 7) shows enhanced C/EBPa DNA binding as
compared to NE extract from cells transfected with C/EBPa alone
(lane 3); no binding was observed in NE from mock-transfected
cells (lane 2). Shifted complexes are indicated with an arrow (S;
lanes 3 and 7); for competition analysis, 50-fold molar excess of
unlabelled oligonucleotide probe was used (lanes 4, 6 and 10); super
shift was observed with C/EBPa antibody (SS; lane 5 and 9).
Results are representative of three separate experiments.
(c) Western blot analysis for C/EBPa expression (and b-tubulin
expression as loading) for the experiment is shown in (b).
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JNK1 is inactive and downregulated in certain AML
subtypes
In order to ascertain the correlation of C/EBPa and
JNK1 interaction in myeloid cells, we assessed the JNK1
mRNA expression and its kinase activity in patients
from different AML subtypes where C/EBPa is reported
to be inactive. Affymetrix analysis shows that JNK1
mRNA expression is downregulated in AML patients as
compared to the normal bone marrow mononuclear
cells (Figure 6a) from healthy volunteers. Total mRNA
was isolated and processed as described before (Schoch
et al., 2002). Standard affymetrix software (Micro array
Suite, Version 5.0) and the HG-U133A set of nor-
malization controls were used for data analysis. As
recommended by the manufacturer, 100 human main-
tenance genes served as a tool to normalize and scale the
data before performing data comparisons. AML patient
samples included French-American-British M2 patients
with translocation t(8;21), normal karyotype, complex
karyotype, M3 with t(15;17), M4eo inversion 16 (inv 16)
and mixed lineage leukemia (MLL). As amount of
mRNA expression of a gene does not always correspond
to its protein expression and moreover our data suggests
that active JNK is required for C/EBPa activity, we
therefore analysed phospho-JNK protein expression.
Patient samples (M2 with t(8;21), M3 with t(15;17),
MLL and chronic myeloid leukemia (CML)) were lysed
in RIPA buffer and 50 mg of protein was resolved on 8%
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Figure 6 JNK1 is inactive and downregulated in AML subtypes. (a) JNK1 mRNA expression is decreased in AML patient samples
(n¼ 225) in comparison with normal bone marrow (nBM) mononuclear cells (n¼ 9). Expression signal intensities are given as absolute
numbers. The error bars indicate the s.e.m., n indicates the number of patient samples analysed in each subgroup. (b) pJNK expression
is decreased in some AML subtypes. Patient samples from different AML subtypes M1, M2 with t(8,21); M3 with t(15,17); and CML
were lysed in RIPA lysis buffer, equal amount of protein was separated on 10% SDS–PAGE; immunoblot against pJNK antibody
shows that pJNK expression is decreased in M2 and M3 (upper panel) as compared to normal bone marrow; subsequently, the same
membrane stripped and blotted for phospho-c-Jun shows that c-Jun phosphorylation is consistent with decreased JNK1 kinase activity
in these patients. Lower panel is loading control. 293T co-transfected with c-Jun and MEKK1 was used as positive control. (c) Model
for C/EBPa activation by inhibition of JNK targeted ubiquitination of C/EBPa: Diagrammatic representation of C/EBPa physical
association with active and inactive JNK. Active JNK1 (pJNK) interaction prevents C/EBPa ubiquitination presumably by
phosphorylating later and changing its conformation and thereby contributes to enhanced C/EBPa transcriptional activation.
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SDS–PAGE. Immunoblot against pJNK antibody
shows that pJNK expression (served as measure of
JNK1 kinase activity Figure 6b; upper panel) is
decreased in these AML patients as compared to normal
bone marrow mononuclear cells. Also, phospho-c-Jun
expression (Figure 6b; middle panel) was consistent with
decreased JNK kinase activity as shown by re-blotting
the same membrane. The same membrane was stripped
and blotted with calreticulin as loading control. As
expected, JNK kinase activity was increased in CML
patients (Raitano et al., 1995). These ﬁndings led us to
hypothesize that physical interaction of active JNK with
C/EBPa may positively regulate later whereas down-
regulation and/or inactivation of JNK may lead to
C/EBPa inactivation as seen in AML.
Discussion
Protein–protein interactions operative at every biologi-
cal step are important to the formation of complexes
and signal transduction through protein pathways.
Perturbation in such multiprotein complexes often leads
to improper functioning as seen in leukemia. The
molecular mechanism by which C/EBPa is regulated at
protein level in normal stem cell development and AML
is not fully elucidated. Therefore, we applied a mass
spectrometry-based proteomic approach to identify
interacting proteins of C/EBPa. The signiﬁcance of our
approach stems from the fact that we could identify
JNK1, PAK6, MADP-1, ZNF45 and other proteins
(Figure 1f) interacting with the DBD of C/EBP
transcription factors. Furthermore, we show that
JNK1 indeed interacts with full-length C/EBPa and
modulates its activity via ubiquitination.
JNK, a prompt stress-responsive kinase has been
reported to regulate protein stability of its associated
substrates. Several recent studies have shown the
requirement of physical association of the stress-
responsive factor JNK1 with other proteins in order to
affect protein stability (Fuchs et al., 1996, 1997). Our
ﬁnding shows, like with other proteins, JNK does
physically associate with C/EBPa in vivo and in vitro in
co-immunoprecipitation and GST pull down, respec-
tively; Note that JNK and phospho-JNK both interact
with C/EBPa (Figure 2b and 3i). We show that physical
association of JNK with C/EBPa inhibits ubiquitination
of C/EBPa. In vivo ubiquitination assay showed that,
under normal conditions, JNK interaction with C/EBPa
targets ubiquitination of C/EBPa presumably by
attracting the enzymes of the ubiquitination machinery
to C/EBPa, thereby marking it for proteasome-depen-
dent degradation. However, in response to stress, that is,
when phosphorylated active JNK interacts with C/
EBPa, this ubiquitination is inhibited (Figure 3f and g).
Our data are consistent with the ﬁndings that JNK
regulates ubiquitination-dependent degradation of a
different subset of substrates by acquiring a speciﬁc
phosphorylation pattern that affects conformation,
stability and transcriptional activation (Musti et al.,
1997; Fuchs et al., 1998; Ronai, 2004). JNK regulates
C/EBPa protein stability is even more evident from
upregulation of C/EBPa protein expression in different
myeloid cell lines upon JNK activation (Figure 3a–d).
Additionally, amount of C/EBPa immunoprecipitated
from anisomycin-induced U937RIPA lysates was more
as compared to the uninduced cells (Figure 3g; lanes 7
and 8). Moreover, MEKK1-induced JNK activation
leading to C/EBPa protein stability was abrogated when
these cells were treated with JNK inhibitor, which
strengthens the fact that JNK does regulate C/EBPa
protein stability (Figure 3d). More recently, Yoon K
et al. have shown that C/EBPa protein is upregulated up
to 70-fold upon ultraviolet B (UVB) irradiation in
keratinocytes which supports our ﬁnding, as UVB is a
potent activator of JNK (Yoon and Smart, 2004).
In addition to its function as a transcription factor,
C/EBPa acts as tumor suppressor which inhibits cell
proliferation via transcription-independent mechanism
in which C/EBPa forms a complex with cdk2 and cdk4
preventing cyclin/cdk complex formation, E2F inhibi-
tion and cell cycle progression. In case of signal-
dependent transcription factors, it is apparent that
changes in their half-life could have a signiﬁcant impact
on the activity of the corresponding target genes.
Therefore, regulation of C/EBPa protein levels through
an ubiquitin–proteasomal pathway would serve to
control both the transcription-dependent and transcrip-
tion-independent activities of C/EBPa (Shim and Smart,
2003). Active JNK-induced increase in C/EBPa protein
was accompanied by a signiﬁcant increase in C/EBPa
transactivation activity, which dramatically reduced
with JNK inhibitor treatment suggesting JNK-speciﬁc
C/EBPa activation (Figure 5a). Additionally, we also
observed an increase in DNA-binding capacity of
C/EBPa in the presence of active JNK in EMSA
(Figure 5b). Taken together, our ﬁndings suggest that
JNK is required for C/EBPa stability which has impact
on its activity.
The fact that c-Jun is protected from ubiquitination
after being phosphorylated by JNK (Fuchs et al., 1996;
Musti et al., 1997) prompted us to investigate whether
JNK apart from physically associating, also phospho-
rylates C/EBPa in order to inhibit its ubiquitination. In
in vitro JNK kinase assay, we show that wild-type
JNK does phosphorylate C/EBPa and GST-C/EBPa
whereas kinase-dead JNK could partially phosphorylate
(Figure 4). However, further study is required to more
fully determine the contribution of direct CEBPa phos-
phorylation in its stabilization and the amino-acid
residues of C/EBPa being targeted by JNK. In any
case, physical interaction of JNK with C/EBPa and
phosphorylation of later led us to hypothesize that JNK
inhibits C/EBPa ubiquitination by phosphorylating and
presumably changing its conformation making it in-
accessible to the ubiquitin ligase and ubiquitination
machinery as such to target C/EBPa for degradation.
Affymetrix analysis of JNK1 mRNA using an indirect
measure for JNK activity in AML subtypes where C/
EBPa function is impaired such as M2 with transloca-
tion t(8;21), M3 with t(15;17) and AML with inversion
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16, shows reduced JNK1 mRNA expression in compa-
rison with normal bone marrow mononuclear cells from
healthy volunteers (Figure 6a). Additionally, phospho-
JNK protein expression (kinase activity) in these
subtypes is also decreased (Figure 6b). A function for
JNK is implicated in cancer but the mechanism of JNK
action is unclear. Although number of patient samples
used for pJNK expression is very few to state if pJNK
kinase activity in AML is downregulated in general.
However, it gives a rough estimate that JNK kinase
activity is decreased in certain AML patients. A follow-
up study on the expression levels of pJNK and C/EBPa
in large number of patients might give important
insights into JNK-regulated C/EBPa expression.
In conclusion, we propose a hypothetical model
(Figure 6c) for the importance of physical interaction
of JNK with C/EBPa. Targeting ubiquitination of C/
EBPa by JNK requires tight interaction with C/EBPa;
whereas interaction with pJNK and subsequent C/EBPa
phosphorylation at unidentiﬁed amino-acid residue by
JNK inhibits its ubiquitination, probably owing to
altered conformation of C/EBPa, which is likely to
inhibit the ubiquitination machinery. This results in
increased C/EBPa stability and availability which is
reﬂected by enhanced DNA binding and transcriptional
activity of C/EBPa. Moreover, downregulation of JNK
mRNA and kinase activity in different AML subtypes
implicates that JNK activity is required for C/EBPa
activation in myeloid cells and that loss of JNK-
regulated C/EBPa expression may render it inactive.
Materials and methods
GST pull down
We used plasmid constructs in which full-length C/EBPa and
region comprising amino acids 270–358 encoding the con-
served DBD of C/EBPs are cloned in frame with the GST in
pGEX bacterial expression vector. Fusion proteins were
expressed in transformed DH5a E. coli bacterial strain after
0.5mM IPTG induction at 371C for 2 h and subsequently
puriﬁed using immobilized glutathione sepharose 4B beads
(Amersham Biosciences, Germany) by lysing in NETN buffer
as described before (Rangatia et al., 2002). Following washing,
puriﬁed fusion proteins were lysed in SDS sample buffer,
separated on 12% SDS–PAGE and visualized by commassie
blue staining. NE of U937 cells was prepared using lysis buffer
A and C, respectively, as described before (Rangatia et al.,
2002). Equal amount of fusion proteins were incubated with
1mg of NE (in NETN buffer) for 3 h at 41C on a rotating
shaker. After GST pull down, protein-bound GST sepharose
beads were washed three times in NETN buffer. In addition,
S35-methionine-labelled ivt JNK1 was pulled down with GST
fusion proteins as described before (Reddy et al., 2002).
2D-gel electrophoresis and MALDI–TOF mass spectrometry
GST and GST-DBD were incubated with NE of myelomono-
cytic U937 cells. Beads with their associated proteins from NE
were lysed in urea lysis buffer (66% urea plus one, 1% DTE,
4% CHAPS, 2.5mM ethylenediaminetetraacetic acid (EDTA)
and 2.5mM ethyleneglycoltetraacetate) for 1 h at room
temperature. Lysed beads were passed through RNA quiash-
redder (Quiagen, Germany), and resulting supernatant was
ultracentrifuged for 1 h at 50 000 r.p.m. at 221C to eliminate
DNA and other cellular debris. In the ﬁrst dimension, 350 ml of
dissolved proteins were separated on 18 cm long immobiline
dry strip in the pH range 3–10 (Amersham Biosciences,
Germany) by IEF. The reduction and alkylation of separated
proteins were carried out in urea buffer containing 2% DTE
and 2.5% iodoacetamide. Proteins were then separated in the
second dimension using 12% SDS–PAGE. 2D gels were silver
stained to visualize the protein spots. After comparison of the
two silver-stained gels, differentially appearing protein spots
from GST-DBD gel were excised and digested with 200 ng
Trypsin (Promega, Mannheim, Germany) in ammonium
bicarbonate solution for 16 h. Digested peptides were eluted
in 70% acetonitrile, lyophilized and resuspended in 5ml of
0.1% triﬂuoacetic acid in 10% acetonitrile. The dissolved
peptides were mixed in 1:1 ratio with 2,5-dihydroxybenzoic
acid matrix solution and loaded on anchorChip target plate
(Bruker Daltonics, Leipzig, Germany). Peptide mass ﬁnger-
print and peptide sequencing was performed by MALDI–TOF
(Reﬂex III, Bruker) and conﬁrmed by MALDI–TOF–TOF
(AB4700, Applied Biosystems, Darmstadt, Germany) mass
spectrometer, corresponding proteins were identiﬁed by
MASCOT database search.
Cell culture, plasmids
293T, U937 and HL 60 cells were cultured as described
previously (Reddy et al., 2002). NB4 cells were maintained in
Rosewell Park Memorial Institute medium (RPMI) supple-
mented with 20% fetal bovine serum (FBS), 2.5% pen-strep
and 2.5% glutamine. K562C/EBPa-Er and K562Er cells were
maintained in RPMI (without phenol red) supplemented with
10% charcoal treated FBS (Hyclone, Nu¨rtingen, Germany)
and 2mg/ml puromycin. HA-JNK and kinase-dead HA-JNK
mutant were provided by Dr A Keiser, GST-c-Jun correspond-
ing to 35 kDa (1–79 amino acids fused with GST) was bought
from Cell Signalling technology (Beverly, MA, USA), whereas
GST-c-Jun with 40 kDa molecular size was bacterially puriﬁed.
pCDNA3-human C/EBPa is described previously (Pabst et al.,
2001b). BR3 harbors mutations in the basic region that
prevent DNA binding (amino acids: 297R, 298K, 300R and
302K of C/EBPa mutated to glycine, threonine, glycine and
aspargine, respectively); Leu1, 2-Val cannot dimerize or bind
DNA because of mutation of two leucines to valine within the
leucine zipper; and GZ is a variant in which the C/EBPa
leucine zipper is replaced with the leucine zipper from a yeast
protein, GCN4. GZ retains the ability to homodimerize, bind
DNA, and activate transcription, but is not expected to
interact with endogenous basic region leucine zipper (bZIP)
proteins via the leucine zipper. C/EBP-DBD plasmid con-
structs were kindly provided by Dr Alan Friedman and is
described elsewhere (Landschulz et al., 1989). Plasmid
construct HA-ubiquitin (pMT123HA-Ubi) was kind gift from
Dr Dirk Bohmann.
Co-immunoprecipitation and in vitro kinase assay
Co-immunoprecipitation assay was performed form RIPA
lysate of U937 cells (RIPA: 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 0.15M NaCl, 5mM EDTA and
50mM Tris pH8.0) as described previously (Rangatia et al.,
2002). Immunoprecipitated proteins were heated at 561C for
90min in 2 SDS loading buffer and then boiled at 951C for
5min before separation on 8% SDS–PAGE. Proteins were
immunoblotted with JNK1 and C/EBPa antibody (Santa Cruz
Biotechnology Inc., Heidelberg, Germany), other antibodies
used are HA (Roche Diagnostics, Manheim, Germany) and
Phospho-JNK antibody (Cell Signalling Technologies, USA).
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In vitro kinase assay was performed as described before (Zada
et al., 2003).
EMSA and reporter assays
For EMSA analysis, a double-stranded G-CSF receptor
promoter oligonucleotide extending from bp 57 to 38 was
used as a probe; OligoA (AAG GTG TTG CAA TCC CCA
GC) and OligoB (GCT GGG GAT TGC AAC ACC TT) were
annealed and labelled with g-[32P]dATP (GE Health Care,
Munich, Germany) using T4 polynucleotide kinase (Invitrogen,
Karlsruhe, Germany). EMSA was performed by incubating
10mg of NE with 1 ng of the radiolabelled probe in binding
buffer (10mM HEPES pH 7.9, 50mM KCl, 2.5mM MgCl2,
1mM dithiothreitol and 10% glycerol) and 0.5 mg of poly
(dI–dC) (Amersham Biosciences, Munich, Germany) for
30min as described before (Behre et al., 2002b). For reporter
assays, 293T cells were transfected using LipofectAMINE Plus
as described by the manufacturer (Invitrogen, Karlsruhe,
Germany). Fireﬂy luciferase activities from the constructs
phC/EBPa, pTK, pCDNA3-MEKK1, p(C/EBP)2TK and
Renilla luciferase activity from the internal control plasmid
pRL-null were determined 24 h after the initiation of the
transfection protocols as described previously (Behre et al.,
2002b), The reporter construct p(C/EBP)2TK contains two
adjacent ATTGCGCAAT consensus C/EBPa-binding sites
cloned into pTK81 luciferase, was kindly provided by Dr Alan
Friedman and is described previously (Nordeen, 1988;
Friedman, 1996). Results are given as means 7s.e.m. of three
independent experiments.
In vivo HA ubiquitination assay, pulse chases labelling and
Western blotting
For in vivo HA ubiquitination assay, 1 106 293T cells were
transiently transfected with different constructs as described.
Twenty-four hours post-transfection, cells were lysed in RIPA
buffer and C/EBPa was immunoprecipitated from 500 mg
protein. For pulse chase labelling, 3 105/ml HL60 cells
in 50ml were plated in normal RPMI medium 1 day before
the experiment. Next day cells were washed twice with
phosphate-buffered saline and grown in 3ml labelling medium
(RPMI without methionine and cysteine, supplemented with
0.2% dialysed FBS) for 15min with 200 mCi/ml methionine
with constant shaking at 371C in water bath. The cells were
then washed and chased for various time points with normal
RPMI medium in the absence or presence of anisomycin. Cells
were lysed and C/EBPa was immunoprecipitated from equal
amount of lysates. The resulting precipitates were subjected to
10% SDS–PAGE, autoradiography and densitometry analy-
sis. Western blotting was performed as described before
(Rangatia et al., 2002).
Patient samples and affymetrix: Patient samples were
referred to the Laboratory for Leukemia Diagnostics, Depart-
ment of Internal Medicine III, Hospital Grosshadern, for
routine cytomorphologic and cytogenetic analyses. At the time
each AML patient was diagnosed, mononuclear cells from the
bone marrow aspirate with more than 90% blast cells were
puriﬁed by Ficoll gradient separation. The percentage of blast
cells within the bone marrow carrying the respective fusion
genes as detected by ﬂuorescence in situ hybridization ranged
from 52 to 99% (median 90%). For Western blot analysis, the
healthy bone marrow cells were purchased from stem cell
technologies (Cell Systems biotechnology, Vertrieb Gmbh,
St Katharinen, Germany). There was no correlation between
the percentage of blast cells and the fusion gene transcript
levels. Microarray analyses were performed as reported
previously (Schoch et al., 2002) by use of the GeneChip
System (Affymetrix U95Av2 and U133A microarrays, Santa
Clara, CA, USA).
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Proteomic discovery of Max as a novel interacting partner of C/EBPa: a Myc/Max/Mad
link
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The transcription factor CCAAT/enhancer binding protein a
(C/EBPa) is important in the regulation of granulopoiesis and is
disrupted in human acute myeloid leukemia. In the present
study, we sought to identify novel C/EBPa interacting proteins
in vivo through immunoprecipitation using mass spectrometry-
based proteomic techniques. We identified Max, a heterodi-
meric partner of Myc, as one of the interacting proteins of
C/EBPa in our screen. We confirmed the in vivo interaction of
C/EBPa with Max and showed that this interaction involves the
basic region of C/EBPa. Endogenous C/EBPa and Max, but not
Myc and Max, colocalize in intranuclear structures during
granulocytic differentiation of myeloid U937 cells. Max en-
hanced the transactivation capacity of C/EBPa on a minimal
promoter. A chromatin immunoprecipitation assay revealed
occupancy of the human C/EBPa promoter in vivo by Max and
Myc under cellular settings and by C/EBPa and Max under
retinoic acid induced granulocytic differentiation. Interestingly,
enforced expression of Max and C/EBPa results in granulocytic
differentiation of the human hematopoietic CD34þ cells, as
evidenced by CD11b, CD15 and granulocyte colony-stimulating
factor receptor expression. Silencing of Max by short hairpin
RNA in CD34þ and U937 cells strongly reduced the differentia-
tion-inducing potential of C/EBPa, indicating the importance of
C/EBPa–Max in myeloid progenitor differentiation. Taken to-
gether, our data reveal Max as a novel co-activator of C/EBPa
functions, thereby suggesting a possible link between C/EBPa
and Myc–Max–Mad network.
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Introduction
Hematopoietic differentiation proceeds in a largely irreversible
fashion and the role of transcription factors in regulating
hematopoiesis has been well documented. This is particularly
true for CCAAT/enhancer binding protein a (C/EBPa), one of the
lineage-specific transcription factors that is essential for commit-
ment to and development of the granulocytic lineage.1,2 Recent
data have indicated that C/EBPa may also regulate hematopoie-
tic stem cell activity3 and act as a tumor suppressor gene in
acute myeloid leukemias (AMLs), indicating an important role
for C/EBPa in the control of cellular proliferation in vivo.4
Inactivation of C/EBPa is an important event in AML, and
ectopic overexpression of C/EBPa leads to differentiation and
growth arrest in AML.5 It is therefore suggested that C/EBPa has a
crucial role in regulating the balance between cell proliferation
and differentiation, which is crucial for lineage commitment of
any cell type. These findings and data from our laboratory
indicate that for AML to develop, the activity of C/EBPa must be
curbed by either mutations or antagonistic protein–protein
interactions.
C/EBPa can form protein–protein interactions with other bZIP
and non-bZIP factors. Among them, c-Jun and PU.1,6,7 E2F,
p21, and cyclin-dependent kinases CDK2 and CDK4 have been
well characterized.8–10 Thus, it has become increasingly clear
that like most proteins, C/EBPa might not work alone, but in
association with other factors regulates gene transcription.
However, studies involving protein–protein interactions of
C/EBPa at the global proteomic level are lacking. We therefore
took advantage of high-throughput proteomics by mass spectro-
metry (LC-MS/MS) to identify proteins that specifically associate
with C/EBPa in vivo. In our screen, Max was identified as a
novel interacting partner of C/EBPa in addition to other new and
known partners of C/EBPa.
Max is a member of the basic region-helix–loop–helix-leucine
zipper protein that belongs to a network of transcription factors,
which includes the Myc and Mad families of protein (commonly
referred to as a Myc–Max–Mad network).11 The Myc–Max–Mad
proteins can affect different aspects of cell behavior, including
cell cycle, proliferation and differentiation, by modulating
distinct target genes.12–15 Max can form a homo- or a
heterodimer and bind specifically to E-box DNA elements in
target promoters (consensus CACGTG).16,17 To function as
transcriptional regulators, the members of the Myc and Mad
families must heterodimerize with Max. Whereas Myc–Max
activates transcription, Mad–Max and Mnt–Max repress tran-
scription.18–20 Indirect evidences to the fact that C/EBPa could
be a part of the Myc–Max–Mad network do exist in the
literature.21,22 However, no direct evidence has been reported
so far.
In this study, we have characterized the role of Max as an
interacting partner of C/EBPa. We show that Max is an important
co-activator of C/EBPa and the stable silencing of Max inhibits
the differentiation-inducing potential of C/EBPa. C/EBPa and
Max not only colocalize but also the heterocomplex is
preferentially formed on the human C/EBPa (hC/EBPa) promoter
in vivo during granulocytic differentiation, thereby contributing
to increased transactivation and differentiation capacity of
C/EBPa.
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Materials and methods
Transfection of human hematopoietic CD34þ
progenitors
Human CD34þ hematopoietic cells were selected, using a
magnetic CD34 selection kit system (Milteny Biotec, Bergisch,
Gladbach, Germany), from small aliquots of leukapheresis
products collected from either healthy donor or a patient
undergoing stem/progenitor cell collection after granulocyte-
colony stimulating factor treatment for non-hematologic malig-
nancy at Klinikum Krollwitz Hospital Halle, Germany, following
their informed consent. After magnetic selection, more than
85% of the cells expressed the CD34 antigen. An aliquot
containing 5 105 CD34þ cells was cultured in Iscove’s
modified Dulbecco’s medium with 20% heat-inactivated fetal
calf serum, 100 ng/ml Flt3-ligand, 100 ng/ml of stem cell factor,
100 ng/ml thrombopoietin, 100 ng/ml of interleukin-6 (IL-6) and
50 ng/ml of IL-3, 100 U/ml penicillin/streptomycin and 2 mM
L-glutamine. The cells were transfected with various expression
constructs using AMAXA nucleofection technology essentially
as described by the manufacturer and analyzed for CD11b and
CD15 expression by flow cytometry.
Cell lines, antibodies and treatments
Human myeloid cell lines U937 and K562-ER-C/EBPa were
cultured under standard conditions. b-Estradiol and retinoic acid
(RA) (Sigma-Aldrich, Munich, Germany) were used at a
concentration of 1–5mM and 106 M, respectively. The anti-
bodies used in this study were purchased from Santa Cruz
(Heidelberg, Germany); for C/EBPa, SC-61 (14AA), SC-9315
(N-19) Max, SC-765 (C-124) and c-Myc, SC-42 (C-33) and
Molecular Probes, Gmbh, Karlsruhe, Germany).
Immunoprecipitation and immunoblotting
The immunoprecipitation (IP) was performed from 500–1000 mg
nuclear extracts of U937 cells in an IP buffer (50 mM Tris pH 7.5,
150 mM NaCl, 0.5% NP-40, 0.25% sodium deoxycholate),
followed by washing in the buffer (50 mM Tris pH 7.5, 0.1%
NP-40, 0.05% sodium deoxycholate) with respective antibodies
(Santa Cruz) and the corresponding IgGs as controls. A Western
blot analysis was used to confirm the identity of immuno-
precipitated and/or co-precipitated proteins as described pre-
viously.23 Alternatively, the immunocomplexes were incubated
with urea lysis buffer for further proteomic analysis.
Proteomic analysis: two-dimensional gel
electrophoresis and protein identification by mass
spectrometry
The proteomics methodology was used essentially as described
recently by our group.34
Transient transfections using AMAXA and effectene
Effectene transfection reagent (Qiagen, Gmbh, Hilden, Ger-
many) and lipofectamine (Invitrogen, Gmbh, Karlsruhe, Ger-
many) were used for transient transfections according to the
manufacturer’s instructions. Transient transfections were carried
out with minimal promoter/luciferase construct, which has been
derived from an oligo 50-GATCCAGATTGCGCAATCG-30 by
self-annealing, followed by ligation into a BamHI site of the
thymidine kinase (TK) promoter and co-transfected with expres-
sion plasmids for hC/EBPa, Renilla Luciferase-null and/or Max as
described.23 The Nucleofector kit (AMAXA, Gmbh, Cologne,
Germany) was used essentially as described by the manufac-
turer. A 5mg portion of plasmid DNA constructs was used for
each transfection and the transfection efficiency was analyzed
using a plasmid with eGFP marker (2 mg). For CD34þ and U937
cells, nucleofector solution kits used were VPA-1003 and VCA-
1003 with nucleofection programs U-08 and V-01, respectively.
The voltages are automatically adjusted according to the
program and are essentially 110 V AC with a frequency of
50–60 Hz and a power consumption of 16 VA/fuse.
Immunofluorescence and flow cytometry
U937 cells (3 105), under uninduced condition or induced
with RA (Sigma-Aldrich), were cytocentrifuged on glass slides
with coverslips, fixed using 1:1 methanol/acetone and permea-
bilized using 0.3% Triton X. After blocking in PBG (0.5% BSA,
0.045% Fish–gelatin in phosphate-buffered saline) containing
5% FBS, the fixed cells were incubated with anti-C/EBPa (anti-
goat; Santa Cruz), anti-Max (anti-rabbit; Santa Cruz) and anti-
Myc (anti-mouse; Santa Cruz) antibodies, followed by incuba-
tion with corresponding Alexa Fluor 488 chicken anti-goat,
Alexa Fluor 594 chicken anti-rabbit and anti-mouse IgG
secondary antibodies (Molecular Probes) and 40,60-diamidino-
2-phenylindole dihydrochloride (DAPI, 1 mg/ml) for 15 min. The
cells were mounted in aqueous mounting medium and the
images were acquired and analyzed using a fluorescence
microscope ( 100,  60). Flow cytometry was performed for
CD11b, CD14 and CD15 expression on Bectin Dikinson flow
cytometer, using the supplied analysis software.
Quantitative real-time PCR
RNA isolation from CD34þ and U937 cells, transfected with
different expression constructs, by TRIZOL (Invitrogen, Ger-
many) was followed by cDNA synthesis using standard
conditions. Equal amount of cDNA was taken for a subsequent
quantitative real-time PCR (Q-RT-PCR) using the Quantitech
SyBR Green PCR kit (Qiagen, Germany) in a Rotor-Gene RG-
3000 (Corbett Research, Sydney, Australia). The delta ct value
(Dct) was then calculated from the given ct value by the formula
Dct¼ ctsamplectcontrol). The fold change was calculated as fold
change¼ 2Dct. The following primer sequences were used:
myeloperoxidase (MPO), 50-TCG GTA CCC AGT TCA GGA
AG-30 (forward) and 50-CCA GGT TCA ATG CAG GAA GT-30
(reverse); neutrophilelastase (NE), 50-TGC TCA ACG ACA TCG
TGA TT-30 (forward) and 50-CTC ACG AGA GTG CAG ACG
TT-30 (reverse); GCSFR, 50-AAG AGC CCC CTT ACC CAC TAC
ACC ATC TT-30 (forward) and 50-TGC TGT GAG CTG GGT CTG
GGA CAC TT-30 (reverse); CD14, 50-CAA CTT CTC CGA ACC
TCA GC-30 (forward) and 50-CCA GTA GCT GAG CAG GAA
CC-30 (reverse).
Chromatin immunoprecipitation assay
Logarithmically growing and differentiating U937 cells
(B1 108 cells) were fixed with formaldehyde (final concentra-
tion 1% (v/v)) in serum free RPMI-1640 medium, at 41C for 1 h.
Glycine was added to a final concentration of 0.125 M to stop
cross-linking. Fixed cells were pelleted by centrifugation and
sequentially washed and sonicated (five times for 20 s each) to
make soluble chromatin. Samples of total chromatin were taken
at this point to use as a positive control in the PCRs (input
chromatin). Antibodies against C/EBPa, Max and c-Myc were
used overnight at 41C. After serial elution, washing and cross-
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link reverse, the samples were extracted twice with phenol/
chloroform and precipitated with ethanol overnight in the
presence of 20mg glycogen as a carrier. DNA fragments were
recovered by centrifugation, resuspended in ddH2O, and used
for PCR amplification. For detection of immunoprecipitated
C/EBPa promoter region, two primers, forward (50-ACCGC
TACCGACCACGTGGGCG-30) and reverse (50-AGCACCTC
CGGGTCGCGAATGG-30), specific for a 280 bp region in the
cellular C/EBPa promoter that encompasses the C/EBP site were
used for Q-RT-PCR amplification.
Results
Identification of Max, a heterodimeric partner of Myc,
as a novel interacting protein of C/EBPa
To identify interacting proteins of C/EBPa in vivo under
physiological conditions on a global level, we applied
proteomics technique coupled with mass spectrometry using
the IP conditions of endogenous C/EBPa from myeloid U937
cells as a model system.
Under our experimental conditions, we could specifically
immunoprecipitate endogenous C/EBPa from the nuclear
extracts of U937 cells (Figure 1a) and co-immunoprecipitate
other endogenous proteins (as positive controls) such as c-Jun
and CDK4 (Figure 1b and data not shown) that were not present
in the isotype IgG control. Immunocomplexes were further
processed for proteomic analysis. The protein spots excised from
the 2D gels (Figure 1c, spots are numbered) were identified by
MALDI-TOF MS. Additionally, the individual bands were
excised from Coomassie/silver-stained sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gels (Figure 1d) and pro-
cessed for LC-MS/MS. From both screens, we were able to reveal
the identity of 10 proteins by MS, which specifically interact
with C/EBPa (Table 1). Among these proteins, we identified Max
as one interacting partner of C/EBPa. C/EBPa was also identified
by MS analysis of the corresponding band (Figure 1d), thereby
serving as a control for our experimental setup. Proteins in other
bands could not be determined because of the poor quality of
the spectrum. The discovery of Max as a novel C/EBPa partner is
intriguing because of the role Max plays in switching of the
complexes during myeloid differentiation.24 We therefore
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Figure 1 MS-based proteomics identifies proteins specifically interacting with C/EBPa in vivo after its immunoprecipitation from myeloid U937
cells. (a) C/EBPa IP from nuclear extracts of U937 cells and a corresponding immunoblotting (IB) with anti-C/EBPa antibody to confirm the
presence of C/EBPa protein in the IP complex. In vitro-translated C/EBPa (ivt, lane 1) was used as a positive control in the Western blot. (b) C/EBPa
IP and corresponding IB with anti-c-Jun antibody to show endogenous proteins co-precipitated with C/EBPa. ivt c-Jun was used as a positive
control for c-Jun. (c) Silver-stained 2D gels showing proteins specifically interacting with C/EBPa. C/EBPa was immunoprecipitated from nuclear
extracts using anti-C/EBPa antibody (anti-rabbit; Santa Cruz) and the immunocomplex separated in the first dimension by pH 4–7 IPGphor strips
followed by their separation in the second dimension using 12% SDS-PAGE. As a specificity control, we used immunoprecipitation with IgG under
similar conditions. (d) Silver-stained SDS-PAGE gels after IP with anti-C/EBPa and anti-IgG. The bands were excised and peptide mixture after
trypsin digestion was run on a reverse-phase high-pressure liquid chromatography and the peptides identified by MALDI-TOF-TOF (Applied
Biosystems, Darmstadt, Germany).
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selected Max for further functional and biological characteriza-
tion.
C/EBPa and Max interact in a cellular setting:
confirmation of proteomics data
To confirm the observed interaction of Max with CEBPa by an
alternative technique, we performed reciprocal immunoprecipi-
tation. Our results demonstrate that C/EBPa interacts with Max
and vice versa (Figure 2a) in vivo, and thereby confirm proteomic
results. It is important to note that for the same amounts of nuclear
extracts used (5 and 10mg) as input controls, the levels of the two
transcription factors are dramatically different, which is likely due
to Max being more stable than C/EBPa.
BR3 region of C/EBPa is involved in its interaction with
Max
To investigate the protein domains that might be involved in
C/EBPa–Max interaction, we performed co-immunoprecipita-
tion studies using different mutants of C/EBPa as shown. C/EBPa
and its various mutants (kind gift from Dr Alan Friedman;
Figure 2b) were transiently transfected into 293 cells, and co-
transfected with an expression plasmid for Max (a kind gift from
Dr Dirk Eick) containing a carboxy-terminal HA tag.25 Max was
then immunoprecipitated from nuclear extracts using anti-Max
antibody. The associated complexes were assayed by immuno-
blotting for C/EBPa using anti-C/EBPa antibody. Our results
demonstrate that C/EBPa could be co-immunoprecipitated when
IP was performed using anti-Max antibody in samples in which
wild-type C/EBPa: wild-type Max, GZ/LZ C/EBPa: wild-type
Max and L1-2V C/EBPa: wild-type Max were coexpressed
(Figure 2c, lanes 4, 3, 1, respectively). However, C/EBPa could
not be co-immunoprecipitated in immunoprecipitated samples
in which basic region mutant BR3-C/EBPa: wild-type Max was
co-expressed (Figure 2c, lane 2). We also show that Max could
be specifically immunoprecipitated (as controls) with immuno-
blot for Max using anti-HA antibody (Figure 2c, lower panel).
The relative expression of C/EBPa mutants was the same (data
not shown). These data show that the basic region of C/EBPa is
involved in its interaction with Max in a cellular setting.
Furthermore, we observed that wild-type Max and its basic
region mutants have the same ability to interact with C/EBPa
(Supplementary Figure S1a and b).
C/EBPa and Max colocalize
Given the fact that C/EBPa and Max are nuclear transcription
factors and the observation that they interact in vivo, we next
investigated the localization of these proteins by indirect
immunofluorescence in myeloid U937 cells. We observed both
endogenous C/EBPa and Max to be localized in intranuclear
structures (Figure 3a) and the overlay of the two images shows
Table 1 MS results of the proteins interacting with C/EBPa: MALDI-TOF Reflex III (Bruker Daltonics) and LC-MS/MS
Spot no. Acc. no. Protein name Score Mol. wt. pI Sequence coverage
1 A42611 Max 85 21.029 5.64 53
2 Q9UP93 Macrophin1 fragment 95 620 (full) 5.27 35
3 M2OM_Hum Mitochondrial2-oxoglutarate/malate carrier protein 65 34.08 9.92 37
8 A47213 Beta fodrin 68 146.55 5.18 14
12 Q96QA8 RPGR interacting protein 1 88 147.33 5.47 14
13 Q9P1U9 ZNF45 71 80.44 9.0 16
15 FAHUAA Actinin 1 238 103.48 5.22 31
16 Q9UKD2 60 S ribosomal protein 74 127.60 7.68 29
* NMD3A N-methyl-D-aspartate receptor 3A * 126.67 * *
* SMADIP1 Smad interacting protein 1 * 137.84 * *
Abbreviations: C/EBPa, CCAAT/enhancer binding protein a; LC-MS/MS, liquid chromatography-coupled tandem mass spectrometry.
Proteins identified by MALDI-TOF mass spectrometry and LC-MS/MS from 2D gels and normal SDS-PAGE gels (represented as *), respectively.
Acc. no: SwissProt. protein accession numbers; Mol. wt: apparent molecular weight; pI: isoelectric point of the protein.
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Figure 2 In vivo interaction of C/EBPa with Max confirmed by
reciprocal IP involves the DNA-binding domain of C/EBPa. (a)
Reciprocal IPs: C/EBPa and Max were immunoprecipitated (IP C/EBPa,
IP Max) from nuclear extracts of U937 cells by incubation with anti-C/
EBPa and anti-Max, respectively, and respective IgG as controls. The blot
was first probed with anti-C/EBPa antibody, stripped and reprobed with
anti-Max antibody. (b) Basic region of C/EBPa is involved in its
interaction with Max. Schematic representation of wild-type hC/EBPa
and different mutants used in this study. TAD, transactivation domains 1
and 2; BR, basic region; LZ, leucine zipper domain; HLH, helix–loop–
helix. (c) hC/EBPa wild type and its mutants were transfected in 293T
cells and co-transfected with wild-type Max expression plasmid. At 24 h
post-transfection, the nuclear extracts were prepared and IP of Max
performed for the samples followed by immunoblot for C/EBPa or Max
using anti-C/EBPa and HA antibodies, respectively.
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that both proteins colocalize in these intranuclear structures
(Figure 3a,panel 4; yellow signal).
C/EBPa–Max but not Myc–Max remains colocalized
during granulocytic differentiation of myeloid U937
cells
We next investigated the effect on C/EBPa–Max colocalization
when the cells were triggered for granulocytic differentiation by RA
for 24 h. We observed intranuclear staining with C/EBPa and Max
antibodies, and the overlay of the two images shows that both
proteins remain colocalized even after RA treatment of the cells
(Figure 3b, panel 4; yellow signal). As Max is associated with Myc,
we also analyzed their localization in U937 cells. We observed
that endogenous Myc–Max colocalize in the nucleus under
uninduced condition (Figure 3a, panels 5 and 6). On the other
hand, no intranuclear c-Myc signal could be detected after RA
treatment (Figure 3c, panel 4; only green signal from Max). We
next investigated the expression of c-Myc, Max and C/EBPa before
and after RA treatment from various fractions (whole-cell lysates,
nuclear fraction (NF) and cytoplasmic fraction (CF)) by Western
blotting, using specific antibodies (Figure 3d). Our results revealed
that the c-Myc protein level was drastically decreased in all the
three fractions (Figure 3d, upper and lower panels) by RA.
However, C/EBPa was undetectable in the CF and slightly
increased in the NF by RA when analyzed by immunoblotting.
Dot blot analysis revealed the presence of CEBPa in the CF as well.
This indicates that the concentration of C/EBPa in the CF is quite
low, so as not to be detected by immunoblotting (data not shown).
Max, on the other hand, was relatively unchanged under induced
and uninduced conditions. These data demonstrate that retention/
colocalization of C/EBPa–Max, and not Myc–Max heterocom-
plexes, in the nucleus might be important events during
granulocytic differentiation of U937 cells.
Max enhances the ability of C/EBPa to transactivate a
minimal thymidine kinase promoter
To investigate the functional importance of C/EBPa–Max
interaction and their colocalization, we performed transient
transfection assays in the fibroblast 293T and the myeloid U937
cells using a minimal TK promoter containing two CCAAT
binding sites cloned upstream of the luciferase reporter gene.
Transfection of a Max expression construct significantly en-
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hanced the ability of C/EBPa to transactivate a minimal TK
promoter containing two CCAAT binding site in a dose-
dependent manner (Figure 4a). In control experiments, no effect
of Max on C/EBPa activity was observed when promoter with no
CCAAT binding sites was used, whereas C/EBPa alone was able
to transactivate the minimal promoter construct ninefold. Similar
results were obtained with myeloid U937 cells (Figure 4b).
Interestingly, co-transfection studies with the human B2200 bp
C/EBPa promoter (which has intact E-box site and no CCAAT
site) revealed that C/EBPa alone was unable to transactivate the
promoter, whereas, co-transfection of Max led to a significant
increase in the promoter activity (Figure 4c). It is important to
point out that Max itself does show some activation.
C/EBPa and Max associate in vivo: a Myc–Max–Mad
link
To further elucidate the mechanism by which Max augments the
transcriptional activity of C/EBPa, we hypothesized that Max
might associate with the hC/EBPa promoter in vivo because
similar to C/EBPa, Max also possesses a DNA binding basic
region. To test this possibility, we performed quantitative
radioactive and non-radioactive chromatin immunoprecipita-
tion (ChIP) in U937 cells (Figure 5). Chromatin was subjected to
IP by using antibodies directed against C/EBPa, c-Myc and Max.
The presence of C/EBPa promoter was detected by amplifying a
promoter region using primers specific for a 280 bp region in the
C/EBPa promoter that encompasses the CACGTG site (com-
monly referred to as E-box; Figure 5a). The E-box is conserved in
the human and mouse C/EBPa promoter (Figure 5a). We
observed that under normal physiological conditions (unin-
duced), endogenous c-Myc and Max appeared on C/EBPa
promoter and there was undetectable endogenous C/EBPa
occupancy on the hC/EBPa promoter (Figure 5b). IP using an
isotype-matched IgG served as a negative control.
We next investigated the affect on heterocomplex formation
at the hC/EBPa promoter upon differentiation by RA. We
observed that both Max and C/EBPa appeared on C/EBPa
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Figure 4 Max enhances the transactivation capacity of C/EBPa in transient transfection assays. (a, b) Transient transfection in 293T and U937 cells
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promoter and in fact, more C/EBPa was associated with the
promoter in the context of chromatin upon differentiation
induction (Figure 5c, lane 4). The amount of Max bound to
the promoter was fairly constant. DNA recovery was quantified
as a percentage of the total input chromatin (lanes 5–7). Q-RT-
PCR confirmed this observation and the histograms shown
represent the average values from two independent experiments
(Figure 5c, lower panel). A promoter without the CACGTG site,
such as GAPDH promoter (Figure 5d), was used as a negative
control for C/EBPa and Max occupancy and hTERT promoter
(Figure 5e) as a positive control for Myc and Max interaction on
the CACGTG site (E-box). The size of the DNA fragments before
and after sonication is also shown (Figure 5f). Thus, C/EBPa and
Max associate in vivo in the context of chromatin and are
associated together more strongly on the hC/EBPa promoter
when the cells are induced towards granulocytic differentiation.
Overexpression of Max and C/EBPa promotes
differentiation along the granulocytic pathway
in human hematopoietic CD34þ cells
We next asked whether interaction of Max with C/EBPa is
biologically important for C/EBPa functions. Hence, we
performed overexpression studies using three different experi-
mental systems: human hematopoietic CD34þ cells, estradiol-
inducible K562-C/EBPa-ER cells and U937 cells. Our results
revealed that overexpression of Max or C/EBPa alone in CD34þ
cells leads to a significant increase in the proportion of
CD11bþ (Figure 6a, dot plot 44 vs 20%) and CD15þ
(Figure 6a, dot plot 29 vs 13%) cells compared with the
mock-transfected control, respectively. The histograms represent
the average values from three different experiments, and the
viable cell count data (Trypan blue staining) under different
conditions are also shown for days 1 and 4 (Figure 6b). Q-RT-
PCR in these cells revealed increased GCSF receptor expression
(Figure 6c). Similar results were observed with U937 and K562-
C/EBPa-ER cells (Supplementary Figure S2a and data not
shown). The morphology of the cells was observed to correlate
with the surface marker expression (Supplementary Figure S2b).
Q-RT-PCR in U937 cells for various granulocytic/ monocytic
markers was also performed to complement the fluorescence-
activated cell sorting results (Supplementary Figure S2c).
Stable silencing of Max by short hairpin RNA reduces
the differentiation-inducing capacity of C/EBPa in
human hematopoietic CD34þ cells
If Max is a biologically important co-activator of C/EBPa,
silencing of Max should inhibit differentiation induction by
C/EBPa. To address this, we performed RNA interference
experiments in human hematopoietic CD34þ cells and
myeloid U937 cells (Supplementary Figure S2d) by using short
hairpin RNA (shRNA) against Max (cat. no. RHS1764-9690535;
Open Biosystems, Heidelberg, Germany) and control shRNA
(cat. no. RHS1707; Open Biosystems). Cells were transfected
with expression plasmids for C/EBPa alone and/or co-expressed
with shRNA against Max, control shRNA, and the cells cultured
in media containing puromycine. After selection, the cells were
analyzed for granulocytic differentiation, using CD15 expres-
sion as a marker. Our results revealed that C/EBPa alone induces
granulocytic differentiation (CD15þ ) five- to six-fold as
compared with the mock-transfected CD34þ (Figure 6d).
Coexpression of Max shRNA led to a significant decrease in
CD15þ population (about twofold), whereas control shRNA
did not lead to any significant reduction in CD15þ population
(Figure 6d, compare histograms). The reduction of Max protein
level with shRNA was confirmed by Western blotting and Max
shRNA did not affect the expression of C/EBPa (Figure 6e). In
conclusion, we propose a model shown as Figure 6f. Thus, Max
is important for C/EBPa-mediated effects on granulocytic
differentiation and might have an important role in stem cell
development.
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Figure 5 Max is associated at the hC/EBPa promoter in vivo and
Max–C/EBPa associate strongly during granulocytic differentiation. A
ChIP assay was performed on logarithmically growing and RA-treated
U937 cells, and the precipitated chromatin was PCR-amplified using
specific primers. (a) Comparison of the human and mouse C/EBP
promoters encompassing a consensus CACGT sequence, commonly
referred to as E-box and known to be occupied by MycþMax
heterodimers. (b) In vivo occupancy by Myc and Max at the hC/EBPa
promoter in logarithmically growing and (c) by Max-C/EBPa in RA-
treated U937 cells. Input: Radioactive and Q-RT-PCR performed on
total chromatin. The histograms beneath show the Q-RT-PCR average
Dct values from two independent experiments normalized with the
control sample. (d, e) ChIP assay using GAPDH promoter and human
TERT promoter as controls with a non-radioactive RT-PCR. (f) Sheared
DNA from U937 cells following 10 sonication pulses shows the
optimal size range for IP (200–1000 bp). Lane: 1, unsheared; lanes: 2
and 3, sheared DNA.
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Discussion
It has become increasingly clear that interaction of C/EBPa with
other nuclear proteins plays an important role not only in
lineage commitment and differentiation in the hematopoietic
system but also in the pathogenesis of AML. Although the
lineage commitment decision by C/EBPa was proposed by our
laboratory to involve the functional inactivation of the myeloid
master regulator PU.1 and/or its co-activator c-Jun through
protein–protein interactions,6,7 relatively little is known about
how C/EBPa interacts with other nuclear proteins to activate
gene transcription. The results presented in this article provide
evidence that Max, a heterodimerization partner of Myc, is a
novel, functionally and biologically important co-activator of
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CEBPa. C/EBPa and Max not only colocalize but also the
heterocomplex is preferentially formed on the hC/EBPa promo-
ter during granulocytic differentiation, thereby contributing to
increased transactivation and differentiation capacity of C/EBPa.
We used MS-based proteomic analysis as a means of
identifying the interacting partners of C/EBPa, utilizing IP of
C/EBPa from myeloid U937 cells as a model system. U937 cells
are a good model system for studying myeloid differentiation in
general, as they are bipotential and can be differentiated into
granulocytic lineage by RA and in particular, with respect to the
functions of C/EBPa, as a threefold level of C/EBPa protein
(above the level of endogenous C/EBPa) in U937 cells is
sufficient for their granulocytic differentiation.26 In addition to
nine other proteins (see Table), we identified Max, an essential
heterodimerization partner of Myc,16 as a novel interacting
partner of C/EBPa in our screen (Figure 1). The discovery of Max
as a novel C/EBPa partner is intriguing because of the role Max
plays in switching of the complexes during myeloid differentia-
tion.24 Of particular importance is the fact that transgenic mice
carrying an inserted transgene encoding Max have been shown
to exhibit a 50- to 60-fold elevation of blood neutrophils.27
Additionally, Max is an essential heterodimerization partner of
Myc family members to regulate transcription11 and c-Myc is an
important target of C/EBPa.26 We confirmed the in vivo
interaction of C/EBPa with Max by IP technique and showed
that the basic DNA-binding region of C/EBPa is involved in this
interaction, as the mutant of CEBPa (C/EBPa BR3), which lacks
DNA-binding region, could not be co-precipitated with Max
(Figure 2). C/EBPa BR3 carries mutations in four amino acids,
residues Arg297, Lys298, Arg300 and Lys302.28 Of these, only
Arg300 is expected to contact DNA. Neither the BR3 nor the
Leu12Val variants bind DNA, suggesting that interaction with
Max is likely via Arg297, Lys298 and/or Lys302. Arg297 is
known to participate in the interaction between C/EBPa and
E2F.8 Further study is required to pin point the exact amino acid
involved in the C/EBPa and Max interaction.
The endogenous C/EBPa and Max proteins are not distributed
evenly throughout the nucleoplasm (Figure 3), but are localized
in intranuclear structures within the nucleus. These structures
represent, presumably, centromeres, which are chromosomal
structures associated with intranuclear chromosome positioning
and cell cycle regulation. Interestingly, C/EBPa is associated
with cell cycle regulation.29,30 In other cell systems, such as
pituitary progenitor GHFT1-5 cells, C/EBPa has been shown to
concentrate at chromatin surrounding the centromeres.31 The
observation that C/EBPa–Max but not Myc–Max remain
colocalized during granulocytic differentiation (Figure 3) in-
dicates that these intranuclear structures (centromeres) are
selectively targeted by C/EBPa–Max during granulocytic differ-
entiation. We observed the occupancy of the hC/EBPa promoter
by Max in vivo under physiological conditions, and recruitment
of more C/EBPa whereas Max is retained on the promoter during
granulocytic differentiation. It is possible that the C/EBPaMax
heterocomplex regulates the balance of acetylated histones to
modify chromatin structure at the hC/EBPa promoter and lead to
transcriptional activation, as was shown by our results. In fact,
TIP60, a histone acetyl transferase, was identified as an
interacting partner of C/EBP to regulate histone acetylation at
the hC/EBPa promoter a in an alternative approach (Bararia
et al., manuscript submitted for publication). To our knowledge,
this is a first report showing occupancy of the hC/EBPa promoter
by Max in vivo.
The occupancy by Max of the hC/EBPa promoter raises a
possibility that Myc could also form a part of the complex
under physiological conditions, as Max requires dimerization
with Myc for efficient DNA binding. In fact, it was shown that
purified MycþMax heterodimers form stable complexes on
the mouse C/EBPa promoter that includes the USF binding
site.21 The USF DNA recognition site CACGTG (which is the
same as the E-box, occupied by Myc–Max) is found in both
the human and the mouse C/EBPa promoter, and the USF
binding site (for HLH-bZIP) is crucial for activation of the hC/
EBPa promoter by C/EBPa.32 Our colocalization and ChIP
data (Figures 4 and 5) and the data that C/EBPa is co-precipitated
with Myc IP (unpublished observation) support this Myc–Max
link. Thus, it is tempting to speculate that C/EBPa exists in
association with the Myc–Max–Mad network to regulate differ-
entiation under cellular settings. Given that the C/EBPa–Max
heterocomplex is formed on hC/EBPa promoter, specifically
during granulocytic differentiation, this would mean that the
balance between such complexes, under the influence of
growth and differentiation signals, could be an important part
of a molecular switch that is regulating genes important for
growth and differentiation.
By using overexpression studies, we have demonstrated that
enforced expression of C/EBPa and Max in human hematopoie-
tic CD34þ cells induces granulocytic differentiation. The role
of C/EBPa in the transition from CMPs to GMPs in myeloid
progenitors has been recently characterized.3 The role of Max in
inducing granulocytic differentiation indicates that Max can
activate myeloid differentiation program either independent of
C/EBPa or in association with it. In vivo interaction and retention
of C/EBPa–Max heterocomplex in myeloid cells (Figures 2, 4
and 5) and inhibition of differentiation-inducing capacity of
C/EBPa by stable silencing of Max using shRNA against MAX in
CD34þ cells (Figure 6) suggest CEBPa–Max association likely
plays an important role in this process of myeloid progenitor
differentiation. A very recent data from Alan Friedman’s group
has shown the role of C/EBPa in monopoiesis.33 This means that
the commitment decisions do not necessarily depend upon a
single transcription factor but, in fact, on a number of
cooperating factors.
In summary, we conclude that Max is a biologically
and functionally important and relevant interacting partner of
Figure 6 Overexpression of Max induces differentiation along granulocytic pathway in human hematopoietic CD34þ cells. (a) The expression
plasmids for human C/EBPa and Max were transfected into human hematopoietic CD34þ cells by using AMAXA technology. The surface
expression of CD11b and CD15 was analyzed by flow cytometry at day 4. The histograms underneath represent data from three different
experiments. (b) Trypan blue staining, showing the number of viable cells under different conditions. (c) Q-RT-PCR for GCSF receptor expression
under the conditions shown from two experiments. (d) Stable silencing of Max by shRNA inhibits C/EBPa-induced differentiation in human
hematopoietic CD34þ cells. The expression plasmid for human C/EBPa and/or expression Arrest shRNA_Max plasmid (Open Biosystems) were
transfected into human hematopoietic CD34þ cells or U937 cells by using the AMAXA technology. After their selection in puromycine, the cells
were analyzed for the surface expression of CD15 by flow cytometry and the data shown as dot plot with percentage of positive cells representative
of one experiment. shRNA control was also used in all the experiments and is shown. The histograms represent the data from three different
experiments. (e) A Western blot for Max using anti-Max antibody showing silencing of Max at the protein level by shRNA_MAX. The blot was
stripped and reprobed with C/EBPa antibody. (f) Model, a summary of our data showing the importance of Max as a co-activator of C/EBPa in the
differentiation of myeloid progenitors. Enforced expression of Max and CEBPa induces differentiation along the granulocytic pathway, and stable
silencing of Max inhibits CEBPa-induced differentiation.
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C/EBPa and has important co-activator functions for C/EBPa-
induced granulocytic differentiation in myeloid progenitors.
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